<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004639.pub2" GROUP_ID="HTN" ID="010403102709521049" MERGED_FROM="" MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca" REVIEW_NO="A039" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca">
<TITLE>Calcium supplementation for the management of primary hypertension in adults</TITLE>
<CONTACT MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="13343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Dickinson</LAST_NAME><POSITION>Reader in Epidemiology</POSITION><EMAIL_1>heather.dickinson@newcastle.ac.uk</EMAIL_1><URL>www.staff.ncl.ac.uk/heather.dickinson</URL><ADDRESS><DEPARTMENT>Institute of Health and Society</DEPARTMENT><ORGANISATION>Newcastle University</ORGANISATION><ADDRESS_1>21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2223699</PHONE_1><PHONE_2>+44 191 2227045</PHONE_2><FAX_1>+44 191 2226043</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="13343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Dickinson</LAST_NAME><POSITION>Reader in Epidemiology</POSITION><EMAIL_1>heather.dickinson@newcastle.ac.uk</EMAIL_1><URL>www.staff.ncl.ac.uk/heather.dickinson</URL><ADDRESS><DEPARTMENT>Institute of Health and Society</DEPARTMENT><ORGANISATION>Newcastle University</ORGANISATION><ADDRESS_1>21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2223699</PHONE_1><PHONE_2>+44 191 2227045</PHONE_2><FAX_1>+44 191 2226043</FAX_1></ADDRESS></PERSON><PERSON ID="16CCDCCA82E26AA201B4268B9B5303F1" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Donald</FIRST_NAME><LAST_NAME>Nicolson</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>D.J.Nicolson@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Healthcare</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Baines Wing</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS2 9UT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="449431EA82E26AA200991D56CB932841" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Cook</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>julia.cook@ncl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Health and Society</DEPARTMENT><ORGANISATION>Newcastle University </ORGANISATION><ADDRESS_1>21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2225364</PHONE_1><FAX_1>+44 191 2226043</FAX_1></ADDRESS></PERSON><PERSON ID="18181" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><LAST_NAME>Campbell</LAST_NAME><EMAIL_1>f.campbell@sheffield.ac.uk</EMAIL_1><MOBILE_PHONE>07788710296</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Health and Related Research</DEPARTMENT><ORGANISATION>University of Sheffield</ORGANISATION><ADDRESS_1>Regent Street</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S1 4DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 2220767</PHONE_1></ADDRESS></PERSON><PERSON ID="14189" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Beyer</LAST_NAME><POSITION>Information Specialist</POSITION><EMAIL_1>fiona.beyer@ncl.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>Institute for Health and Society</DEPARTMENT><ORGANISATION>University of Newcastle</ORGANISATION><ADDRESS_1>19-21 Claremont Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE2 4AA</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 222 3803</PHONE_1></ADDRESS></PERSON><PERSON ID="67BB6FBE82E26AA201D1E765C74EB0EF" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gary</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Ford</LAST_NAME><POSITION>Professor of Pharmacology of Old Age</POSITION><EMAIL_1>g.a.ford@ncl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Research Facility</DEPARTMENT><ORGANISATION>Royal Victoria Infirmary</ORGANISATION><CITY>Newcastle upon Tyne</CITY><ZIP>NE1 4LP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 222 8090</PHONE_1></ADDRESS></PERSON><PERSON ID="18996" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>James</FIRST_NAME><LAST_NAME>Mason</LAST_NAME><POSITION>Professor of Health Economics, Director of Research</POSITION><EMAIL_1>j.m.mason@durham.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine and Health</DEPARTMENT><ORGANISATION>Durham University, Queen's Campus</ORGANISATION><ADDRESS_1>Wolfson Research Institute</ADDRESS_1><ADDRESS_2>University Boulevard</ADDRESS_2><CITY>Stockton-on-Tees</CITY><ZIP>TS17 6BH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)191 334 0373</PHONE_1><FAX_1>+44 (0)191 334 0374</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca">

<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca"><DATE DAY="12" MONTH="11" YEAR="2008"/><DESCRIPTION><P>Contact details updated</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-13 00:30:48 +0100" MODIFIED_BY="Ciprian Jauca">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-13 10:55:50 +0300" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="24" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute for Clinical Excellence</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-13 11:26:24 +0300" MODIFIED_BY="Ciprian D Jauca">
<SUMMARY MODIFIED="2008-08-13 10:57:48 +0300" MODIFIED_BY="Ciprian D Jauca">
<TITLE MODIFIED="2008-08-13 10:57:42 +0300" MODIFIED_BY="Ciprian D Jauca">Calcium supplementation for the management of primary hypertension in adults</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-13 10:57:48 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>This review did not find robust evidence that oral calcium supplementation reduces high blood pressure in adults. It reviewed 13 trials enrolling 485 people, which compared calcium supplementation with placebo or no treatment, and measured blood pressure 8 to 15 weeks later. On average, people receiving extra calcium achieved slightly lower systolic blood pressure at the end of trials. However, most trials were of poor quality, so their results may not be reliable. Trials were too small and short to measure whether extra calcium reduces the risk of death, heart attack or stroke. Calcium usually had no more adverse effects than placebo. Larger, longer duration, better quality trials are needed to clarify whether calcium supplementation can lower high blood pressure.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-13 11:01:20 +0300" MODIFIED_BY="Ciprian D Jauca">
<ABS_BACKGROUND MODIFIED="2008-08-13 11:00:01 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>Metabolic studies suggest calcium may have a role in the regulation of blood pressure. Some epidemiological studies reported people with a higher intake of calcium tend to have lower blood pressure. Previous systematic reviews and meta-analyses reached conflicting conclusions about whether oral calcium supplementation can reduce blood pressure.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of oral calcium supplementation as a treatment for primary hypertension in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Inclusion criteria were: 1) RCTs comparing oral calcium supplementation with placebo, no treatment, or usual care; 2) treatment and follow-up &#8805;8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) &#8805;140 mmHg or diastolic blood pressure (DBP) &#8805;85 mmHg; 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or calcium supplementation was combined with other interventions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included 13 RCTs (n=485), with between eight and 15 weeks follow-up. The results of the individual trials were heterogeneous. Combining all trials, participants receiving calcium supplementation as compared to control had a statistically significant reduction in SBP (mean difference: -2.5 mmHg, 95% CI: -4.5 to -0.6, I<SUP>2 </SUP>=<SUP> </SUP>42%), but not DBP (mean difference: -0.8 mmHg, 95% CI: -2.1 to 0.4, I<SUP>2</SUP> = 48%). Sub-group analyses indicated that heterogeneity between trials could not be explained by dose of calcium or baseline blood pressure. Heterogeneity was reduced when poor quality trials were excluded. The one trial reporting adequate concealment of allocation and the one trial reporting adequate blinding yielded results consistent with the primary meta-analysis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-13 11:01:20 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>Due to poor quality of included trials and heterogeneity between trials, the evidence in favour of causal association between calcium supplementation and blood pressure reduction is weak and is probably due to bias. This is because poor quality studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of calcium supplementation on blood pressure and cardiovascular outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-13 11:26:24 +0300" MODIFIED_BY="Ciprian D Jauca">
<BACKGROUND MODIFIED="2008-08-13 11:15:31 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>High blood pressure (BP), or hypertension, is associated with a variety of structural changes in the blood vessels and heart which can lead to cardiovascular disease, stroke and renal diseases. It is one of the ten leading risk factors influencing the global burden of disease and is estimated to lead to over 7 million deaths each year, about 13% of the total deaths worldwide (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Reducing blood pressure levels is associated with significant reduction in cardiovascular and cerebrovascular morbidity and mortality (<LINK REF="REF-MacMahon-1990" TYPE="REFERENCE">MacMahon 1990</LINK>; <LINK REF="REF-PSC-2002" TYPE="REFERENCE">PSC 2002</LINK>). The most common form of hypertension, occurring in around 95% of all cases, is primary hypertension which is defined as high blood pressure with no identifiable cause (<LINK REF="REF-Brown-1997" TYPE="REFERENCE">Brown 1997</LINK>). Secondary hypertension is high blood pressure with an identifiable cause, e.g. renal disease or endocrine disturbances.</P>
<P>Epidemiological evidence about the effects of dietary calcium intake on blood pressure is unclear. Although some epidemiological studies, especially those in populations with low intakes of dietary calcium, report an inverse association between calcium intake and blood pressure, other studies report conflicting results (<LINK REF="REF-Hamet-1995" TYPE="REFERENCE">Hamet 1995</LINK>; <LINK REF="REF-Cutler-1990" TYPE="REFERENCE">Cutler 1990</LINK>; <LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK>; <LINK REF="REF-Cappuccio-1995" TYPE="REFERENCE">Cappuccio 1995</LINK>). This could be because of different recruitment protocols and different methods of measuring blood pressure, assessing dietary calcium intake, and statistical analysis. Due to these inconsistencies and to the difficulties in drawing conclusions about single nutrients from survey data, it is not at present possible to make a definitive link between calcium intake and blood pressure.</P>
<P>Despite numerous clinical studies in humans, the mechanism whereby dietary calcium might affect blood pressure is unclear, although it is plausible that it may affect the concentrations of free intracellular calcium ions, which are known to regulate blood pressure (<LINK REF="REF-Hamet-1995" TYPE="REFERENCE">Hamet 1995</LINK>; <LINK REF="REF-Nowson-1986" TYPE="REFERENCE">Nowson 1986</LINK>). It is also possible that the hypertensive effect of sodium chloride (common salt) may be affected by consumption of calcium, in particular that calcium may lower blood pressure in people with a low calcium but high sodium diet (<LINK REF="REF-Kotchen-1998" TYPE="REFERENCE">Kotchen 1998</LINK>).<BR/>
<BR/>While studies in animals have provided more consistent evidence of a link between dietary calcium and blood pressure, most studies were in young animals and demonstrated that calcium prevented the rise in blood pressure associated with aging (<LINK REF="REF-Hamet-1995" TYPE="REFERENCE">Hamet 1995</LINK>). However, studies in animals may not be relevant to humans.</P>
<P>We found two reviews (<LINK REF="REF-Burgess-1999" TYPE="REFERENCE">Burgess 1999</LINK>; <LINK REF="REF-Hamet-1995" TYPE="REFERENCE">Hamet 1995</LINK>) and several meta-analyses (<LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK>; <LINK REF="REF-Cappuccio-1989" TYPE="REFERENCE">Cappuccio 1989</LINK>; <LINK REF="REF-Cutler-1990" TYPE="REFERENCE">Cutler 1990</LINK>; <LINK REF="REF-Griffith-1999" TYPE="REFERENCE">Griffith 1999</LINK>; <LINK REF="REF-Allender-1996" TYPE="REFERENCE">Allender 1996</LINK>) summarising the findings of randomised controlled trials of oral calcium supplements on blood pressure in both normotensive and hypertensive participants. The 3 meta-analyses which carried out sub-group analyses of hypertensive participants reported different overall findings: no significant change in blood pressure (<LINK REF="REF-Cappuccio-1989" TYPE="REFERENCE">Cappuccio 1989</LINK>), a significant reduction in SBP only (<LINK REF="REF-Allender-1996" TYPE="REFERENCE">Allender 1996</LINK>), and a significant reduction in both systolic and DBP (<LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK>). However, they all included studies which treated participants with calcium for very short periods e.g. less than 2 weeks. Furthermore, conflicting results may be due to the effect of calcium supplementation being influenced by dietary calcium intake, vitamin D status, type of medication (e.g. calcium antagonists), or degree of elevation of blood pressure.</P>
<P>The aim of this review was to summarise the evidence about the benefits and harms of dietary calcium supplementation for patients with primary hypertension, in order to inform decisions about recommendations for treatment.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effects of oral calcium supplementation in adults with primary hypertension.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>RCTs of parallel or crossover design that had an intervention period of at least 8 weeks and allowed an intention-to-treat analysis. Crossover trials were restricted to designs with 2 interventions and 2 treatment periods.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults over 18 years of age, with elevated blood pressure (a minimum of 140 mmHg for SBP or 85 mmHg for DBP), without a known primary cause. The inclusion criterion for diastolic blood pressure is slightly lower than the standard (90 mmHg) for hypertension (<LINK REF="REF-JNC-VII-2003" TYPE="REFERENCE">JNC VII 2003</LINK>), in order to include individuals at the lower end of the spectrum of raised blood pressure. <BR/>We excluded:<BR/>
</P>
<UL>
<LI>studies of pregnant women, since hypertension during pregnancy is often due to syndromes such as preeclampsia, with a pathophysiology very different from that of other forms of hypertension (<LINK REF="REF-NIH-2000" TYPE="REFERENCE">NIH 2000</LINK>)</LI>
<LI>studies including patients on antihypertensive medication which varied during the course of the study, since the results of such studies are difficult to interpret.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<UL>
<LI>Intervention: oral calcium supplementation, or dietary intervention which attempted to manipulate only calcium intake; </LI>
<LI>Control: placebo, no treatment, or usual care.</LI>
</UL>
<P>
<BR/>We excluded trials which combined change in calcium intake with other interventions: for example, those that aimed to increase calcium while reducing sodium intake, and those that changed several aspects of diet.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome measures</B>:<BR/>
</P>
<UL>
<LI>death from all causes</LI>
<LI>coronary heart disease events (fatal or non-fatal myocardial infarction, excluding heart failure and if possible angina)</LI>
<LI>cerebrovascular events (fatal or non-fatal strokes, excluding transient ischaemic attacks if possible)</LI>
<LI>SBP at end of follow-up</LI>
<LI>DBP at end of follow-up.</LI>
</UL>
<P>
<BR/>If the mean or standard deviation of final BP was not reported, the difference in BP between baseline and the end of the study (change score) was used instead, if its standard deviation was available. If BP was measured both supine and standing, supine measurements were preferred; if BP was measured both sitting and supine, sitting measurements were preferred. If blood pressure was measured in clinic and at home or in the workplace, clinic measurements were preferred. If only ambulatory blood pressure was measured, 12/7 was added to these measurements, as the British Hypertension Society recommends an upward correction of 12/7 mmHg to ambulatory values before comparing them with clinic values (<LINK REF="REF-Bruce-1999" TYPE="REFERENCE">Bruce 1999</LINK>).</P>
<P>
<B>Secondary outcome measures</B>:<BR/>
</P>
<UL>
<LI>total withdrawals from treatment</LI>
<LI>withdrawals due to adverse effects</LI>
<LI>reported adverse effects (gastro-intestinal disturbances, bradycardia and arrhythmias have been associated with oral calcium supplements (<LINK REF="REF-BNF-2004" TYPE="REFERENCE">BNF 2004</LINK>)).</LI>
<LI>serum calcium levels at end of follow-up; although not specified in the initial protocol this was abstracted and post-hoc meta-analysis performed. Final values or change scores were abstracted as for blood pressure (see above).</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched the following for RCTs:<BR/>
</P>
<UL>
<LI>Cochrane Library (2004 issue 1)</LI>
<LI>MEDLINE (2000 - 9th Jan 2004)</LI>
<LI>EMBASE (1999 - end 2003)</LI>
<LI>Science Citation Index (1982 - end 2003)</LI>
<LI>ISI Proceedings (1999 - end 2003)</LI>
<LI>ClinicalTrials.gov</LI>
<LI>Current Controlled Trials</LI>
<LI>CAB abstracts (up to end July 2005)</LI>
</UL>
<P>
<BR/>Since the Cochrane Library incorporates RCTs from MEDLINE and EMBASE, searches of these databases were restricted to recent years. </P>
<P>We also identified systematic reviews and meta-analyses from these databases and checked their reference lists, as well as those of randomised controlled trials included in the review.</P>
<P>We based the search on the following strategy (where terms in capitals are MeSH headings). This strategy was constructed and developed further within MEDLINE, and was adjusted accordingly for the other databases:</P>
<P>#1 HYPERTENSION/<BR/>#2 hypertens$.tw<BR/>#3 (blood ADJ pressure).tw<BR/>#4 #1 OR #2 OR #3<BR/>#5 DIETARY supplements/<BR/>#6 CALCIUM, DIETARY/<BR/>#7 calcium.tw AND (diet$ OR oral$ OR supplements$ OR intake$).tw<BR/>#8 #5 OR #6 OR #7 <BR/>#9 Cochrane highly sensitive search strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>)<BR/>#10 #4 AND #8 AND #9<BR/>#11 EXP PREGNANCY/<BR/>#12 (pre eclampsia or pre-eclampsia).tw<BR/>#13 (calcium antagonist or channel blocker).tw<BR/>#14 #11 OR #12 OR #13<BR/>#15 #10 NOT #14</P>
<P>We also carried out a general web search using the search engines Google, Zapmeta and Dogpile, and searched the websites of the following organizations: Blood Pressure Association, British Hypertension Society, American Society of Hypertension, and Canadian Hypertension Society.</P>
<P>There was no language restriction.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>All titles and abstracts retrieved by electronic searching were screened independently by two reviewers and those studies which clearly did not meet the inclusion criteria were excluded. Copies of the full text of potentially relevant references were obtained and their eligibility was assessed by one of two methods: one reviewer was primary assessor and decisions were checked by a second reviewer or assessments were done independently by two reviewers. Differences between reviewers were resolved by discussion or by appeal to a third reviewer. </P>
<P>Methodological quality of included trials was assessed independently by two reviewers using the following criteria:</P>
<P>
<U>Blinding</U> <BR/>We coded the blinding of participants, treatment providers and outcome assessors as:<BR/>
</P>
<UL>
<LI>yes</LI>
<LI>no</LI>
<LI>unclear.</LI>
</UL>
<P>
<BR/>
<U>Randomisation</U>
<BR/>We coded the randomisation of participants to intervention groups as:<BR/>
</P>
<UL>
<LI>adequate e.g. a computer-generated random sequence or a table of random numbers;</LI>
<LI>inadequate e.g. date of birth, clinic id-number or surname;</LI>
<LI>unclear e.g. not reported.</LI>
</UL>
<P>
<BR/>
<U>Allocation concealment</U>
<BR/>We coded the concealment of the allocation sequence from treatment providers and participants as:<BR/>
</P>
<UL>
<LI>adequate (A) i.e. where the allocation sequence could not be foretold;</LI>
<LI>inadequate (B) e.g. a method of allocation which allowed treatment providers to predict which arm of the trial the next participant was assigned to; this included use of sealed opaque envelopes;</LI>
<LI>unclear (C) e.g. not reported</LI>
</UL>
<P>
<BR/>
<U>Loss to follow-up<BR/>
</U>We recorded the number of participants in each intervention arm whose blood pressure was not reported at the end of the study. We noted if loss to follow-up was not reported.</P>
<P>
<U>Carryover effects</U>
<BR/>For crossover trials, we noted whether carryover effects were assessed and, if so, whether any were detected.</P>
<P>Two reviewers independently abstracted endpoint data and data which might facilitate interpretation of any heterogeneity in the findings of trials: country in which the study was conducted, inclusion criteria, patient characteristics at baseline (age, gender, ethnicity, mean blood pressure, whether previously treated with antihypertensive drugs), trial quality and duration of follow-up using a pre-specified form. Differences were reconciled by discussion or by consultation with a third reviewer. Authors were contacted for missing endpoint data.</P>
<P>The findings of all included trials were aggregated in separate meta-analyses for (i) parallel and (ii) crossover designs; these were combined in the same meta-analysis if they did not show heterogeneity (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>; <LINK REF="REF-Curtin-2002" TYPE="REFERENCE">Curtin 2002</LINK>). For meta-analysis of parallel trials separately, final SBP and DBP (and standard deviations) in calcium and control arms were input to the weighted mean difference facility of RevMan. For crossover trials separately, and for parallel and crossover trials combined, the generic inverse variance facility of RevMan was used. The mean difference (and standard deviation) between final blood pressure for calcium and control interventions for both SBP and DBP was calculated. If standard deviations of final values were not available, change scores were used if their standard deviations were available. If no standard deviations were available, they were imputed. In particular, the standard deviation of the crossover treatment effect was imputed (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>), assuming the mean within-person correlation observed in other crossover trials which evaluated the effect on blood pressure of oral supplements of calcium, sodium and magnesium (<LINK REF="REF-Australian-1989" TYPE="REFERENCE">Australian 1989</LINK>; <LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="REF-Kawano-1998-_x0028_ii_x0029_" TYPE="REFERENCE">Kawano 1998 (ii)</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>). If trials had more than one treatment arm (e.g. <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>), we used a weighted mean of the outcome for all treatment arms. Mean differences were weighted according to the precision of each trial and combined in meta-analyses using a random effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) to estimate an overall pooled mean difference and its 95% confidence interval (CI). Heterogeneity between trials was assessed using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>Sub-group analyses were performed, grouping the trials into those in which (i) participants in the active treatment arm received higher (1.2 - 2 g/day) and lower (&lt;1.2 g/day) doses of calcium, and (ii) participants' mean baseline systolic blood pressure was higher (SBP&gt;145 mmHg) and lower (SBP&lt;=145 mmHg).</P>
<P>Sensitivity analyses were performed excluding trials which did not report (i) adequate concealment of allocation, (ii) double blinding, and (iii) sufficient data to allow estimation of the standard deviation of the treatment effect. Further post-hoc analyses evaluated the effect of calcium supplementation on serum calcium levels using similar methods to above.</P>
<P>For parallel trials, we assessed the tolerability of the intervention by calculating the difference in the rate of withdrawal in treatment and control arms, and using a random effects model to calculate a pooled risk difference. Crossover trials are designed with the intention that all participants receive both the active and control interventions, and the treatment effect is estimated from the differences in response of the same participant to the different treatments. Hence participants who withdraw from either treatment cannot be included in the analysis and so the question of differential withdrawal between treatment arms does not arise. </P>
<P>We assessed gastro-intestinal adverse effects by calculating the difference in the rate of these effects in treatment and control arms, and using a random effects model to calculate a pooled risk difference.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-13 11:23:55 +0300" MODIFIED_BY="Ciprian D Jauca">
<STUDY_DESCRIPTION>
<P>The search strategy found 1,577 potentially relevant references which we electronically screened (see Additional Figures: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded 1,529 references and retrieved 48 for detailed evaluation. Of these we excluded 33 references for the following reasons: normotensive participants (15 trials), follow-up of less than eight weeks (nine trials), not an RCT (four trials), not a controlled trial (two trials), each participant took only two of three possible treatments (one trial), participants had secondary hypertension (one trial), and study design uninterpretable (one trial) - see table <B>Characteristics of excluded studies</B>. The 14 remaining RCTs (reported in 15 references) met our inclusion criteria and are described in the table <B>Characteristics of included studies</B>. One of these trials, reported only as an abstract, was excluded from the meta-analysis because it did not report either overall mean baseline or final values of blood pressure for the treatment or control groups (<LINK REF="STD-Morris-1988" TYPE="STUDY">Morris 1988</LINK>). </P>
<P>The 13 RCTs included in the meta-analysis included 485 participants. Five were of parallel design (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>) and eight of crossover design (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>). No trials were designed for or reported mortality or cardiovascular endpoints; no trials assessed quality of life.</P>
<P>The number of participants in each trial ranged from 9 to 90. There was substantial heterogeneity between trials in terms of the participants enrolled and the interventions administered. Entry criteria varied between trials, but participants' SBP ranged from 131 to 169 mmHg and their DBP from 78 to 99 mmHg. Overall mean blood pressure at baseline was 148/91 mmHg. Sixty-five percent of the participants were male. The mean age was 45 years (range: 16 to 86 years); the trial of <LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK> was untypical in that it enrolled young adults aged 16-29 years. Only two trials reported ethnicity: (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>) and (<LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>) and in these 88% of the participants were caucasian. However, seven of the other 11 trials were conducted in Europe or Australia, therefore it is likely that most of their participants were caucasian. Four trials were conducted in the USA (<LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>), two in Italy (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>), two in Japan (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>), two in Spain (<LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>), one in Denmark (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>), one in Australia (<LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>) and one in the Netherlands (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>). </P>
<P>Only 6 of the 14 included studies reported the mean dietary calcium intake of the populations studied (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>): this varied from 500 mg/day (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>) to 1411 mg/day (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>). Vitamin D status was not reported in any of the trials. </P>
<P>Participants in two trials (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>) were receiving anti-hypertensive medication; 32/60 (53%) of those in one trial (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>) were receiving calcium antagonists. Treatment status of participants was not reported in three trials (<LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>), although one of these (<LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>) reported that participants were not receiving any medication which could affect calcium metabolism. The remaining trials enrolled participants who were either treatment naive (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>), currently untreated (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Morris-1988" TYPE="STUDY">Morris 1988</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>) or a mixture of both (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>); one of these (<LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>) reported that participants were not receiving any medication which could affect calcium metabolism. Participants in the trial of <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK> were hospitalised.</P>
<P>The intervention was provided as calcium supplements, either as tablets or in powdered form. The mean dose was 1.1g/day (range: 0.4 to 2 g/day). (For calcium, 1g is 25 mmol). <B>
<I> </I>
</B>All trials gave a placebo to participants in the control group, except <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK> which gave no treatment. The median duration of follow-up was 8 weeks (range: 8 to 15 weeks). </P>
<P>All trials measured BP in the clinic; the trial of <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK> reported the mean over 24 hours of hourly readings taken while resting in a supine position, whereas other trials reported the mean of up to 6 readings. All trials except that of <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK> reported the final values and standard deviations of SBP and DBP. Three of the eight crossover trials reported the standard deviation of the treatment effect (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>), but the others did not. We requested the missing standard deviations from the corresponding authors of these papers but none have yet replied. Therefore standard deviations for these trials were imputed from the within person correlation of trials of similar interventions for hypertension (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
<P>Five trials reported adverse effects by treatment arm (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>); two further trials reported adverse effects but not by treatment arm (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>). </P>
<P>Three of the five parallel trials reported the number of withdrawals from treatment by treatment arm (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>); two reported withdrawals but not by treatment arm (<LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>). All crossover trials except <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK> and <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK> reported withdrawals. </P>
<P>Baseline values for serum total calcium concentrations were reported in five trials (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>). The mean baseline serum total calcium concentration was 2.4 mmol/l. Final values of serum total calcium were reported in eight trials (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>). In the trials of <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK> and <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>, the standard errors of the crossover treatment effects were estimated from the reported p-values. The standard errors of the crossover treatment effect in the trials of <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK> and <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK> were estimated using the within-person correlation observed in the trial of <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK> (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-13 11:17:34 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>Although all trials claimed to be randomised, the method of randomisation was confirmed to be adequate in only two trials (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>) and was not reported in the other 12 trials. Concealment of allocation was confirmed as adequate in only one trial (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>). One trial blinded participants only (<LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>); one trial blinded participants, treatment providers and outcome assessors (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>); one study did not implement blinding (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>); two trials were unclear in reporting blinding (<LINK REF="STD-Morris-1988" TYPE="STUDY">Morris 1988</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>); and the remaining trials blinded both participants and treatment providers. Three of the trials of crossover design confirmed no carryover effects (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>). The other five crossover trials did not report this (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>). Loss to follow-up, reported in all trials (except <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>), was around 7% in both treatment and control groups.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-13 11:23:55 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>As no trials reported deaths or cardiovascular events, we were able to meta-analyse only blood pressure, adverse events, overall withdrawals from treatment and serum calcium levels.</P>
<P>
<B>Primary meta-analyses<BR/>
</B>One parallel trial found a statistically significant reduction in both SBP and DBP (<LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>). Meta-analysis of five parallel trials found calcium supplements were associated with a statistically significant reduction in SBP (mean difference: -3.2 mmHg, 95% CI: -6.2 to -0.2) compared to control, and a non-significant reduction in DBP (mean difference: -2.4 mmHg, 95% CI: -4.8 to 0.0) - see comparison 1. There was no heterogeneity for SBP (I<SUP>2</SUP> =0%) and little heterogeneity for DBP (I<SUP>2</SUP> =23%).<BR/>
<B>
<BR/>
</B>One crossover trial found a statistically significant reduction in both SBP and DBP (<LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>); and one in SBP alone (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>). The meta-analysis of the eight crossover trials found calcium supplements were associated with a statistically non-significant reduction in SBP (mean difference: -2.3 mmHg, 95% CI: -4.9 to 0.3) compared to control and no effect on DBP (mean difference: -0.3 mmHg, 95% CI: -1.7 to 1.1) - see comparison 2. There was considerable heterogeneity for SBP (I<SUP>2</SUP> =60%); and DBP (I<SUP>2 </SUP>=51%).</P>
<P>As the confidence intervals of the treatment effects for the five parallel and eight crossover trials overlapped substantially (for both SBP and DBP), we combined these trials in a single meta-analysis - see comparisons 3 and 4. This showed that, overall, participants receiving calcium supplements had a statistically significant reduction in SBP (mean difference: -2.5 mmHg, 95% CI: -4.5 to -0.6), but little change in DBP (mean difference: -0.8 mmHg, 95% CI: -2.1 to 0.4). There was moderate heterogeneity for SBP (I<SUP>2</SUP> =42%) and DBP (I<SUP>2</SUP> =48%), and this was not explained by differences in either calcium dose or baseline blood pressure: overall, trials administering higher (1.2 - 2 g/day) and lower (&lt;1.2 g/day) doses of calcium showed similar changes in blood pressure (see comparison 3); likewise for trials in populations with higher (SBP&gt;145 mmHg) and lower (SBP&lt;= 145 mmHg) mean baseline blood pressure (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>
<B>Sensitivity analysis - concealment of allocation</B>
<BR/>Only one trial reported adequate concealment of allocation (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>); consistent with our primary meta-analysis, this trial found a significant reduction in SBP (mean difference: -3.8 mmHg, 95%CI: -6.5 to -1.1) but not DBP (mean difference: 0.0 mmHg, 95%CI: -1.9 to 1.9) among participants receiving calcium supplements compared to control.</P>
<P>
<B>Sensitivity analysis - blinding</B>
<BR/>We conducted a sensitivity analysis, excluding trials which did not confirm blinding of both participants and treatment providers (<LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>, <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>) - see comparison 5. The results were similar to those of the main analysis: a significant decrease in SBP among participants receiving calcium supplements (mean difference: -1.9 mmHg, 95% CI: -3.8 to -0.1); but little change in DBP (mean difference: -0.3 mmHg, 95% CI: -1.7 to 1.0). Heterogeneity was substantially reduced for SBP (I<SUP>2</SUP> =17%) but not for DBP (I<SUP>2</SUP> =39%).</P>
<P>Only one trial (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>) reported blinding of participants, treatment providers and outcome assessors: this crossover trial enrolling 18 participants reported non-significant reductions in both SBP (mean difference: -3.0 mmHg, 95% CI: -7.1 to 1.1) and DBP (mean difference: -1.0 mmHg, 95% CI: -3.4 to 1.4).</P>
<P>
<B>Sensitivity analysis excluding trials which did not report the standard deviation of the treatment effect</B>
<BR/>We conducted a sensitivity analysis, excluding trials which did not report the standard deviation of the treatment effect (<LINK REF="STD-Morris-1988" TYPE="STUDY">Morris 1988</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>; <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK>; <LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>) - see <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK> and <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>. The results were again similar to those of the main analysis: a significant reduction in SBP among participants receiving calcium supplements (mean difference: -2.7 mmHg, 95% CI: -4.3 to -1.2); but little change in DBP (mean difference: -1.4 mmHg, 95% CI: -2.7 to -0.1). Heterogeneity was greatly reduced for both SBP (I<SUP>2</SUP> =0%) and DBP (I<SUP>2</SUP> =20%).</P>
<P>
<B>Overall withdrawal from treatment<BR/>
</B>Two parallel trials reported no withdrawals from treatment either among participants receiving calcium or among those in the control group (<LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>); one parallel trial reported 5/46 withdrawals among participants receiving calcium and 5/44 among those in the control group (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>). Meta-analysis of these trials confirmed no significant difference in rate of withdrawal between the treatment groups (risk difference = 0.0, 95%CI: -0.06 to 0.06) - see <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.</P>
<P>The overall rate of withdrawal in the six crossover trials which reported withdrawals was 15%.<BR/>
<B>
<BR/>Adverse effects<BR/>
</B>Three parallel trials (<LINK REF="STD-Lyle-1992" TYPE="STUDY">Lyle 1992</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Sanchez-1997" TYPE="STUDY">Sanchez 1997</LINK>) and three crossover trials (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>) did not report whether participants suffered any adverse effects. Two parallel trials (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>; <LINK REF="STD-Martinez-1989" TYPE="STUDY">Martinez 1989</LINK>) reported that 8 participants suffered diarrhoea. Meta-analysis of these trials showed very little difference in risk of adverse effects between calcium and placebo (risk difference = -0.02, 95%CI: -0.09 to 0.05, I<SUP>2</SUP> =0%) - see <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>.</P>
<P>Three crossover trials (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>; <LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>) reported adverse effects by treatment phase: overall in these three trials 15 participants suffered gastro-intestinal problems, but meta-analysis did not show a difference between calcium and placebo ( risk difference = -0.01, 95%CI: -0.09 to 0.08, I<SUP>2</SUP> = 22%) - see <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>. In one crossover trial (<LINK REF="STD-Zoccali-1988" TYPE="STUDY">Zoccali 1988</LINK>), 6 participants suffered headache during the treatment phase and 3 during the placebo phase (risk difference = 0.14, 95%CI: 95%CI: -0.10 to 0.39). In one crossover trial, (<LINK REF="STD-Galloe-1993" TYPE="STUDY">Galloe 1993</LINK>) one participant suffered high blood pressure while on placebo. One crossover trial (<LINK REF="STD-Tanji-1991" TYPE="STUDY">Tanji 1991</LINK>) reported that one participant suffered a headache but did not specify whether this was during the calcium or placebo phase of treatment.</P>
<P>
<B>Serum calcium</B>
<BR/>Overall, participants receiving calcium supplements had higher serum calcium levels than those in the control groups (mean difference: 0.04 mmol/l, 95% CI: 0.02 to 0.6) - see <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>. There was little evidence of heterogeneity between the trials: I<SUP>2</SUP> = 12%.</P>
<P>
<B>Funnel plot analysis<BR/>
</B>We considered the potential for small study effects by visually examining funnel plots of SBP and DBP outcome data; these provided little evidence for publication bias (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-13 11:26:24 +0300" MODIFIED_BY="Ciprian D Jauca">
<P>
<B>Effect of intervention<BR/>
</B>Our meta-analysis of 13 randomised controlled trials enrolling 485 participants, with between eight and 15 weeks follow-up, found that calcium supplementation was associated with a small, statistically significant reduction in SBP (mean difference: -2.5, 95% CI: -4.5 to -0.6), but had little effect on DBP. Funnel plots showed little evidence of publication bias. As the majority of trials were not of good quality (see below); the results of the primary meta-analyses must be interpreted with caution.</P>
<P>There was substantial heterogeneity between the findings of the trials (I<SUP>2</SUP> = 42% and 48% for SBP and DBP respectively), which could reflect heterogeneity in either the patient populations, the interventions or the methods used in the trials. Some of these possible confounding factors were evaluated by sub-group analyses. Sub-group analyses by dose of calcium supplementation showed little difference in estimated treatment effect between trials administering higher and lower doses. Likewise, sub-group analyses showed little difference in response in relation to mean baseline blood pressure. Hence it seems unlikely that either dose of calcium or baseline blood pressure explain the heterogeneity. However, other differences between the populations studied, e.g. dietary calcium status, use of anti-hypertensive drugs, were not amenable to sub-group analysis. Furthermore, findings from multiple subgroup analyses may be misleading as subgroup analyses are observational by nature and not based on randomised comparisons (<LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>; <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). False negative and false positive significance tests increase in likelihood rapidly as more subgroup analyses are performed. When we excluded trials which did not confirm blinding of both the participant and the treatment provider, heterogeneity between trials was reduced (I<SUP>2</SUP> = 17% and 39% for SBP and DBP respectively); when we excluded trials which did not report the standard deviation of the treatment effect, there was little heterogeneity between trials (I<SUP>2 </SUP>= 0% and 19% for SBP and DBP respectively). These sensitivity analyses suggest that the poor quality trials are contributing to the heterogeneity.</P>
<P>The trial of <LINK REF="STD-Takagi-1991" TYPE="STUDY">Takagi 1991</LINK> reported an unusually large reduction in blood pressure with calcium supplementation. This trial measured mean hourly BP averaged over 24 hours, whereas all other trials measured BP at one clinic visit. This could suggest a diurnal effect of calcium that was not detected by the other trials. However, this was a cross-over trial with only 9 subjects and thus requires confirmation by a larger trial.</P>
<P>Withdrawals were reported in 11 trials enrolling 374 participants; overall the rate of withdrawal was similar in treatment and control groups. As reasons for withdrawals were not well reported, we were not able to distinguish between withdrawals due to adverse effects and lack of persistence. However, discontinuation of treatment for any reason would need be taken into account in framing recommendations. Adverse effects were reported by treatment arm in only 6 trials. The most commonly reported adverse effects were gastro-intestinal symptoms and headache. These were reported at a similar frequency in the calcium and control groups.</P>
<P>As expected, participants receiving calcium supplements had higher serum calcium levels than those in the control groups. One trial reported that DBP fell more in participants with baseline serum calcium lower than the median than in other participants (<LINK REF="STD-Grobbee-1986" TYPE="STUDY">Grobbee 1986</LINK>); one trial reported no association between SBP and serum calcium levels (<LINK REF="STD-Kawano-1998" TYPE="STUDY">Kawano 1998</LINK>). We were unable to investigate possible relationships between change in blood pressure and change in serum calcium levels through meta-regression, due to the small number of trials reporting serum calcium, without the risk of spurious false positive findings (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>
<B>Previous findings<BR/>
</B>Our main findings - that calcium supplementation produces a small reduction in SBP, but has little effect on DBP - are consistent with a previous meta-analysis (<LINK REF="REF-Allender-1996" TYPE="REFERENCE">Allender 1996</LINK>). The meta-analysis of <LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK> (updated by <LINK REF="REF-Griffith-1999" TYPE="REFERENCE">Griffith 1999</LINK>) found that calcium supplements produced a small statistically significant reduction in both SBP and DBP in hypertensive populations. <LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK> and <LINK REF="REF-Griffith-1999" TYPE="REFERENCE">Griffith 1999</LINK> included the same six trials. We included three of these (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>; <LINK REF="STD-Nowson-1989" TYPE="STUDY">Nowson 1989</LINK>; <LINK REF="STD-Weinberger-1993" TYPE="STUDY">Weinberger 1993</LINK>), but excluded three trials: one because follow-up was less than eight weeks (<LINK REF="REF-Sunderrajan-1984" TYPE="REFERENCE">Sunderrajan 1984</LINK>), one because it was not randomised (<LINK REF="STD-Johnson-1985" TYPE="STUDY">Johnson 1985</LINK>) and one because it had missing data (<LINK REF="STD-Morris-1988" TYPE="STUDY">Morris 1988</LINK>). These three excluded studies showed reductions in blood pressure from calcium supplements.<I>
<B> </B>
</I>Another difference of <LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK> and <LINK REF="REF-Griffith-1999" TYPE="REFERENCE">Griffith 1999</LINK> from this meta-analysis is that they analysed the change in blood pressure between baseline and the end of the study (change scores) rather than blood pressure at the end of the study (final values) and estimated missing standard deviations from test statistics. Despite the differences <LINK REF="REF-Bucher-1996" TYPE="REFERENCE">Bucher 1996</LINK> and <LINK REF="REF-Griffith-1999" TYPE="REFERENCE">Griffith 1999</LINK> concluded that the modest effects on blood pressure were not sufficient to justify recommending calcium supplements as a treatment for hypertension.</P>
<P>The DASH trial (<LINK REF="REF-DASH-1999" TYPE="REFERENCE">DASH 1999</LINK>; <LINK REF="REF-DASH-2000" TYPE="REFERENCE">DASH 2000</LINK>) found a marked reduction in blood pressure after 8 weeks follow-up among hypertensive participants on a "combination" diet high in calcium compared to those on a control diet low in calcium; however, as the "combination" diet also had higher potassium, magnesium, fibre and protein levels than the control diet, it is not possible to know what component(s) of the diet may have been responsible for the decrease in blood pressure.</P>
<P>
<B>Quality of trials<BR/>
</B>Trials with inadequate or unclear concealment of allocation are more likely than adequately concealed trials to show beneficial effects of the intervention (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). The one trial which reported adequate concealment of allocation (<LINK REF="STD-McCarron-1985" TYPE="STUDY">McCarron 1985</LINK>) reported a statistically significant reduction in SBP and no change in DBP among participants receiving calcium, consistent with our primary meta-analysis.</P>
<P>Likewise, trials which are not double blinded are more likely to report beneficial effects of the intervention (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). The one small trial which reported blinding of participants, treatment providers and outcome assessors (<LINK REF="STD-Strazzullo-1986" TYPE="STUDY">Strazzullo 1986</LINK>) reported non-significant reductions in blood pressure, which were nevertheless consistent with our primary meta-analysis. This trial was unusual in that over half the participants were also receiving calcium antagonists.</P>
<P>No trials satisfied both of these important quality criteria.</P>
<P>
<B>Conclusions<BR/>
</B>This meta-analysis demonstrated a statistically significant reduction in systolic blood pressure and no reduction in diastolic blood pressure with calcium supplementation as compared to control. It also demonstrated evidence that calcium supplementation is not associated with adverse effects. However, in view of the poor quality of the trials and the heterogeneity between the trials, we conclude that the evidence in favour of a causal association between calcium supplementation and blood pressure reduction is weak. It is our opinion that, as poor quality studies generally tend to over-estimate the effects of treatment, the apparently significant reduction in systolic blood pressure is more likely to be due to bias. However, a decrease in systolic blood pressure with calcium supplementation cannot be discounted.</P>
<P>Even if increasing calcium intake results in a reduction in systolic blood pressure, this reduction is small, 2.5 mmHg, is not known to be sustained beyond 15 weeks and is not known to cause a decrease in morbidity and mortality. This is compared to the evidence for drugs, which singly result in average reductions of about 9.1 mmHg (95%CI: 8.8 to 9.3) in SBP and 5.5 mmHg (95%CI: 5.4 to 5.7) in DBP (<LINK REF="REF-Law-2003" TYPE="REFERENCE">Law 2003</LINK>), are known to have sustained effects and to reduce morbidity and mortality. However, even small changes in blood pressure in large proportions of the population in a common condition such as hypertension could reduce adverse cardiovascular outcomes. Hence, if a clear sustained effect of calcium supplementation on blood pressure were established, an increase in dietary calcium at a population level could have important benefits.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Overall we did not find robust enough evidence that dietary calcium supplementation reduced raised blood pressure to justify its use as a treatment for elevated blood pressure. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More placebo controlled trials are warranted to clarify whether calcium supplementation can reduce blood pressure in people with elevated blood pressure. These trials should be randomized, with adequate concealment of allocation of participants to treatment arms, double-blinded and large enough and of at least one year duration in order to be able to detect a sustained effect of calcium supplementation on blood pressure. Large longer term placebo controlled trials of calcium for other indications (eg. osteoporosis) should also report blood pressure and cardiovascular outcomes. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Sarah Hull for help with data abstraction and Beth Anderson and Sylvia Hudson for secretarial support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. The funding source was not in a position to benefit financially from the results of the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JM designed the study; HOD and JVC wrote the protocol; FRB and HOD performed the searches and managed the references; DJN, FC and HOD sifted the references; DJN, HOD, FC, JVC and JM abstracted the data; JM, HOD and DJN performed the statistical analysis; HOD and DJN wrote the review, GAF advised on clinical aspects and interpretation of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Galloe-1993" NAME="Galloe 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galloe AM, Graudal N, Moller J, Bro H, Jorgensen M, Christensen HR</AU>
<TI>Effect of oral calcium supplementation on blood pressure in patients with previously untreated hypertension: a randomised double-blind placebo-controlled crossover study</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>43-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grobbee-1986" NAME="Grobbee 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grobbee D, Hofman A</AU>
<TI>Effect of calcium supplementation on diastolic blood pressure in young people with mild hypertension</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>2</VL>
<PG>703-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawano-1998" NAME="Kawano 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawano Y, Yoshimi H, Matsuoka H, Takishita S, Omae T</AU>
<TI>Calcium supplementation in patients with essential hypertension: assessment by office, home and ambulatory blood pressure</TI>
<SO>Journal of Hypertension</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1693-1699</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyle-1992" NAME="Lyle 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyle RM</AU>
<TI>Does baseline serum total calcium level influence the blood pressure response to calcium supplementation? A double-blind study</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1992</YR>
<VL>41</VL>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-1989" NAME="Martinez 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olivan Martinez J, Perez Cano R, Miranda Garcia MJ, Montoya Garcia MJ, Moruno Garcia R, Cuenca Lopez L, Garrido Peralta M</AU>
<TI>Effect of an oral calcium supplement in the treatment of slight-to- moderate essential arterial hypertension</TI>
<SO>Anales de Medicina Interna</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>192-196</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarron-1985" NAME="McCarron 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarron DA, Morris CA</AU>
<TI>Blood pressure response to oral calcium in persons with mild to moderate hypertension: a randomized, double-blind, placebo-controlled, crossover trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1985</YR>
<VL>103</VL>
<PG>825-831</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-1988" NAME="Morris 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris CD, Karanja N, McCarron DA</AU>
<TI>Dietary versus supplemental calcium to reduce blood pressure</TI>
<SO>Clinical Research</SO>
<YR>1988</YR>
<VL>36</VL>
<PG>A139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nowson-1989" NAME="Nowson 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nowson C, Morgan T</AU>
<TI>Effect of calcium carbonate on blood pressure in normotensive and hypertensive people</TI>
<SO>Hypertension</SO>
<YR>1989</YR>
<VL>13</VL>
<PG>630-639</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-1997" NAME="Sanchez 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez M, de la Sierra A, Coca A, Poch E, Giner V, Urbano-Marquez A</AU>
<TI>Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients</TI>
<SO>Hypertension</SO>
<YR>1997</YR>
<VL>29</VL>
<PG>531-536</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strazzullo-1986" NAME="Strazzullo 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strazzullo P, Siani A, Gugliemi S</AU>
<TI>Controlled trial of long-term oral calcium supplementation in essential hypertension</TI>
<SO>Hypertension</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>1084-1088</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takagi-1991" NAME="Takagi 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takagi Y, Fukase M, Takata S, Fujimi T, Fujita T</AU>
<TI>Calcium treatment of essential hypertension in elderly patients evaluated by 24 H monitoring</TI>
<SO>American Journal of Hypertension</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>836-839</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanji-1991" NAME="Tanji 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanji JL, Lew EY, Wong GY, Treguboff C, Ward JA, Amsterdam EA</AU>
<TI>Dietary calcium supplementation as a treatment for mild hypertension</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>145-150</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberger-1993" NAME="Weinberger 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger MH, Wagner UL, Fineberg NS</AU>
<TI>The blood pressure effects of calcium supplementation in humans of known sodium responsiveness</TI>
<SO>American Journal of Hypertension</SO>
<YR>1993</YR>
<VL>6</VL>
<PG>799-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-1988" NAME="Zoccali 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali C, Mallamaci F, Delfino D, Ciccarelli M, Parlongo S, Iellamo D, Moscato D, Maggiore Q</AU>
<TI>Double-blind randomized crossover trial of calcium supplementation in essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>451-455</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali C, Mallamaci F, Delfino D, Ciccarellie M, Parlongo S, Iellamo D, Moscato D, Maggior Q</AU>
<TI>Long-term oral calcium supplementation in essential hypertension: a double-blind, randomized, crossover study</TI>
<SO>Journal of Hypertension</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>S676-S678</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Appel-1995" NAME="Appel 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appel LJ, Hebert PR, Cohen JD, Obarzanek E, Yamamoto M, Buring J</AU>
<TI>Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>149-155</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belizan-1983" NAME="Belizan 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belizan JM, Villar J, Pineda O, Gonzalez AE, Sainz E, Garrera G, Sibrian R</AU>
<TI>Reduction of blood pressure with calcium supplementation in young adults</TI>
<SO>JAMA</SO>
<YR>1983</YR>
<VL>249</VL>
<PG>1161-1165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buonopane-1992" NAME="Buonopane 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buonopane GJ, Kilara A, Smith JS, McCarthy RD</AU>
<TI>Effect of skim milk supplementation on blood cholesterol concentration, blood pressure, and triglycerides in a free-living human population</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>1992</YR>
<VL>11</VL>
<PG>56-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cappuccio-1987_x0028_a_x0029_" NAME="Cappuccio 1987(a)" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cappuccio FP, Markandu ND, Singer DR, Smith SJ, Shore AC, MacGregor GA</AU>
<TI>Does oral calcium supplementation lower high blood pressure? A double blind study</TI>
<SO>Journal of Hypertension</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>67-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cappuccio-1987_x0028_b_x0029_" NAME="Cappuccio 1987(b)" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cappuccio FP, Elliott P, Allender PS, Pryer J, Follman DA, Cutler JA</AU>
<TI>Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>142</VL>
<PG>935-945</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1996" NAME="Davis 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis IJ, Grim C, Dwyer K, Nicolson L, Dwyer J</AU>
<TI>The effects of calcium supplementation on ambulatory blood pressure in African-American adolescents</TI>
<SO>Journal of the Natal Medical Association</SO>
<YR>1996</YR>
<VL>88</VL>
<PG>774-778</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinlieb-1984" NAME="Feinlieb 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinlieb M, Lenfant C, Miller SA</AU>
<TI>Hypertension and calcium</TI>
<SO>Science</SO>
<YR>1984</YR>
<VL>226</VL>
<PG>384-386</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruchow-1988" NAME="Gruchow 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruchow HW, Sobocinski KA, Barboriak JJ</AU>
<TI>Calcium intake and the relationship of dietary sodium and potassium to blood pressure</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1988</YR>
<VL>48</VL>
<PG>1463-1470</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebert-1995" NAME="Hebert 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebert PR, Bolt RJ, Borhani NO, Cook NR, Cohen JD, Cutler JA, Hollis JF, Kuller LH, Lasser NL, Oberman A, Miller ST, Morris CA, Whelton PK, Hennekens C</AU>
<TI>Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels: Trials of Hypertension Prevention (phase II)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>130-139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollis-1995" NAME="Hollis 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollis JF, Satterfield S, Smith F, Fouad M, Allender PS, Borhani N, Charleston J, Hirlinger M, King N, Schultz R, Sousoulas BG</AU>
<TI>Recruitment for Phase II of the Trials of Hypertension Prevention: effective strategies and predictors of randomization</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>140-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jespersen-1993" NAME="Jespersen 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jespersen B, Brock A, Pedersen EB</AU>
<TI>Lack of effect of calcium carbonate supplementation on 24th blood pressure, angiotensin II reactivity and PTH (1-84) in essential hypertension (letter)</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>103-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1985" NAME="Johnson 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson NE, Smith EL, Freudenheim JL</AU>
<TI>Effects on blood pressure of calcium supplementation of women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1985</YR>
<VL>42</VL>
<PG>12-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kromhout-1985" NAME="Kromhout 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kromhout D, Bosschieter EB, Coulander CD</AU>
<TI>Potassium calcium alcohol intake and blood pressure: the Zutphen Study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1985</YR>
<VL>41</VL>
<PG>1299-1304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kynast_x002d_Gales-1992" NAME="Kynast-Gales 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kynast-Gales SA, Massey LK</AU>
<TI>Effects of dietary calcium from dairy products on ambulatory blood pressure in hypertensive men</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1992</YR>
<VL>92</VL>
<PG>1497-1501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyle-1987" NAME="Lyle 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyle RM, Melby CL, Hyner GC</AU>
<TI>Blood pressure and metabolic effects of calcium supplementation in normotensive white and black men</TI>
<SO>JAMA</SO>
<YR>1987</YR>
<VL>257</VL>
<PG>1772-1776</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyle-1988" NAME="Lyle 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyle RM, Melby CL, Hyner GC</AU>
<TI>Metabolic differences between subjects whose blood pressure did or did not respond to oral calcium supplementation</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1988</YR>
<VL>47</VL>
<PG>1030-1035</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacGregor-1987" NAME="MacGregor 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacGregor GA, Cappuccio FP, Markandu ND</AU>
<TI>Sodium intake high blood pressure and calcium channel blockers</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>82</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meese-1987" NAME="Meese 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meese RB, Gonzales DG, Casparian JM, Ram CV, Pak CM, Kaplan NM</AU>
<TI>The inconsistent effects of calcium supplements upon blood pressure in primary hypertension</TI>
<SO>American Journal of Medical Science</SO>
<YR>1987</YR>
<VL>294</VL>
<PG>219-224</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-1992" NAME="Morris 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris CD, McCarron DA</AU>
<TI>Effect of calcium supplementation in an older population with mildly increased blood pressure</TI>
<SO>American Journal of Hypertension</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>230-237</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-1993" NAME="Pan 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan WH, Wang CY, Li LA</AU>
<TI>No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese</TI>
<SO>Chinese Journal of Physiology</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>85-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1994" NAME="Petersen 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen LJ, Rudnicki M, Hojsted J</AU>
<TI>Long-term oral calcium supplementation reduces diastolic blood pressure in end stage renal disease: a randomized double-blind placebo controlled study</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacks-1994" NAME="Sacks 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, Cutler JA, Kirchner KA, Kuller LH, Roth KJ, et al</AU>
<TI>Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention</TI>
<SO>Journal of Hypertension</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>209-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1995" NAME="Schneider 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider RH, Staggers F, Alexander C, Sheppard W, Rainforth M, Kodwani K, et al</AU>
<TI>A randomized controlled trial of stress reduction for hypertension in older African Americans</TI>
<SO>Hypertension</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>820-827</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siani-1987" NAME="Siani 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siani A, Strazzullo P, Guglielmi S, Mancini M</AU>
<TI>Clinical studies of the effects of different oral calcium intakes in essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>S311-S313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siani-1988" NAME="Siani 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siani A, Srazzullo P, Guglielmi S, Pacioni D, Giacco A, Lacone R</AU>
<TI>Controlled trial of low calcium versus high calcium intake in mild hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>253-256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomsen-1987" NAME="Thomsen 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomsen K, Nilas L, Christiansen C</AU>
<TI>Dietary calcium intake and blood pressure in normotensive subjects</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1987</YR>
<VL>222</VL>
<PG>51-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOHP-1992" NAME="TOHP 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trials of Hypertension Prevention Collaboration Research Group</AU>
<TI>The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<PG>1213-1220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Beresteyn-1986" NAME="van Beresteyn 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Beresteyn ECH, Schaafsma G, de Waard H</AU>
<TI>Oral calcium and blood pressure: a controlled intervention trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1986</YR>
<VL>44</VL>
<PG>883-888</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinson-1987" NAME="Vinson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinson JA, Mazur T, Bose P</AU>
<TI>Comparison of different forms of calcium on blood pressure of normotensive young males</TI>
<SO>Nutrition Reports International</SO>
<YR>1987</YR>
<VL>36</VL>
<PG>497-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-1995" NAME="Yamamoto 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto ME, Applegate WB, Klag MJ, Borhani NO, Cohen JD, Kirchner KA et al, Trials of Hypertension Prevention (TOHP) Collaborative Research Group</AU>
<TI>Lack of blood pressure effect with calcium and magnesium supplementation in adults with high-normal blood pressure: Results from Phase I of the Trials of Hypertension Prevention (TOHP)</TI>
<SO>Annals of Epidemiology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>96-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zemel-2005" NAME="Zemel 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zemel MB, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E</AU>
<TI>Dairy augmentation of total and central fat loss in obese subjects</TI>
<SO>International Journal of Obesity</SO>
<YR>2005</YR>
<VL>29</VL>
<PG>391-397</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-1994" NAME="Zhou 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou C, Fan S, Zhou L, Yanping N, Huang T, Shi Y</AU>
<TI>Clinical observation of treatment of hypertension with calcium</TI>
<SO>American Journal of Hypertension</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>363-367</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-1987" NAME="Zoccali 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali C, Mallamaci F, Delfino D, Parlongo S, Iellamo D, Moscato D et al</AU>
<TI>Does calcium have a dual effect on arterial pressure? Response to 1,25 dihydroxy vitamin D3 and calcium supplements in essential hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>S267-S269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Allender-1996" NAME="Allender 1996" TYPE="JOURNAL_ARTICLE">
<AU>Allender PS, Cutler JA, Follman D, Cappucio FP, Pryer J, Elliott P</AU>
<TI>Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<PG>825-831</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Australian-1989" NAME="Australian 1989" TYPE="JOURNAL_ARTICLE">
<AU>Australian National Health and Medical Research Council Dietary Salt Study Management Committee</AU>
<TI>Effects of replacing sodium intake in subjects on a low sodium diet: a crossover study</TI>
<SO>Clinical and Experimental Hypertension</SO>
<YR>1989</YR>
<VL>A11</VL>
<PG>1011-1024</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2004" NAME="BNF 2004" TYPE="COMPUTER_PROGRAM">
<TI>British National Formulary 47</TI>
<YR>2004</YR>
<PB>British Medical Association and Royal Pharmaceutical Society of Great Britain</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1997" NAME="Brown 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brown MJ</AU>
<TI>Science, Medicine and the Future: Hypertension</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1258-1261</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruce-1999" NAME="Bruce 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bruce MP, Saty BM, Furberg CD</AU>
<TI>British guidelines on managing hypertension.</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>589-590</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1996" NAME="Bucher 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Cook RJ, Guyatt GH, Lang J, Cook DJ, Hatala R, Hunt DL</AU>
<TI>Effects of Dietary Calcium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Control Trials</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<PG>1016-1022</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burgess-1999" NAME="Burgess 1999" TYPE="JOURNAL_ARTICLE">
<AU>Burgess E, Lewanczuk R, Bolli P, Chockalingam A, Cutler H, Taylor G, Hamet P</AU>
<TI>Recommendations on potassium, magnesium and calcium</TI>
<SO>Can Med Assoc J</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>S35-S45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cappuccio-1989" NAME="Cappuccio 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cappuccio FP, Siani A, Strazzullo P</AU>
<TI>Oral calcium supplementation and blood pressure: an overview of randomized controlled trials</TI>
<SO>J Hypertens</SO>
<YR>1989</YR>
<VL>7</VL>
<PG>941-946</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cappuccio-1995" NAME="Cappuccio 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cappuccio FP, Elliott P, Allender PS, Pryer J, Follman DA, Cutler JA</AU>
<TI>Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>142</VL>
<PG>935-945</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook" NAME="Cochrane Handbook" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins, JPT, Altman DG, editors</AU>
<TI>Analysing and presenting results</TI>
<SO>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8</SO>
<YR>2005</YR>
<PB>The Cochrane Library, Issue 3, 2005. John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002" NAME="Curtin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials</TI>
<SO>Stats in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2131-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cutler-1990" NAME="Cutler 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cutler JA, Brittain E</AU>
<TI>Calcium and blood pressure. An epidemiologic perspective</TI>
<SO>Am J Hypertens</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>137S-146S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DASH-1999" NAME="DASH 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vogt TM, Appel LJ, Obarzanek E, Moore TJ, Vollmer WM, Svetkey LP, et al</AU>
<TI>Dietary Approaches to Stop Hypertension: rationale design and methods.</TI>
<SO>J Am Diet Assoc</SO>
<YR>1999</YR>
<VL>99</VL>
<PG>S12-S28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DASH-2000" NAME="DASH 2000" TYPE="JOURNAL_ARTICLE">
<AU>Conlin PR, Chow D, Miller ER, Svetkey LP, Lin PH, Harsha DW, et al</AU>
<TI>The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial.</TI>
<SO>Am J Hypertens</SO>
<YR>2000</YR>
<VL>13</VL>
<PG>949-955</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Systematic reviews: identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-1291</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" NAME="Egger 2003" TYPE="OTHER">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technol. Assess. 2003</SO>
<YR>2003</YR>
<VL>7</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffith-1999" NAME="Griffith 1999" TYPE="JOURNAL_ARTICLE">
<AU>Griffith LE, Guyatt GH, Cook RJ, Bucher HC, Cook DJ</AU>
<TI>The influence of dietary and non-dietary calcium supplementation on blood pressure: an updated meta analysis of randomized controlled trials</TI>
<SO>Am J Hypertens</SO>
<YR>1999</YR>
<VL>12</VL>
<PG>84-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamet-1995" NAME="Hamet 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hamet P</AU>
<TI>The evaluation of the scientific evidence for a relationship between calcium and hypertension</TI>
<SO>J Nutr</SO>
<YR>1995</YR>
<VL>125</VL>
<PG>311S-400S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-JNC-VII-2003" NAME="JNC VII 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al</AU>
<TI>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>2560-2572</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kawano-1998-_x0028_ii_x0029_" NAME="Kawano 1998 (ii)" TYPE="JOURNAL_ARTICLE">
<AU>Kawano Y, Matsuoka H, Takishita S, Omae T</AU>
<TI>Effects of magnesium supplementation in hypertensive patients: assessment by office, home and ambulatory blood pressures</TI>
<SO>Hypertension</SO>
<YR>1998</YR>
<VL>32</VL>
<PG>260-265</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotchen-1998" NAME="Kotchen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kotchen TA, McCarron DA</AU>
<TI>Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association nutrition committee</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<PG>613-617</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Law-2003" NAME="Law 2003" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Wald NJ, Morris JK, Jordan RE</AU>
<TI>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1427-1434</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacMahon-1990" NAME="MacMahon 1990" TYPE="JOURNAL_ARTICLE">
<AU>MacMahon S, Cutler PR</AU>
<TI>Blood pressure stroke and coronary heart disease. Part I prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>765-774</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-613</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2000" NAME="NIH 2000" TYPE="OTHER">
<AU>National High Blood Pressure Education Program Working Group</AU>
<TI>Report on High Blood Pressure in Pregnancy</TI>
<SO>NIH Publication No 00-3029</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowson-1986" NAME="Nowson 1986" TYPE="JOURNAL_ARTICLE">
<AU>Nowson C, Morgan T</AU>
<TI>Effect of calcium carbonate on blood pressure</TI>
<SO>Journal of Hypertension</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>S673-S675</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PSC-2002" NAME="PSC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Prospective Studies Collaboration</AU>
<TI>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>1903-1913</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sunderrajan-1984" NAME="Sunderrajan 1984" TYPE="JOURNAL_ARTICLE">
<AU>Sunderrajan S, Bauer JH</AU>
<TI>Oral calcium supplementation does not alter blood pressure or vascular response in normotensive men</TI>
<SO>Circulation</SO>
<YR>1984</YR>
<VL>70</VL>
<PG>II-130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The world health report 2002: reducing risks, promoting healthy life</SO>
<YR>2002</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Galloe-1993">
<CHAR_METHODS>
<P>Method of randomisation adequate.<BR/>Crossover design.<BR/>Blinding:<BR/>Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 adults (42-75) with treatment naive hypertension (SBP 160-220 and DBP 90-110 mmHg).<BR/>Denmark. Mean age 63 years, 67% male, ?% white.<BR/>Inclusion criteria: without serious disease.<BR/>Baseline BP: 169/97<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=30) 2g/d calcium as calcium gluconate (powdered form)<BR/>C: (n=30) matching placebo<BR/>No washout period<BR/>No carryover effect.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 12 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>10/30 (33%): 4 because of gastro-intestinal symptoms (2 on calcium), 1 started anti-hypertensive medication, 5 reason not given (2 on calcium).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>10/30 (33%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grobbee-1986">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>90 adults (16-29) with currently untreated essential hypertension (SBP &gt;140 and/or DBP &gt;90 mmHg).<BR/>The Netherlands. Mean age 24 years, 86% male, ?% white.<BR/>Baseline BP: 143/83<BR/>I: 143.2/82.3<BR/>C: 143.2/82.8<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D status not reported; mean baseline calcium intake 1411 mg/day in treatment and 1267mg/day in control groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=46) 1g/d calcium as calcium citrate (powdered form)<BR/>C: (n=44) matching placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP and serum calcium at 12 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>I: 5/46 (10.9%)<BR/>C: 5/44 (11.4%).<BR/>No serious adverse effects due to calcium; 5 participants had diarrhoea (2 on calcium).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 0/46 (0%)<BR/>C: 0/44 (0%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kawano-1998">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - no<BR/>Treatment provider - no<BR/>Outcome assessor - no.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 adults (35-74) with currently treated moderate essential hypertension: using calcium anatgonists (n=32), beta-blockers (n=15), ACE inhibitors (n=9) diuretics (n=6), alpha-blockers (n=6) (SBP &gt;140 and/or DBP &gt;90 mmHg). Antihypertensive medication did not vary during trial.<BR/>Japan. Mean age 58 years, 58% male, ?% white. <BR/>Baseline BP: 149/90<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=60) 1g/d calcium as calcium carbonate (powdered form)<BR/>C: (n=60) no treatment.<BR/>No washout period.<BR/>Carryover effects not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP and serum calcium at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>not reported.<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lyle-1992">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 adults with treatment naive hypertension (DBP 85-104 mmHg).<BR/>Inclusion criteria: free from renal disease.<BR/>USA. Mean age 34 years, 76% male, ?% white.<BR/>Baseline BP: 132.6/87.4<BR/>I: 132.4/88.2<BR/>C: 132.7/86.5<BR/>% baseline CVD unclear<BR/>% baseline diabetes unclear.<BR/>Vitamin D status not reported; calcium intake &lt; 1000mg/day, not receiving any medication that affected calcium metabolism.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=22) 1.5g/d calcium as calcium carbonate (3 tablets)<BR/>C: (n=22) matching placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>2/44 (4.5%), not reported by treatment arm.<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 1/22 (4.5%)<BR/>C: 1/22 (4.5%)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Martinez-1989">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - unclear<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>51 adults (34-54) with mild to moderate essential hypertension. Treatment status not reported.<BR/>Spain. Mean age 44 years, 39% male, ?% white.<BR/>Baseline BP: 157/99<BR/>I: 157/99<BR/>C: 157/99<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=31) 1g/d calcium<BR/>C: (n=20) matching placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>I: 0/31 (0%)<BR/>C: 0/20 (0%).<BR/>No serious adverse effects; 3 participants had diarrhoea (2 on calcium).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 0/31 (0%)<BR/>C: 0/20 (0%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McCarron-1985">
<CHAR_METHODS>
<P>Method of randomisation adequate.<BR/>Crossover design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 adults (21-70) with treatment naive and currently untreated essential hypertension (mean arterial pressure &gt;105 mmHg).<BR/>Inclusion criteria: no myocardial infarction in last year, no congestive heart failure, no cerebrovascular accident, no renal disease.<BR/>USA. Mean age 52 years, 52% male, 96% white.<BR/>Baseline BP: 152/94<BR/>0% baseline CVD<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported; not receiving any medication that affected calcium metabolism.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=48) 1g/d calcium as calcium carbonate<BR/>C: (n=48) matching placebo.<BR/>4 week washout period.<BR/>Carryover effects not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP and serum calcium at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>1/49 (0.5%).<BR/>No significant differences in adverse effects between calcium and placebo; 4 participants reported constipation (1 on calcium), 8 participants reported gastro-intestinal symtpoms (4 on calcium), 3 participants reported headache (1 on caclium), 1 participant on calcium reported increased urination and 1 reported flank pain, 1 participant on placebo reported chest pain, 1 reported insomnia, 1 reported atrial tachycardia, 1 reported confusion, 1 reported itching.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>1/49 (0.5%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Morris-1988">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - unclear<BR/>Treatment provider - unclear<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>82 adults with untreated hypertension (mean arterial pressure &lt;105 mm Hg).<BR/>USA. Mean age 45 years, ?% male, ?% white.<BR/>Baseline BP: 138/94<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I1: (n=?) 1.5g/d dietary calcium <BR/>I2: (n=?) 1g/d calcium carbonate<BR/>C: (N=?) matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 12 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>not reported.<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>not reported<BR/>Not included in meta-analysis due to missing data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nowson-1989">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>47 adults (22-77) with DBP &gt;90 mmHg or mean arterial pressure &gt;105 mmHg. Treatment status not reported. <BR/>Australia. Mean age 57 years, 87% male, ?% white.<BR/>Baseline BP: 153/91<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D status not reported; mean baseline calcium intake 720 mg/day.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I1: (n=16) 0.4g/d calcium as calcium carbonate<BR/>I2: (n=14) 0.8g/d calcium as calcium carbonate<BR/>C: (N=17) matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>3/47 (6.4%), not reported by treatment arm, reasons for withdrawal not reported.<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanchez-1997">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Parallel design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 adults (25-56) with previously untreated mild-to-moderate essential hypertension (BP &gt;140/90 mmHg).<BR/>Inclusion criteria: no diagnosed diabetes mellitus.<BR/>Spain. Mean age 45 years, 60% male, ?% white.<BR/>Baseline BP: 166/99<BR/>I: 164.8/99.8<BR/>C: 166.5/98.3 <BR/>0% baseline CVD<BR/>0% baseline diabetes.<BR/>Vitamin D status not reported; all participants received a low calcium diet (~500 mg/day).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=10) 1.5g/d calcium<BR/>C: (n=10) matching placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP and serum calcium at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>I: 0/10 (0%) <BR/>C: 0/10 (0%) <BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>I: 0/10 (0%) <BR/>C: 0/10 (0%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Strazzullo-1986">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 adults with currently treated and treatment naive uncomplicated essential hypertension (DBP 90-104 mmHg). <BR/>Italy. Mean age 43 years, 62% male, ?% white.<BR/>Baseline BP: 145/91<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D status not reported; mean baseline calcium intake 602 mg/day.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=18) 1g/d calcium as calcium lactogluconate and calcium carbonate(2 tablets)<BR/>C: (n=18) matching placebo.<BR/>12 week washout period<BR/>No carryover effect.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP and serum calcium at 15 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>1/18 (5.6%), because of increase in BP while on placebo.<BR/>Adverse effects: no adverse effects on calcium.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>1/18 (5.6%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Takagi-1991">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - unclear<BR/>Treatment provider - unclear<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>9 adults (65-86) with mild-to-moderate essential hypertension, treatment status not reported, not receving any medication which could affect calcium metabolism.<BR/>Japan. Mean age 77 years, 33% male, ?% white.<BR/>Baseline BP: 146/78<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D status not reported; all participants received a diet containing 500 mg/day calcium.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=9) 1g/d calcium as oystershell electrolysate<BR/>C: (n=9) matching placebo.<BR/>Both groups received a diet containing 20 mmol calcium, 87 mmol/d sodium, 76.8 mmol/d potassium.<BR/>4 week washout period.<BR/>Carryover effects not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>BP measurements were average over 24 hours of hourly readings taken after 5 minutes rest in supine position.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>0/9 (0%).<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>0/9 (0%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tanji-1991">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 adults (30-65) with currently untreated mild hypertension (DBP 90-104 mmHg).<BR/>Inclusion criteria: no myocardial infarction in last 6 months, without unstable angina or stable angina treated with a calcium channel blocker, unstable hypertensive end-organ damage or renal disease.<BR/>USA. Mean age 48 years, 33% male, 75% white.<BR/>Baseline BP: 146/95<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=28) 1.2g/d calcium as calcium carbonate<BR/>C: (n=28) matching placebo.<BR/>1 week washout period.<BR/>Carryover effects not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 13 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>9/28 (32.1%): 1 because of lack of consent by primary care physician, 5 participants moved geographically, 1 reported headache, 2 changed their work schedule.<BR/>Adverse effects: no further adverse effects reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>9/28 (32.1%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Weinberger-1993">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 adults (26-68) with currently untreated mild essential hypertension.<BR/>USA. Mean age 45 years, 59% male, ?% white.<BR/>Baseline BP: 131/87<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=17) 1.5g/d calcium as calcium carbonate<BR/>C: (n=17) matching placebo.<BR/>2 week washout period.<BR/>Carryover effects not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>not reported.<BR/>Adverse effects: not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>0/17 (0%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zoccali-1988">
<CHAR_METHODS>
<P>Method of randomisation unclear.<BR/>Crossover design.<BR/>Blinding: Participant - yes<BR/>Treatment provider - yes<BR/>Outcome assessor - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 adults (27-59) with currently untreated and treatment naive uncomplicated essential hypertension (SBP &gt;140 mmHg, DBP &gt;90 mmHg).<BR/>Italy. Mean age 43 years, 70% male, ?% white.<BR/>Baseline BP: 142/87<BR/>% baseline CVD not reported<BR/>% baseline diabetes not reported.<BR/>Vitamin D and dietary calcium status not reported; no patients had been treated with calcium antagonists.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>I: (n=23) 1g/d calcium as calcium gluconate and calcium carbonate<BR/>C: (n=23) matching placebo.<BR/>2 week washout period<BR/>No carryover effect.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BP at 8 weeks.<BR/>Deaths and cardiovascular events not reported.<BR/>Withdrawn:<BR/>2/23 (8.7%), 1 because of poor compliance and 1 because of missing an appointment.<BR/>Adverse effects: during calcium phase, 6 participants reported headache; during placebo phase, 3 participants reported headache, 1 reported diarrhoea. No participants reported flank pain or eliminated renal calculi.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up:<BR/>2/23 (8.7%)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Appel-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belizan-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buonopane-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cappuccio-1987_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cappuccio-1987_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feinlieb-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gruchow-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hebert-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hollis-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jespersen-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kromhout-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kynast_x002d_Gales-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lyle-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lyle-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacGregor-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meese-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Each participant took only 2 of 3 possible treatments</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morris-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pan-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petersen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants had secondary hypertension</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sacks-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siani-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siani-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomsen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TOHP-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Beresteyn-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive; less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yamamoto-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline normotensive</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zemel-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normotensive. Dietary interventions which combined increased calcium intake with a reduced calorie diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhou-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study design uninterpretable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zoccali-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Less than 8 weeks follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Galloe-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Grobbee-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kawano-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lyle-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McCarron-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Morris-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nowson-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Strazzullo-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Takagi-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tanji-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Weinberger-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zoccali-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Calcium vrs control (parallel trials only)</NAME>
<CONT_OUTCOME CHI2="2.870288688285531" CI_END="-0.24366398256059796" CI_START="-6.187871058770422" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.21576752066551" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.5797616333105625" P_Q="1.0" P_Z="0.03395134772412612" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="112" UNITS="" WEIGHT="100.00000000000003" Z="2.1206490427910465">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.493902436347872" CI_START="-5.293902436347883" EFFECT_SIZE="-0.4000000000000057" ESTIMABLE="YES" MEAN_1="138.9" MEAN_2="139.3" ORDER="813" SD_1="13.5" SD_2="10.0" SE="2.4969348799010365" STUDY_ID="STD-Grobbee-1986" TOTAL_1="46" TOTAL_2="44" WEIGHT="36.88223708264774"/>
<CONT_DATA CI_END="-1.2069661919234527" CI_START="-11.39303380807657" EFFECT_SIZE="-6.300000000000011" ESTIMABLE="YES" MEAN_1="124.5" MEAN_2="130.8" ORDER="814" SD_1="5.8" SD_2="10.4" SE="2.5985343854528753" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="34.05451905994278"/>
<CONT_DATA CI_END="2.6971732605828382" CI_START="-10.697173260582838" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="155.0" ORDER="815" SD_1="10.0" SD_2="13.0" SE="3.416987920905326" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="19.694492778362765"/>
<CONT_DATA CI_END="9.403631912792871" CI_START="-12.803631912792873" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-3.0" ORDER="816" SD_1="25.6" SD_2="13.2" SE="5.665222422644959" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="7.164695813611559"/>
<CONT_DATA CI_END="19.419475486710894" CI_START="-20.619475486710883" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="163.5" MEAN_2="164.1" ORDER="817" SD_1="25.9" SD_2="19.3" SE="10.21420579389313" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.2040552654351746"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.200012187977198" CI_END="0.011454924643505393" CI_START="-4.792799551705375" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.390672313530935" ESTIMABLE="YES" I2="23.077103372021178" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.26738381826839375" P_Q="1.0" P_Z="0.05110255370484998" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.7288184051107354" TOTALS="YES" TOTAL_1="138" TOTAL_2="112" UNITS="" WEIGHT="100.0" Z="1.9506175854858754">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.108013031895819" CI_START="-5.90801303189583" EFFECT_SIZE="-1.9000000000000057" ESTIMABLE="YES" MEAN_1="78.8" MEAN_2="80.7" ORDER="818" SD_1="9.9" SD_2="9.5" SE="2.0449421844026316" STUDY_ID="STD-Grobbee-1986" TOTAL_1="46" TOTAL_2="44" WEIGHT="25.413457451066076"/>
<CONT_DATA CI_END="-1.9749177808322043" CI_START="-9.025082219167796" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="81.8" MEAN_2="87.3" ORDER="819" SD_1="4.8" SD_2="6.7" SE="1.7985443849852316" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="30.26221974257196"/>
<CONT_DATA CI_END="2.2853998090548577" CI_START="-6.285399809054858" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="96.0" MEAN_2="98.0" ORDER="820" SD_1="7.0" SD_2="8.0" SE="2.1864686508821305" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="23.075474117803005"/>
<CONT_DATA CI_END="6.572087402161372" CI_START="-3.772087402161373" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-2.0" ORDER="821" SD_1="9.5" SD_2="8.2" SE="2.6388685929732065" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="17.28040191840967"/>
<CONT_DATA CI_END="11.179693354290396" CI_START="-12.379693354290385" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="98.2" MEAN_2="98.8" ORDER="822" SD_1="16.1" SD_2="10.1" SE="6.0101580678048725" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.9684467701492974"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Calcium vrs control (crossover trials only)</NAME>
<IV_OUTCOME CHI2="17.456847377210977" CI_END="0.2829418546078992" CI_START="-4.878898525278378" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="-2.297978335335239" ESTIMABLE="YES" I2="59.901121612954334" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.5483028041133888" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.014676372562245632" P_Q="1.0" P_Z="0.08096807378638612" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="7.181275528487224" TOTALS="YES" TOTAL_1="214" TOTAL_2="214" WEIGHT="100.0" Z="1.7450964939018923">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_DATA CI_END="11.000238290584843" CI_START="-6.600238290584843" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="823" SE="4.49" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="6.342093027982068"/>
<IV_DATA CI_END="0.35195678144806486" CI_START="-4.351956781448065" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="824" SE="1.2" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="20.113212545137756"/>
<IV_DATA CI_END="-1.0560504216439242" CI_START="-6.5439495783560755" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="825" SE="1.4" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="18.969075658455107"/>
<IV_DATA CI_END="1.096324727688713" CI_START="-7.096324727688713" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="826" SE="2.09" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="15.01393271757015"/>
<IV_DATA CI_END="-6.924948383694977" CI_START="-23.075051616305025" EFFECT_SIZE="-15.0" ESTIMABLE="YES" ESTIMATE="-15.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="827" SE="4.12" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="7.178501255746825"/>
<IV_DATA CI_END="7.114669263880397" CI_START="-7.114669263880397" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="828" SE="3.63" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="8.517538660181868"/>
<IV_DATA CI_END="4.213085830991972" CI_START="-8.213085830991972" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="829" SE="3.17" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="10.06382940370908"/>
<IV_DATA CI_END="7.547116444132926" CI_START="-1.547116444132926" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="830" SE="2.32" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.801816731217144"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="14.318427789540863" CI_END="1.0972087805439936" CI_START="-1.6617006658287599" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="-0.28224594264238323" ESTIMABLE="YES" I2="51.11195095656195" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.04028927443973402" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.04579920609125898" P_Q="1.0" P_Z="0.6884038259633364" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.7845542789749558" TOTALS="YES" TOTAL_1="214" TOTAL_2="214" WEIGHT="100.00000000000001" Z="0.4010221379965422">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_DATA CI_END="8.689900957485149" CI_START="-2.089900957485149" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="831" SE="2.75" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="5.299610529959682"/>
<IV_DATA CI_END="0.25237514933263716" CI_START="-2.4523751493326373" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="832" SE="0.69" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="21.912128599964998"/>
<IV_DATA CI_END="1.9403643446946537" CI_START="-1.9403643446946537" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="833" SE="0.99" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="17.917519618158774"/>
<IV_DATA CI_END="1.4107557009842666" CI_START="-3.4107557009842666" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="834" SE="1.23" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="15.022421265036924"/>
<IV_DATA CI_END="-3.39533973998459" CI_START="-18.60466026001541" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="835" SE="3.88" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="2.9417353631520036"/>
<IV_DATA CI_END="3.724349938510675" CI_START="-1.724349938510675" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="836" SE="1.39" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="13.32804817525891"/>
<IV_DATA CI_END="2.0967430955732858" CI_START="-4.096743095573286" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="837" SE="1.58" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.571192788543716"/>
<IV_DATA CI_END="4.998744896346283" CI_START="-0.9987448963462833" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="838" SE="1.53" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="12.007343659924995"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Calcium vrs control (calcium dose subgroups)</NAME>
<IV_OUTCOME CHI2="20.612786868220162" CI_END="-0.60415482434686" CI_START="-4.449225193772657" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_SIZE="-2.526690009059758" ESTIMABLE="YES" I2="41.783708934083805" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.056346366273257176" P_Q="0.8931653277787209" P_Z="0.009998511626133499" Q="0.01803650066971585" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.415203032284206" TOTALS="YES" TOTAL_1="349" TOTAL_2="323" WEIGHT="100.0" Z="2.5758807730709226">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.7597608865556316" CI_END="0.4748418751417507" CI_START="-5.858425299260177" DF="4.0" EFFECT_SIZE="-2.691791712059213" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.3234509886621137" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.4394939062052252" P_Z="0.0957006308617485" STUDIES="5" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="25.551264528116064" Z="1.666064185905021">
<NAME>Calcium dose 1.2 -2g/day</NAME>
<IV_DATA CI_END="-1.213893460118559" CI_START="-11.38610653988144" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="2.595" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="8.629936759773253"/>
<IV_DATA CI_END="19.42103210207665" CI_START="-20.621032102076654" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="10.215" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.8846622794465631"/>
<IV_DATA CI_END="11.000238290584843" CI_START="-6.600238290584843" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="4.49" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="3.915196191579199"/>
<IV_DATA CI_END="7.114669263880397" CI_START="-7.114669263880397" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="3.63" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.469336591670176"/>
<IV_DATA CI_END="4.213085830991972" CI_START="-8.213085830991972" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="3.17" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="6.652132705646872"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="16.834989480994814" CI_END="-0.18078196937098978" CI_START="-5.150447726970196" DF="7.0" EFFECT_SIZE="-2.6656148481705926" ESTIMABLE="YES" I2="58.41993243950423" ID="CMP-003.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.018491796316950304" P_Z="0.03550428899082182" STUDIES="8" TAU2="6.5037087072316995" TOTAL_1="259" TOTAL_2="233" WEIGHT="74.44873547188394" Z="2.1025595498372">
<NAME>Calcium dose &lt;1.2g/day</NAME>
<IV_DATA CI_END="4.490110141427436" CI_START="-5.290110141427436" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.495" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="9.042769811602273"/>
<IV_DATA CI_END="2.703076827126986" CI_START="-10.703076827126985" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="3.42" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="5.971915559619073"/>
<IV_DATA CI_END="9.403195972419407" CI_START="-12.803195972419406" EFFECT_SIZE="-1.7" ESTIMABLE="YES" ESTIMATE="-1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="5.665" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="2.635549476501529"/>
<IV_DATA CI_END="0.35195678144806486" CI_START="-4.351956781448065" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="1.2" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="16.43275772136087"/>
<IV_DATA CI_END="-1.0560504216439242" CI_START="-6.5439495783560755" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="1.4" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="15.09240291668479"/>
<IV_DATA CI_END="1.096324727688713" CI_START="-7.096324727688713" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="2.09" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="10.95455006906228"/>
<IV_DATA CI_END="-6.924948383694977" CI_START="-23.075051616305025" EFFECT_SIZE="-15.0" ESTIMABLE="YES" ESTIMATE="-15.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="4.12" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.498313161477537"/>
<IV_DATA CI_END="7.547116444132926" CI_START="-1.547116444132926" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" SE="2.32" STUDY_ID="STD-Zoccali-1988" TOTAL_1="23" TOTAL_2="23" WEIGHT="9.820476755575582"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="23.129057971489416" CI_END="0.4409120254703168" CI_START="-2.06888696172193" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_SIZE="-0.8139874681258067" ESTIMABLE="YES" I2="48.117212491783775" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.3556480560292467" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.026650071019410637" P_Q="0.9053976738225268" P_Z="0.20361278755031442" Q="0.014124279579391441" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.150945371692465" TOTALS="YES" TOTAL_1="347" TOTAL_2="321" WEIGHT="100.0" Z="1.2713258149636206">
<NAME>Diastolic blood pressure</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.732866938397736" CI_END="2.2534052722206557" CI_START="-3.8226231580916767" DF="4.0" EFFECT_SIZE="-0.7846089429355104" ESTIMABLE="YES" I2="62.73129981990495" ID="CMP-003.02.01" LOG_CI_END="0.3528393060872499" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.0297361441261752" P_Z="0.6127249273209874" STUDIES="5" TAU2="6.760186301772821" TOTAL_1="90" TOTAL_2="90" WEIGHT="31.75682478679454" Z="0.5061876479806378">
<NAME>Calcium dose 1.2 - 2g/day</NAME>
<IV_DATA CI_END="-1.9720648278279023" CI_START="-9.027935172172098" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="1.8" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="7.604256804293594"/>
<IV_DATA CI_END="11.179383547085726" CI_START="-12.379383547085725" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="6.01" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.0711526854343305"/>
<IV_DATA CI_END="8.689900957485149" CI_START="-2.089900957485149" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="2.75" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.220349366841057"/>
<IV_DATA CI_END="3.724349938510675" CI_START="-1.724349938510675" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="1.39" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="10.040087555352097"/>
<IV_DATA CI_END="2.0967430955732858" CI_START="-4.096743095573286" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="1.58" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="8.820978374873459"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="12.38206675351229" CI_END="0.627181156118476" CI_START="-2.1341921128132113" DF="7.0" EFFECT_SIZE="-0.7535054783473677" ESTIMABLE="YES" I2="43.466626861671664" ID="CMP-003.02.02" LOG_CI_END="-0.20260699866020082" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.08867406045315274" P_Z="0.28477945928569093" STUDIES="8" TAU2="1.4985708203768575" TOTAL_1="257" TOTAL_2="231" WEIGHT="68.24317521320546" Z="1.069644308019121">
<NAME>Calcium dose &lt;1.2g/day</NAME>
<IV_DATA CI_END="2.1179261683071107" CI_START="-5.91792616830711" EFFECT_SIZE="-1.9" ESTIMABLE="YES" ESTIMATE="-1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.05" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="6.452268120052673"/>
<IV_DATA CI_END="2.2923211261427188" CI_START="-6.292321126142719" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="2.19" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="5.90094505375029"/>
<IV_DATA CI_END="6.574304919185744" CI_START="-3.774304919185744" EFFECT_SIZE="1.4" ESTIMABLE="YES" ESTIMATE="1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="2.64" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="4.494701945291717"/>
<IV_DATA CI_END="0.25237514933263716" CI_START="-2.4523751493326373" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="0.69" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="15.6046536028638"/>
<IV_DATA CI_END="1.9403643446946537" CI_START="-1.9403643446946537" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="0.99" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="13.09279430917617"/>
<IV_DATA CI_END="1.4107557009842666" CI_START="-3.4107557009842666" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="1.23" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.188827274479326"/>
<IV_DATA CI_END="-3.39533973998459" CI_START="-18.60466026001541" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="3.88" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="2.3826393564708175"/>
<IV_DATA CI_END="4.998744896346283" CI_START="-0.9987448963462833" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" SE="1.53" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="9.126345551120668"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Calcium vrs control (baseline BP subgroups)</NAME>
<IV_OUTCOME CHI2="20.612786868220162" CI_END="-0.6041548243468602" CI_START="-4.449225193772657" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_SIZE="-2.5266900090597586" ESTIMABLE="YES" I2="41.783708934083805" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.056346366273257176" P_Q="0.9870193653970264" P_Z="0.00999851162613349" Q="2.6469762782355133E-4" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.415203032284209" TOTALS="YES" TOTAL_1="349" TOTAL_2="323" WEIGHT="100.0" Z="2.575880773070923">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.852481780187033" CI_END="-0.8610026538854061" CI_START="-4.109185356602337" DF="6.0" EFFECT_SIZE="-2.4850940052438717" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.8271212218964686" P_Z="0.002708427919079062" STUDIES="7" TAU2="0.0" TOTAL_1="221" TOTAL_2="197" WEIGHT="50.4018207368622" Z="2.999027575881311">
<NAME>Higher baseline blood pressure (SBP&gt;145 mmHg)</NAME>
<IV_DATA CI_END="2.703076827126986" CI_START="-10.703076827126985" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="3.42" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="5.971915559619073"/>
<IV_DATA CI_END="9.403195972419407" CI_START="-12.803195972419406" EFFECT_SIZE="-1.7" ESTIMABLE="YES" ESTIMATE="-1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="5.665" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="2.6355494765015295"/>
<IV_DATA CI_END="19.42103210207665" CI_START="-20.621032102076654" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="10.215" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.8846622794465634"/>
<IV_DATA CI_END="11.000238290584843" CI_START="-6.600238290584843" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="4.49" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="3.9151961915792"/>
<IV_DATA CI_END="0.35195678144806486" CI_START="-4.351956781448065" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="1.2" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="16.43275772136087"/>
<IV_DATA CI_END="-1.0560504216439242" CI_START="-6.5439495783560755" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="1.4" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="15.092402916684788"/>
<IV_DATA CI_END="7.114669263880397" CI_START="-7.114669263880397" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="3.63" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.469336591670178"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="17.760040390405305" CI_END="0.7186345034684858" CI_START="-7.372531887636397" DF="5.0" EFFECT_SIZE="-3.3269486920839557" ESTIMABLE="YES" I2="71.84691087357434" ID="CMP-004.01.02" LOG_CI_END="-0.14349193504921207" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.0032626852386898886" P_Z="0.10700392825119542" STUDIES="6" TAU2="17.862098672643473" TOTAL_1="128" TOTAL_2="126" WEIGHT="49.5981792631378" Z="1.6118070744573485">
<NAME>Lower baseline blood pressure (SBP&lt;= 145 mmHg)</NAME>
<IV_DATA CI_END="4.490110141427436" CI_START="-5.290110141427436" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.495" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="9.042769811602273"/>
<IV_DATA CI_END="-1.213893460118559" CI_START="-11.38610653988144" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="2.595" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="8.629936759773253"/>
<IV_DATA CI_END="1.096324727688713" CI_START="-7.096324727688713" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="2.09" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="10.954550069062279"/>
<IV_DATA CI_END="-6.924948383694977" CI_START="-23.075051616305025" EFFECT_SIZE="-15.0" ESTIMABLE="YES" ESTIMATE="-15.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="4.12" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.498313161477538"/>
<IV_DATA CI_END="4.213085830991972" CI_START="-8.213085830991972" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="3.17" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="6.652132705646874"/>
<IV_DATA CI_END="7.547116444132926" CI_START="-1.547116444132926" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" SE="2.32" STUDY_ID="STD-Zoccali-1988" TOTAL_1="23" TOTAL_2="23" WEIGHT="9.820476755575584"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="23.12905797148942" CI_END="0.44091202547031716" CI_START="-2.0688869617219297" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_SIZE="-0.8139874681258064" ESTIMABLE="YES" I2="48.11721249178378" I2_Q="39.23607554453757" ID="CMP-004.02" LOG_CI_END="-0.3556480560292464" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.026650071019410304" P_Q="0.1995434423797081" P_Z="0.20361278755031464" Q="1.645713322438482" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.150945371692466" TOTALS="YES" TOTAL_1="347" TOTAL_2="321" WEIGHT="100.0" Z="1.27132581496362">
<NAME>Diastolic blood pressure</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.015674291716114" CI_END="0.5791529898697632" CI_START="-1.345023516925364" DF="6.0" EFFECT_SIZE="-0.3829352635278004" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.23720669727487886" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.541804418786691" P_Z="0.4353232882898658" STUDIES="7" TAU2="0.0" TOTAL_1="221" TOTAL_2="197" WEIGHT="54.42468451870946" Z="0.7801148411014828">
<NAME>Higher baseline blood pressure (SBP&gt;145 mmHg)</NAME>
<IV_DATA CI_END="2.2923211261427188" CI_START="-6.292321126142719" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="2.19" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="5.90094505375029"/>
<IV_DATA CI_END="6.574304919185744" CI_START="-3.774304919185744" EFFECT_SIZE="1.4" ESTIMABLE="YES" ESTIMATE="1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="2.64" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="4.494701945291718"/>
<IV_DATA CI_END="11.179383547085726" CI_START="-12.379383547085725" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="6.01" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.0711526854343307"/>
<IV_DATA CI_END="8.689900957485149" CI_START="-2.089900957485149" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="2.75" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.2203493668410585"/>
<IV_DATA CI_END="0.25237514933263716" CI_START="-2.4523751493326373" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="0.69" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="15.604653602863802"/>
<IV_DATA CI_END="1.9403643446946537" CI_START="-1.9403643446946537" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="0.99" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="13.092794309176172"/>
<IV_DATA CI_END="3.724349938510675" CI_START="-1.724349938510675" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="1.39" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="10.040087555352098"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="16.467670357334825" CI_END="0.44813058596908917" CI_START="-4.760378028426632" DF="5.0" EFFECT_SIZE="-2.1561237212287714" ESTIMABLE="YES" I2="69.63747821334691" ID="CMP-004.02.02" LOG_CI_END="-0.34859541345299133" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.00562828030194773" P_Z="0.10465343843341841" STUDIES="6" TAU2="6.923418515883491" TOTAL_1="126" TOTAL_2="124" WEIGHT="45.575315481290545" Z="1.6227005281860916">
<NAME>Lower baseline blood pressure (SBP&lt;=145 mmHg)</NAME>
<IV_DATA CI_END="2.1179261683071107" CI_START="-5.91792616830711" EFFECT_SIZE="-1.9" ESTIMABLE="YES" ESTIMATE="-1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.05" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="6.452268120052674"/>
<IV_DATA CI_END="-1.9720648278279023" CI_START="-9.027935172172098" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="1.8" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="7.6042568042935965"/>
<IV_DATA CI_END="1.4107557009842666" CI_START="-3.4107557009842666" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="1.23" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.188827274479326"/>
<IV_DATA CI_END="-3.39533973998459" CI_START="-18.60466026001541" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="3.88" STUDY_ID="STD-Takagi-1991" TOTAL_1="9" TOTAL_2="9" WEIGHT="2.382639356470818"/>
<IV_DATA CI_END="2.0967430955732858" CI_START="-4.096743095573286" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="1.58" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="8.820978374873459"/>
<IV_DATA CI_END="4.998744896346283" CI_START="-0.9987448963462833" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" SE="1.53" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="9.12634555112067"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Calcium vrs control: excluding trials not confirming double blinding</NAME>
<IV_OUTCOME CHI2="10.852514577355013" CI_END="-0.05744683613322055" CI_START="-3.8065313386616006" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_SIZE="-1.9319890873974106" ESTIMABLE="YES" I2="17.06991097916138" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.28595414396298946" P_Q="1.0" P_Z="0.04338041713276198" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.5139879950223878" TOTALS="YES" TOTAL_1="244" TOTAL_2="229" WEIGHT="100.00000000000001" Z="2.0200286375351806">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_DATA CI_END="4.490110141427436" CI_START="-5.290110141427436" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.495" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="11.819761389716831"/>
<IV_DATA CI_END="-1.213893460118559" CI_START="-11.38610653988144" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="2.595" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="11.090342249495224"/>
<IV_DATA CI_END="9.403195972419407" CI_START="-12.803195972419406" EFFECT_SIZE="-1.7" ESTIMABLE="YES" ESTIMATE="-1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="5.665" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="2.721915944728169"/>
<IV_DATA CI_END="19.42103210207665" CI_START="-20.621032102076654" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="10.215" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.8640950589942944"/>
<IV_DATA CI_END="11.000238290584843" CI_START="-6.600238290584843" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="4.49" STUDY_ID="STD-Galloe-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.220398432178089"/>
<IV_DATA CI_END="-1.0560504216439242" CI_START="-6.5439495783560755" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="1.4" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="26.33091626227481"/>
<IV_DATA CI_END="1.096324727688713" CI_START="-7.096324727688713" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="2.09" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="15.551159226194864"/>
<IV_DATA CI_END="7.114669263880397" CI_START="-7.114669263880397" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="3.63" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="6.226532189482058"/>
<IV_DATA CI_END="4.213085830991972" CI_START="-8.213085830991972" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="3.17" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="7.910937737393981"/>
<IV_DATA CI_END="7.547116444132926" CI_START="-1.547116444132926" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="2.32" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.263941509541691"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="14.831411842382572" CI_END="1.0310094658164861" CI_START="-1.7206661629352247" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_SIZE="-0.3448283485593692" ESTIMABLE="YES" I2="39.31798202594982" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.013262652609408893" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.09567216571242876" P_Q="1.0" P_Z="0.6232646407337432" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.773215601035831" TOTALS="YES" TOTAL_1="258" TOTAL_2="256" WEIGHT="100.00000000000004" Z="0.4912287894422976">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_DATA CI_END="2.1179261683071107" CI_START="-5.91792616830711" EFFECT_SIZE="-1.9" ESTIMABLE="YES" ESTIMATE="-1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.05" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="8.246095899271829"/>
<IV_DATA CI_END="-1.9720648278279023" CI_START="-9.027935172172098" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="1.8" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="9.829284801302935"/>
<IV_DATA CI_END="6.574304919185744" CI_START="-3.774304919185744" EFFECT_SIZE="1.4" ESTIMABLE="YES" ESTIMATE="1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="2.64" STUDY_ID="STD-Nowson-1989" TOTAL_1="44" TOTAL_2="44" WEIGHT="5.636207620240567"/>
<IV_DATA CI_END="11.179383547085726" CI_START="-12.379383547085725" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="6.01" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.3003962079150782"/>
<IV_DATA CI_END="8.689900957485149" CI_START="-2.089900957485149" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="2.75" STUDY_ID="STD-Galloe-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.278258895059836"/>
<IV_DATA CI_END="1.9403643446946537" CI_START="-1.9403643446946537" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="0.99" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="17.897085206787736"/>
<IV_DATA CI_END="1.4107557009842666" CI_START="-3.4107557009842666" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" SE="1.23" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="14.995310541535318"/>
<IV_DATA CI_END="3.724349938510675" CI_START="-1.724349938510675" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" SE="1.39" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="13.298819646871898"/>
<IV_DATA CI_END="2.0967430955732858" CI_START="-4.096743095573286" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" SE="1.58" STUDY_ID="STD-Weinberger-1993" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.54116166826858"/>
<IV_DATA CI_END="4.998744896346283" CI_START="-0.9987448963462833" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="1.53" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="11.977379512746245"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Calcium vrs control: excluding trials not reporting SD</NAME>
<IV_OUTCOME CHI2="5.105002918971438" CI_END="-1.2312548479584307" CI_START="-4.275109451890524" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="-2.753182149924477" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.530418164281056" P_Q="1.0" P_Z="3.917277340990903E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="221" WEIGHT="100.0" Z="3.5455950161086713">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in SBP</EFFECT_MEASURE>
<IV_DATA CI_END="4.490110141427436" CI_START="-5.290110141427436" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.495" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="9.686135361911365"/>
<IV_DATA CI_END="-1.213893460118559" CI_START="-11.38610653988144" EFFECT_SIZE="-6.3" ESTIMABLE="YES" ESTIMATE="-6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="2.595" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="8.953996277305517"/>
<IV_DATA CI_END="2.703076827126986" CI_START="-10.703076827126985" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="3.42" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="5.155127627413759"/>
<IV_DATA CI_END="19.42103210207665" CI_START="-20.621032102076654" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="10.215" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.5778496997019517"/>
<IV_DATA CI_END="11.000238290584843" CI_START="-6.600238290584843" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="4.49" STUDY_ID="STD-Galloe-1993" TOTAL_1="23" TOTAL_2="23" WEIGHT="2.990879746691846"/>
<IV_DATA CI_END="0.35195678144806486" CI_START="-4.351956781448065" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="1.2" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="41.87252415366826"/>
<IV_DATA CI_END="-1.0560504216439242" CI_START="-6.5439495783560755" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="1.4" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="30.7634871333073"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.449877223215212" CI_END="-0.13569966780369214" CI_START="-2.7367465295268665" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="-1.4362230986652793" ESTIMABLE="YES" I2="19.461759969642497" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.2812369280632937" P_Q="1.0" P_Z="0.030428202461802275" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5871208370184254" TOTALS="YES" TOTAL_1="221" TOTAL_2="208" WEIGHT="99.99999999999999" Z="2.164471227776022">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in DBP</EFFECT_MEASURE>
<IV_DATA CI_END="2.1179261683071107" CI_START="-5.91792616830711" EFFECT_SIZE="-1.9" ESTIMABLE="YES" ESTIMATE="-1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="2.05" STUDY_ID="STD-Grobbee-1986" TOTAL_1="41" TOTAL_2="39" WEIGHT="9.192614448575528"/>
<IV_DATA CI_END="-1.9720648278279023" CI_START="-9.027935172172098" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="1.8" STUDY_ID="STD-Lyle-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="11.504506804095461"/>
<IV_DATA CI_END="2.2923211261427188" CI_START="-6.292321126142719" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="2.19" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" WEIGHT="8.178958107533289"/>
<IV_DATA CI_END="11.179383547085726" CI_START="-12.379383547085725" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="6.01" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.1994680257888544"/>
<IV_DATA CI_END="19.42103210207665" CI_START="-20.621032102076654" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="10.215" STUDY_ID="STD-Galloe-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.41959147836532024"/>
<IV_DATA CI_END="0.25237514933263716" CI_START="-2.4523751493326373" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="0.69" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="41.41109370377301"/>
<IV_DATA CI_END="1.9403643446946537" CI_START="-1.9403643446946537" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="0.99" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="28.09376743186853"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Calcium vrs control: (parallel trials)</NAME>
<DICH_OUTCOME CHI2="0.006983688006143332" CI_END="0.06133217920035942" CI_START="-0.06361641321067929" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0011421170051599382" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-1.2123116040736797" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9965142454005725" P_Q="0.0" P_Z="0.9714172205799272" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="74" WEIGHT="100.0" Z="0.03583086696775726">
<NAME>Withdrawal from treatment (all causes)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12499867724930908" CI_START="-0.13488010017421026" EFFECT_SIZE="-0.004940711462450592" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="925" O_E="0.0" SE="0.06629682470530325" STUDY_ID="STD-Grobbee-1986" TOTAL_1="46" TOTAL_2="44" VAR="0.004395268966005707" WEIGHT="23.116448184437154"/>
<DICH_DATA CI_END="0.07809033170380202" CI_START="-0.07809033170380202" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="926" O_E="0.0" SE="0.039842738090989725" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" VAR="0.0015874437785872038" WEIGHT="64.00416107949373"/>
<DICH_DATA CI_END="0.17408193796294572" CI_START="-0.17408193796294572" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="927" O_E="0.0" SE="0.08881894735621768" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.007888805409466567" WEIGHT="12.87939073606911"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Calcium vrs control: (parallel trials)</NAME>
<DICH_OUTCOME CHI2="0.44224961549340347" CI_END="0.049119544839742915" CI_START="-0.09300419907620879" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.02194232711823293" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-1.3087456661849646" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.5060386798284451" P_Q="0.0" P_Z="0.5450505507420129" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="64" WEIGHT="100.0" Z="0.6051933294716165">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.047309930510045964" CI_START="-0.12306750626762171" EFFECT_SIZE="-0.03787878787878787" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="928" O_E="0.0" SE="0.04346443050014774" STUDY_ID="STD-Grobbee-1986" TOTAL_1="66" TOTAL_2="44" VAR="0.0018891567187021732" WEIGHT="69.58395642155278"/>
<DICH_DATA CI_END="0.14336638418625752" CI_START="-0.11433412612174142" EFFECT_SIZE="0.01451612903225806" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="929" O_E="0.0" SE="0.06574113410774578" STUDY_ID="STD-Martinez-1989" TOTAL_1="31" TOTAL_2="20" VAR="0.004321896713772616" WEIGHT="30.416043578447212"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Calcium vrs control: (crossover trials)</NAME>
<DICH_OUTCOME CHI2="2.5717956478080297" CI_END="0.08270306227994632" CI_START="-0.093709147913407" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.005503042816730335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="22.233323565010988" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-1.082478409351196" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.27640243473924475" P_Q="0.0" P_Z="0.9026779604131031" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0013601570768473662" TOTALS="YES" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="0.12227912925473551">
<NAME>Gastro-intestinal effects (including diarrhoea)</NAME>
<GROUP_LABEL_1>Calcium</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.25308878379175814" CI_START="-0.05308878379175813" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="930" O_E="0.0" SE="0.07810795759478384" STUDY_ID="STD-Galloe-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.00610085303962855" WEIGHT="27.14585218637368"/>
<DICH_DATA CI_END="0.09038323846362385" CI_START="-0.1737165717969572" EFFECT_SIZE="-0.04166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="931" O_E="0.0" SE="0.06737363858309811" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" VAR="0.004539207175925926" WEIGHT="34.33174645686304"/>
<DICH_DATA CI_END="0.07474057197889145" CI_START="-0.16997866721698668" EFFECT_SIZE="-0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="932" O_E="0.0" SE="0.062429524503050116" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" VAR="0.0038974455296769345" WEIGHT="38.52240135676328"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Calcium vrs control</NAME>
<IV_OUTCOME CHI2="7.926908650178998" CI_END="0.06186448326428737" CI_START="0.01812978649155746" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.03999713487792241" ESTIMABLE="YES" I2="11.69319202584815" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-1.2085586102560784" LOG_CI_START="-1.7416073104154914" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.3979711174538885" NO="1" P_CHI2="0.3390832732236341" P_Q="1.0" P_Z="3.371668183412284E-4" Q="0.0" RANDOM="YES" SCALE="0.5" SHOW_PARTICIPANTS="YES" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.1834366080402976E-4" TOTALS="YES" TOTAL_1="251" TOTAL_2="236" WEIGHT="99.99999999999997" Z="3.584931399108248">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Net decrease Ca</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Net increase Ca</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD in serum Ca</EFFECT_MEASURE>
<IV_DATA CI_END="0.08546698076248353" CI_START="-0.025466980762483535" EFFECT_SIZE="0.03" ESTIMABLE="YES" ESTIMATE="0.03" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.0283" STUDY_ID="STD-Grobbee-1986" TOTAL_1="46" TOTAL_2="44" WEIGHT="13.54160517130933"/>
<IV_DATA CI_END="0.10546698076248354" CI_START="-0.005466980762483531" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.0283" STUDY_ID="STD-Nowson-1989" TOTAL_1="30" TOTAL_2="17" WEIGHT="13.54160517130933"/>
<IV_DATA CI_END="0.0813134032853379" CI_START="-0.2013134032853379" EFFECT_SIZE="-0.06" ESTIMABLE="YES" ESTIMATE="-0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" SE="0.0721" STUDY_ID="STD-Sanchez-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.341259364065217"/>
<IV_DATA CI_END="0.09390737693254293" CI_START="0.026092623067457063" EFFECT_SIZE="0.06" ESTIMABLE="YES" ESTIMATE="0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" SE="0.0173" STUDY_ID="STD-Kawano-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="29.805785459966803"/>
<IV_DATA CI_END="0.0613468727161037" CI_START="-0.0613468727161037" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" SE="0.0313" STUDY_ID="STD-McCarron-1985" TOTAL_1="48" TOTAL_2="48" WEIGHT="11.336537065421604"/>
<IV_DATA CI_END="0.3079772808327741" CI_START="0.012022719167225915" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" SE="0.0755" STUDY_ID="STD-Strazzullo-1986" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.139331257763989"/>
<IV_DATA CI_END="0.07155123647224915" CI_START="-0.011551236472249149" EFFECT_SIZE="0.03" ESTIMABLE="YES" ESTIMATE="0.03" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" SE="0.0212" STUDY_ID="STD-Tanji-1991" TOTAL_1="19" TOTAL_2="19" WEIGHT="21.92366592085122"/>
<IV_DATA CI_END="0.14192231087492854" CI_START="-0.04192231087492854" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" SE="0.0469" STUDY_ID="STD-Zoccali-1988" TOTAL_1="21" TOTAL_2="21" WEIGHT="5.370210589312492"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 1. Flow chart.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/wAALCALQAhwBAREA/8QAHwAAAQUBAQEB
AQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1Fh
ByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZ
WmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXG
x8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/9oACAEBAAA/APf6KKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK4zxDreo2PxF8GaTbXGyy1H7d9qi2KfM8uEMnJGRgnPB
Ge9cj44+MNpF4d1geG5b5Lq3lS3ttWW1ElnLMHQvGjnILbC55GCFJBPyk9X4o+JejeF9VfTHttR1
K8ht2urqLTYBMbWIY+eXLAKMHPsME4BGX638SND0KPRZZY766j1uJ5bA2luXMuFVlXaSG3PvRVGO
p52jmuV8XfFdj4F1m50Oz1jTdZsri3hkjvLFVe1Eh3LJIrblCMqsoJycleBkGtDxF49utK1K8ubd
dSynhgammkS6en7uRpQoklYOHBXOHToFVjnIxWH4E8UeJb7WPDR1zxDqsiawZwllcaHBbpL5cCyF
xKG3GP5xtYL820ggCurh+LHh668QRaZBDqU1tLeiwj1SO23Wb3BGRGJAckk8dMd/u/NUmt/E3S9E
u7yGHSNc1WGx3LeXem2fmwW7qMujyFgAyjBb0zycggZ9h48uNT+Ltvo1mt9JodzoqXMLfZQEZ2xI
s+4jcIyhEfP8fGM80uj/ABIsNP8Ah3o2sarfX+q3moSvDbRpZxx3V44mZMLCjFRjgfe9P4mAN9fi
loLeEtS8Q+VequmSrDe2Dxqt3buZAgDIWwMk569iOoIEmi/EvSda1610lNP1i0N8kj2F1d2ZihvV
QbiYmJyQV+YEgcdcEgHb8TeJdL8I6HNq2q3Ait4/lVV5eVz0RB3Y4P5EkgAkcpP8VrKTw54hubLT
dSg1nSbcytpl/bbJwCBtlaMNkxAsCxByFBJxlcyfCnUfEOt+H5NU17U7668/y/Jiu9MjtNnybmeM
of3sbb1AYgfcPAzUEPxIsNC0/Vr/AFu/vrq1j8STaUr/AGOOP7KAMhcIxLxqAfn++c/drW0L4i6Z
rOoXlhc2Gq6LdWtp9tdNXtvs+YAcNIDkgKD1Jx14zg4g0D4o6H4i1y20y1tNVhW9877DeXNoUgvP
K+/5bZycAE8gYxg4OBVDwD49l1Dw94Rh1t57nVte+27J0jRUHkOxO4DGPlAAwDnHPrXRS+ONGt7/
AMQ215K9ovh9IHvLiYARkSpuXZgkse2MAkkAZzXI2fxNbxD498Jafpkepafa3q3Ut1a39osbTxeT
vhlVucoWV8FW52nPGM68PxY8PXXiCLTIIdSmtpb0WEeqR226ze4IyIxIDkknjpjv935queIviPon
h3WxpEyX13cpF9ou/sMBmFjDxmSbByq4OeASBzjlcnwv1vUfEXw50rVdVuPtF9P53mS7VTdtmdRw
oAHAA4FR2HxL0bUdevdIhtdSV9PuJ4L66kgAt7URBj5kkm7Co2xwpPOVOQOMx6B8UdD8Ra5baZa2
mqwre+d9hvLm0KQXnlff8ts5OACeQMYwcHArkfC3xB1jVvE+taxrOo32keHNLln8y2uNKRYVRQqL
G8+4uLjc6sYwDkjA6gDtvCfxD0vxZqDWFvYarYXX2Rb2JL+28rz4GOPMQgkFckc8ZzxnBxU0P4s+
HtcsLjUUh1G1062t2muL27t9sETK4XySwJBlIZWCrnIYd+Kt+E/iHpfizUGsLew1Wwuvsi3sSX9t
5XnwMceYhBIK5I54znjODjEg+Nvh64sItRTS9e/s7eEub0WOYbRi+3EjhiM4Kthd3Dr34rX8UfEv
RvC+qvpj22o6leQ27XV1FpsAmNrEMfPLlgFGDn2GCcAjMmsfEnQ9Ii0ryI77VbrVYhcWdnp1uZZ5
ISpYSbCQQuB3568fK2Cf4kaJF4N07xPEl9c22oypb2ttBAWnlmYlfLC5xuBV++Dt4JyM2/C3jOx8
VyX8EFlqNheae6Lc2moW/kyoHXcjYyRggHHOeOmCCenooooooooooooooooooooooooooooooorh
vEtjd3HxQ8CXkNpPJbWv9oefMkZKRboFC7mHC5PAz1rzLULfxPp/wjvvh2fB+q3N7Zy/Ne2yGS2l
h+0CUPGwGXYlguwDIGWONrKNbxfoWqab8StX1WWHxgdM1WKF4ZvCs3zh4kVCkyY+pBz34zltuppP
ha90TW/hlappd3FBYJqTXIMv2gWxlTcqySqirklsdAM8AtjJy/G+havdf8LU+zaVfT/bv7J+y+Xb
u32jZt37MD5tvfGcd60/EdnqWs+KNW1S30jUVgvfAk0MayW7BhM7lhCcZHm4P3Mk1Ys9K1JdY+Ej
tp90FsdNnjuyYWxbsbSNQJOPkJYEYOORiq/gPUvEXhGw0zwNP4P1Ke5tr14ZNRQ4svs7u0hmEpGC
QG+5wTjGQx21zPirTtZ1a+8V2utaD4t1m8M9w2kRRsV02GIJ+6lG04Mqpu+XncTtI3sa6Xwpaajp
vj/wo9xpGpCB/B1vYSTi2by7eZT5hWRjwpwmMdcsoxzWLoOkeINA8JfD7XzoF9ctoct8l7pyRst2
EuJGUOsZGWwOccZyOgywNe0jxBr/AIS+IOvjQL62bXJbFLLTnjZrspbyKpdowMrkc45xg9Rhj3/i
Wxu7j4oeBLyG0nktrX+0PPmSMlIt0ChdzDhcngZ60nxN0zVL7RNMv9Js/ttxo+qwam1or7XnSLdl
U4OW5HHscZOAeVuodZ8Xan4s8SJ4f1HTrMeGJ9Itbe+iKXVzK2ZMrEATjJ29Tk4xk5C+i+DIJbXw
N4ft7iKSGaLTbdJI5FKsjCJQQQeQQeMV5d/YWsf9Aq+/5KT9u/493/49/wDnt0/1f+10966PxJ4f
1LWfiTqyW9s6wXng6awju5EYQCZ5jhS4BGcHOOTjnFSeBPEmuLFonhe68G6rZtY2htr69ucJBH5K
hEaNsYl3kDgEYzkbgCa4zQrDWvDmg/DbV7jw7rFymkvqaXdra2pa4jMxcR5jODg9c9MY9Rmxc6F4
i8aQfEpl0K70ybVk06Syhvxs81Yhuxu+6HKqMrn5WbaxGCa1odX1rxb8SfBOpS+EtY0q0sUu1uJb
yEqFleDlemQgO0K7Y3kkAAqa4rTvA2rpYt4N1Ox8Zy3CzmJVtr4Jo8ke8P5hdo2CAAlsbWJYDgMd
o9Cuptd8IfErxBqEPhq+1i28QRW32SSyIIjmhTywkxIxGpLZ3ngD1+bbs/CKxu9M+GGj2d9az2tz
H52+GeMxuuZpCMqeRkEH8ayvDvh/Ubnwt8RNMe3ktZtU1fUhbNdI0ausqBUccZKE9wD0OM1xvhPw
vqN3qPh/T9Q07xut1pN3FNOuoXqrpsHkHAaElG39AFRccMcPtBatp/CWtax8P/iHpMNnJDeX3iG5
ubVLlTEJ0EkTgqSMEMEIB6E9wMmmeBdFuNS8XaVq09l43EmmxSPLJ4kvB5cLyR7NkKmPdLnJyfkw
FBPJCl+meEta1P8AZuXw7HZSW+qujstvdKYWyt0ZNpDDgso4zgcjJA5pngXRbjUvF2latPZeNxJp
sUjyyeJLweXC8kezZCpj3S5ycn5MBQTyQpr/ANhax/wy9/ZH9lX39pf8+X2d/O/4/d33Mbvu89On
NbepXuteB/iF4l1dPDOo6zZ65bwPavpqGQxywR7PLlAGUBLZ3c8YwGOQuX480jXZfFejeKJrDxHB
bT6WtleReG7kNeWs25pCrYXEkeTtyMDK5yPlDSJ4ch034ZzLf+DtY1u11DV/ts9pdXQl1CONwB9o
IRFIl+UZjBJG87nxuA3/AIWXPiN7bWLfVYtZOlwTr/Zk+tw+XeOrAs6yfMSwUlQG75OOm1fRqKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKwrjxj
4XtLl7e68R6RBPExSSKW+iVkYdQQWyDTP+E78If9DXof/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqj
/hO/CH/Q16H/AODGH/4qj/hO/CH/AENeh/8Agxh/+Ko/4Tvwh/0Neh/+DGH/AOKo/wCE78If9DXo
f/gxh/8AiqP+E78If9DXof8A4MYf/iqP+E78If8AQ16H/wCDGH/4qj/hO/CH/Q16H/4MYf8A4qj/
AITvwh/0Neh/+DGH/wCKo/4Tvwh/0Neh/wDgxh/+Ko/4Tvwh/wBDXof/AIMYf/iqP+E78If9DXof
/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqj/hO/CH/Q16H/AODGH/4qj/hO/CH/AENeh/8Agxh/+Ko/
4Tvwh/0Neh/+DGH/AOKo/wCE78If9DXof/gxh/8AiqP+E78If9DXof8A4MYf/iqP+E78If8AQ16H
/wCDGH/4qr2ma5pOteY2lanZX4iwJDa3CS7M9M7ScZwfyrSooooooooqCaeK2gknmkWKGNS7yOwV
VUDJJJ6ACsb/AITvwh/0Neh/+DGH/wCKo/4Tvwh/0Neh/wDgxh/+Ko/4Tvwh/wBDXof/AIMYf/iq
P+E78If9DXof/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqj/hO/CH/Q16H/AODGH/4qj/hO/CH/AENe
h/8Agxh/+Ko/4Tvwh/0Neh/+DGH/AOKo/wCE78If9DXof/gxh/8AiqP+E78If9DXof8A4MYf/iqP
+E78If8AQ16H/wCDGH/4qj/hO/CH/Q16H/4MYf8A4qj/AITvwh/0Neh/+DGH/wCKo/4Tvwh/0Neh
/wDgxh/+Ko/4Tvwh/wBDXof/AIMYf/iqP+E78If9DXof/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqj
/hO/CH/Q16H/AODGH/4qj/hO/CH/AENeh/8Agxh/+Ko/4Tvwh/0Neh/+DGH/AOKo/wCE78If9DXo
f/gxh/8Aiq1rK+tdStI7uyuYbq2kBKTQOHRsHHDDg8g1aooooooooooooornvBv/ACBLn/sK6l/6
WzV0NFFFFFFFFFFFFFFFFFFFc/Z/8lD1n/sFWH/o27roKKKKKKKKK5/x3/yT3xL/ANgq6/8ARTV0
FFFFFFFFFFFFFFFFFFFFFc94N/5Alz/2FdS/9LZq6Giiiiiiiiiiiiiue8G/8gS5/wCwrqX/AKWz
Vx+o6QNV1vxhHa+GftWqyXaxWes7bcfYpDZ2+xt7OJV2Md+UUkZyuTxS+M/EGr3Hg/V3V7FLK9/t
HTo4TbuZIvIjuNzmTzAG3C2cAbV2mRTlthD6zeK9Wi8Rvpwh+0/ZLu2srhINLuGExkSJnmE4JjhV
RMW8ttxxH975wRiar4i1zVPh3dfbhp8b6v4YudRQQxORCqRx71JLfMXWbI6eWRg+b1OvN4g1C0vd
RtUl06C7jvRHLLBpVxdSXBFrbMX+zxNvxmTBcvhAsaHcWBGJNqd5rPirRNV0+GCG+vrCyubeK4Yt
Gkj2mqMquQASoJAJABxXa+G/EZ8TNcXtrH5emrFbeWJFxN5kkSztuwSNuyaEDHO4P2wTz0XjHW5d
G8Py3ItLe71eya/D2um3N8sSKsPyGONg+WMu7dkBcBPmOHNa68UXtpr6Xgs5LO71XTNNRopLSW6a
0Yi+mIMMe15CPLKYG3Gdx4Ug6B8ZarFZR+dZRx3V5bsmnia3ki3TrdC2EkqOQ6ROZ7ZwvLBTJkkh
d1yLxTdjxbbac7wT213dy2iCCynCxFI5H3G6P7qRv3RVo1AKsxGT5Z3c5qviLXNU+Hd19uGnxvq/
hi51FBDE5EKpHHvUkt8xdZsjp5ZGD5vU9nc6hrEPiDRdIiNk5uLWa4vJ2jdceU8APlpuP3vNYYLf
LkHLbdr49l4r1XUdcktLWHEMl1dWS7tLuClsYfNUTPcZEcqlogPLXaR5gG7KnPOeBPEmoWehaHpd
taI8NsllbyQWuk3BEgnjikaYzqTFGVE+5gwJYxs2V8wBdiLxjrcujeH5bkWlvd6vZNfh7XTbm+WJ
FWH5DHGwfLGXduyAuAnzHDmxd+LddS3ur1LC1tILLQ7fWbq2ug5nDMJi9uPuhTiLG8j5SDlG3fLP
c+KdSs9K1HXZTpzWFu19FFYtuindrbzh8suSHLeQx2hF2qxOTs+aCPxRr7wXUa28koieEnUDoV3E
sauJMgWrN5spUxxglG488EgBDnqtFvX1LSbe5lkgkkbcrPAGVSVYqco/zRtx80bZKNlSSVyaVn/y
UPWf+wVYf+jbuugoooooooorn/Hf/JPfEv8A2Crr/wBFNXQUUV5NYW1qJlni8O/ZL6XxJOBr5jgV
SBfyFkMisZRvRWhGVAZnVM4YZS/8V6t4i8Ba43k7Le80C4vRI+lXEKWw2KfJMjkLOzI7ASJtA8vd
tYHAtHxpqul6VeG1sYHh0+K9t1hh0i4hgtzaxygSeduMZjZoAojXBXzQu4lDu3tb8Q6rpUumWD+R
Fe3kU9xJLBp1xfpGI2jAjEcRDniUfvDgfJ90bwFp2Pi7XboPf3Fha2lnDe2NpJaOHNxuuY7YlSxw
EMbT5ztO8DbhCNxD4u1W38M2ut3D6cyanbwT2ttFDIZrcTSRIMoGY3ITz1ztEZJUAD94NqjxRr72
QItpIlSd4m1BtCu3EuEjZdtoGEqg75F3lioMB/56KBpa54knsdF0e5tzAZtTmSNZreGW/jjzC8pZ
EiCvMpEeARt4bceAQaH/AAlusLb6eJLSCKbUN9vCbmJ4CkiXKw+c0TsG8t0cSBDtIIWPezSpVTxL
q+pX3gzxHcyTadHp8tvqdlFasrJPuhWdNyybiJCfJZtgRcKxO47Pm2rrxHew/wBrbY4D9k1qy0+P
cp5jm+y7iefvDz3wenC8HnPOHxJqS3Fh4pvbe1lgPhi/1S2ghLRsqk2snkuTuBIAA8wY3ZPyLj5t
C18U63NcxaYixia6uI4oNRn0e5tIlJinkZfIlcM5UW4GQ4H75ePlw2h4Vup7XwXeXlwtpDPFe6lL
IslwVgVhdzk5lK5CA/xbenOO1c5qevarrFhPpwuYBcWl/pM32ibR7i1DCW8CqvkyuG+V4lYuGwwJ
UBSN1eo0UVz3g3/kCXP/AGFdS/8AS2auhooooooooooooornvBv/ACBLn/sK6l/6WzVq21lb2095
NBHskupRLOdxO9wixg89PlRRx6euazLjwjol1JdNPaSSJdJKskJuJfKHmKVkZI92xHYM+XUBjvfn
5jmRfDGli9huTDOZIthw93KySMgASSRC22SQbVw7hm+RTnKjA/hbR5dPhsGs82sNg+mxp5r/AC2z
hAyZznkRpz1468mo38J6PJzsu0lZw7TxX08c7Hy0j5lVw5BWKPIzhigY5IzQvhrTbFbaew0+M3Wn
28cNmslxIqgRRypEpPzcBZ5Bkhj82cEgYseHtPn0vSvIuGQzyXFxcyCMkqjTTPKUBIBYKX27sDOM
4GcCOTwxpT2FjYrDPBDYxiC2a2upYZI4wANnmIwcqQq5BOCVUnJANFx4X0e45+x+SyxQwxtbSPA0
SRb9gjKEGPAlkX5cZVypyOKkXw9pKx2SGxjb7E5eEsSzbiwYliTlyXCuS2cuqufmUERr4Z0pNYi1
NIZ1uI5XnjQXUohSR1ZWcQ7vLDEO+TtySzHqSaH8LaPLp8Ng1nm1hsH02NPNf5bZwgZM5zyI0568
deTVyLS7WK4tJwkjz2tu1tFLJK7sEYoWBLEliTGh3Nk8deTmvD4e0y31Q6jFbyCfe0iqZ5DFG7Z3
OkRbYjnc2WVQTvfJ+Zs17fwjolrJatBaSRpapEscIuJfKPlqFjZ492x3UKmHYFhsTn5RiSTwxpT2
FjYrDPBDYxiC2a2upYZI4wANnmIwcqQq5BOCVUnJANSSeHNJlt7q3Nkiw3dkunzRxkopt1DhYwFI
CgCRx8uDz7DEZ8MaObua5ks/M83eWhlld4AXBDssLExqzBn3MFBO98k7mzGPCekC2eLy7p3d1f7T
JezvcKVBA2zlzIoAZxhWAw7j+Ns6djZQadaR2trH5cKZIBYsSSSWZmOSzEkksSSSSSSTXKya7aab
8RdXE8OoOf7Nsl/0bTriccSXR6xo3HzDnoTkdVONX/hMtM/59dc/8EV7/wDGaP8AhMtM/wCfXXP/
AARXv/xmj/hMtM/59dc/8EV7/wDGaP8AhMtM/wCfXXP/AARXv/xmj/hMtM/59dc/8EV7/wDGaP8A
hMtM/wCfXXP/AARXv/xmj/hMtM/59dc/8EV7/wDGaP8AhMtM/wCfXXP/AARXv/xmj/hMtM/59dc/
8EV7/wDGa888QfFrStWsPF3hmSw1CC6Swuo4ZDbSYkHlNy6FQ8fX+IYHUkV7JRRWWdG09tOm0/7P
/ossrzsodgRI8hlLq2cq28lgQQVOCMYGKieEdESC6tzaSNBdW72rRvcSsscLjDRxAsRChGBtj2j5
V/urguPCOiXUl009pJIl0kqyQm4l8oeYpWRkj3bEdgz5dQGO9+fmObeo6NZav5RulnWSLISa2uZL
eRQcZXfGyttOFJXOCVUkZAxHH4d0mOCS3iso4oZLiC5MceVUSQiMREAHChRDGNowPl6cnMEfhHRY
hMi2khjkTYivPKwt1DBgIMt+4AZUIEe3BRCMbFwHwnpBtki8u6R0dn+0x3s6XDFgAd04cSMCFQYZ
iMIg/gXFy60TT7zT4LB7fybe32/ZxbO0DQbRtHltGVZPlJX5SPlJHQkVX/4RjR/J8k2eVEXlKzSu
XX5/MLKxOVkL4cyAh2ZVYklVIjuPCOiXUl009pJIl0kqyQm4l8oeYpWRkj3bEdgz5dQGO9+fmOZb
3wvo9/qK31zZeZOssc4PmuEEsZUpLsB2+YNqrvxuKjaTt4qK38IaBaXEk8WnRs728lqVkdpFEDlS
YQrEgRfKMRgbVydoG45B4T0gWzxeXdO7ur/aZL2d7hSoIG2cuZFADOMKwGHcfxtm5aaHpen6S2k2
thAmnN5gNrszGRIzM67TxtJZvl6AHAGOKof8IZoohuo3S+l+1eT5sk2o3Mkn7lzJFtkaQsm1yWG0
jk10VFFc94N/5Alz/wBhXUv/AEtmroaKKKKKKKKKKKKK57wb/wAgS5/7Cupf+ls1dDRXG6rrd5be
M/7JsIbKK6u4rWNLyaEuVyL2Q7wGUuoFuQq7lwZGOT0PMaf4t1XTLW7s7ey33VtLeXsttb2Fxe/a
Xe+ux5KSRgCHmIgSOpzvztG0g9Pc+I9Xh1fUW2WX9mWOq2un7drmabz1txnOdqbGn3Zw28fLhMbm
4YJqV5pOraTcHR5D/a9qZJW05j5yyavcoUdTL8yCRN4Gfuuy9TvrqpPFV1bx2traQw2clxdamxkg
0ue8UCC7MfMMJDbn3h2kJxuB4y4xWv8AXdY13TobiSyhsrWHVNJiubOYP58UjyWk5O7gHBlEZQoD
wW3fwV0/ibVrrTvssVpcwQyS73O6xnvpCFx92CEhtvzDMhOFO0YJcEYGleNtX1O2Gr/ZbGHTPtVh
b+Rl3mb7VFbH7+Qq+W1xnO07wMYTG4y6FqWpax4o8PaperaLBe6HdXVssIYNEsj2jeW+SQxUEfOC
N2T8i450rvXNUtvEy2kghtrIyxxxie0mK3CuFG8XK/u4m3MUWJ1LMyAZHmKRmf8ACVa6vh/T9XVt
HlfVltJrOyffC8SzTwIVZst5gCzgGQKu0hTsbdgSN4r1aLxG+nCH7T9ku7ayuEg0u4YTGRImeYTg
mOFVExby23HEf3vnBGZa/EDXLrTra9ttPSYXqW0sQnsLm1itzLcQRiFp3BWYlZ2xIgAHlltrBgBb
u/GGrWupNojvCL2GWZXvYNKuLtJAkdvIALeJy6ZF0BuLkDy/9sBYPFWvavqvg/WYo7KCzC+HBe3t
rdB/MHnxzAxhuNjR+Ux5U7yQv7v71ek0UVz9n/yUPWf+wVYf+jbuugoooooooork/F+mWNj4F8Wz
2tnBDNcabdSTyIgDSt5Tcsep/GusorirrxZfr4suNPtrWSWC1vbezkhTTriUyCRYmaX7Sv7qIIJs
lGBJEZ5G8Y5/wf4sv10nQdPtrWSWC1t9Os5IU064lMgkggZpftK/uoggmyUYEkRnkbxi5rWravq3
wy1W9mutLjj1PQJr63txE4mhjMasyEFz5vyybTINgVtp2MGwNK08Q68PDt1f3v8AZpm/tL+y7cwx
OFLfbDbec6licZIPlhv4D8/z4RkXiDxHceIv+EehfSxdQ/aBcXr28mw7EtJFZYRJnpdbCpk7b93G
w09B8V6j4jvfJ0y303TZ75BetNLbtP8AKLWyfa4V4y75ugA+RhYgNpzkdHq2r36eH7K/sEgZrjyz
LcW8Ul9HCjIW3oke151LbVG3HD7yMKRWXD4j1S9aUW91o8SWFkl5dzTxyLHMGkmQqSWU2xH2dt+8
SFCxUg+WS0E/i3WIbEXEi2sQutYuNNtWhs57pkWF7jMjxRkM5IhC7VIxy5Yg7FLjxhqgt9Kj8iSz
u7xLp2lfR7q4JWCVYwfsyESRiQOsgLH5RhTuJBosfF2u3Qe/uLC1tLOG9sbSS0cObjdcx2xKljgI
Y2nznad4G3CEbjUtfFmsReHo7yzs9LgsrDw3Z6xNCsbjO5Ji0EShsIpEQCsc7MfdfPy69t4j1ebV
9ObZZf2Zfardaft2uJofIW4Gc52vvaDdnC7B8uHzuWe71zVLbxMtpIIbayMsccYntJitwrhRvFyv
7uJtzFFidSzMgGR5ikYOk6nq2laB5LahZC5l1XUm3RaXcXTkLdOG228Tliu8sTIWATKIQxbdU9p4
11fVdPt9Xs7ayhsmutOtZreUu0i/aRbOzq4IBwLgIFKjkb938BuaX4t1DUPEi2y2sj2b3tzZsi6d
cKLcQmRfNa5P7pwzRAbAAQZQMkod3bUVz3g3/kCXP/YV1L/0tmroaKKKKKKKKKKKKK57wb/yBLn/
ALCupf8ApbNXQ0VkX3h/TNRuZbm4gf7TIkaefFNJFIojMhXY6MCh/eyAlSCQ5ByDiqa+CvD0cEdv
Dp/kQJvUwQTSRRyKzs5SRFYLJHud8IwKgOwAAJFaMuiafL9p32+ftN1FeS/O3zTReXsbrxjyY+Bw
dvIOTmlD4S0S2nu5o7WTfdzx3M26eVgZI5mnQqCxCgSsz7VwCWOQc1JP4Y0qeBYvJnh8uWaZZLa6
lgkDSuZJB5iMG2s53Fc7chePlGI5vCGhTTwTNpqJ9neGSKON2SJHiK+W4jUhA6hFXdjOwbM7eKt6
jo1lq/lG6WdZIshJra5kt5FBxld8bK204Ulc4JVSRkDENp4X0ey08WNvZ7LYS283l+a5+eARCI5J
z8ogi+u3nOTlNP8ADGjaVqK39nZ+XcrE0COZXbZExU+UoJIWMFF2oMKvO0DccyTeHtMuNUGoy28h
n3rIyieQRSOuNrvEG2O42rhmUkbEwflXFaLwjosL5W1kIVo2iR7iV1g2SLIqxKWIiQNHGdibVOxQ
QQoAszeHtMuNUGoy28hn3rIyieQRSOuNrvEG2O42rhmUkbEwflXFaLwjosL5W1kIVo2iR7iV1g2S
LIqxKWIiQNHGdibVOxQQQoAlu/DOl3k81w8M8VxNL5zzW13LBIWKIhG+NgwUrFHlQdpKKSMjNR6l
4Q0HVIFtrvTIzbi3Ft5EbtFG0QBCoyIQGCZJTIOwnK7TzW/RRXP2f/JQ9Z/7BVh/6Nu66Ciiiiii
iiuf8d/8k98S/wDYKuv/AEU1dBRWRN4e0y41QajLbyGfesjKJ5BFI642u8QbY7jauGZSRsTB+VcV
7fwjolrJatBaSRpapEscIuJfKPlqFjZ492x3UKmHYFhsTn5RgTwjoiQXVubSRoLq3e1aN7iVljhc
YaOIFiIUIwNse0fKv91cWIvD+mwaN/Y6QSGyLtId88jvvZzIX8xmL7953Bs5BwQQQKLHw/pmnXMV
zbwP9pjSRPPlmklkYSGMtvd2Jc/uowCxJAQAYAxVSPwZoUNslvbWs9sse0LJbXk0MgCxRxBfMRw2
3ZDECucEopIJGav3WiafeafBYPb+Tb2+37OLZ2gaDaNo8toyrJ8pK/KR8pI6EiqcnhHRZREjWkgj
jTY6pPKouFLFiJ8N+/BZnJEm7Jdyc72zYm8P6ZNYmyNvIkQnkuVaKaSORJZHZ3dJFYOpJd87SOGK
9Dio5fDOkz2ltbCCeFbfd5ckF1LDN8xy+ZUYO25sM2WO5gGOSAafH4d0mOCS3iso4oZLiC5MceVU
SQiMREAHChRDGNowPl6cnLE8LaPFp81gtni1msE02RPNf5rZA4VM5zwJH5689eBWRH4VnPi621N7
WyihtLuW6juI55Gd/MjkQoIGGyHJl3OyN+8aMMVy3y7c3h7TLjVBqMtvIZ96yMonkEUjrja7xBtj
uNq4ZlJGxMH5VxXbwjpDI6LHdxFp5bnzIL2eJ1eVt0gV1cMqMwDFAQpIBxkZrEuvBG7ULKCzsbGL
TrWW0lhm+0TeZCLcxlR5JykkhWIR+cWVwj7eQvz9HD4e0y31Q6jFbyCfe0iqZ5DFG7Z3OkRbYjnc
2WVQTvfJ+Zs69Fc94N/5Alz/ANhXUv8A0tmroaKKKKKKKKKKKKK57wb/AMgS5/7Cupf+ls1dDRRR
RRRRRRRRRRRRRRRRXP2f/JQ9Z/7BVh/6Nu66Ciiiiiiiiuf8d/8AJPfEv/YKuv8A0U1dBRRRRRRR
RRRRRRRRRRRRRXPeDf8AkCXP/YV1L/0tmroaKKKKKKKKKKKKK57wb/yBLn/sK6l/6WzV0NFFFFFY
vijxHaeEvDt1rd/FPJa22zekCgudzqgwCQOrDvVbw74v0/xLeanZ2sF/b3WmSrHPDe2zQuVYEo4V
udrAEjOG45AyM0NF8fHW9Xt9OHhLxVYeduzc3+m+VCmFLfM244zjA9yKz9X8QeJbX4t+HdIIhttB
vftKqFKvJdmOASF2yPkUMwUAEElWJ4K1mfE3xZq+j67Y2Wm6td6NYwW4uNSv00wXiIssgjhGCDg7
lkJyVyAcbmwp1Nfl8Q2fxF0G2t/F/k2WrXZ2aX/ZsbYhhh3y/vjz8xUDsR5uRnbSeDpPEK+ONa0r
VfF/9tRabaweZF/ZkdtsmmLMOV64RAeCQfM7Fa9Coooooorn7P8A5KHrP/YKsP8A0bd10FFFFFFF
FFc/47/5J74l/wCwVdf+imroKKKKKKK5jxL4zs/C+oabZXNlqN1PqCTtbx2Nv5zMYkDFdoOcnIAw
CO5KgE0Q+MrK98FxeKtNs9S1C0kUMttaW++4Y79jKEzyVbOcHGFJBI6y+GfFP/CS/av+JDrmlfZ9
n/IVs/I83dn7nJzjbz6ZHrXP+BPEHiTVvF3iuw8RLDA1j9jeCzgKstsJY2coXABdsbdx5G4HbgYr
M0rxdq2ofFyWyn1e7tNGe4uLexsJdNG27a3j2zET44Ak3MMM33CG2ZUNiap4t+Ifh9/E9tc31lqd
5a6Wt632K03x6bI9xtEYIAJxCWk/eAnCg8qGLdj8KvE194n8N389/qEeom01Ka0hvlt/INzEoVld
k6KSH6YGBjPOSe/oooooornvBv8AyBLn/sK6l/6WzV0NFFFFFFFFFFFFFc94N/5Alz/2FdS/9LZq
6Giiiiiud8beGv8AhL/CN9oP2z7H9q8v9/5fmbdsiv8AdyM524696NK8MnS/F3iLXheeb/bP2b9x
5e3yfJjKfeyd2c56DHvWfonwu8HeHtXg1XStH+z30G7y5ftUz7dylTwzkHgkcitDVfDJ1Txd4d14
3nlf2N9p/ceXu87zown3sjbjGehz7VyF/wDDrX/FmjWMOv8Ai2+ieSIxalarDHsuIxP5sZCKdkUw
UKpZd4+XALAEt1//AAjI/wCFg/8ACVfbD/yCv7N+y+V/018zfvz+GMe+aPC3hk+Gv7a/0v7R/aWq
z6j/AKrZ5Xmbfk6nONvXjOegroqKKKKKK5+z/wCSh6z/ANgqw/8ARt3XQUUUUUUUUVz/AI7/AOSe
+Jf+wVdf+imroKKKKKKK53VfDJ1Txd4d143nlf2N9p/ceXu87zown3sjbjGehz7Vn6L4A0+w+HMH
gzVX/tSxTd5jYaHzMzGUcK2RgkdG5x74rQ8NeCvD3g83P9g6d9k+1bPO/fSSbtudv32OMbm6etY+
p+FNYsbzxXrHh/VfK1XW/sYt826MLcwgISxckMpBJJxlRnAY4BLbwDcR+Po/Ed34jvr22tpbieys
Z1B+zvOoVwJCcmMAHagAxxz13Zek/DPXtPsdcs38c3ZTVnkuWktbJbaSO7Z0bzg6sTj5NpQEAhjj
HWuo8GeFn8KaZeQT6jJqN5e3kt9dXLRLEHlkxkqg4UYUcZPOegwB01FFFFFFc94N/wCQJc/9hXUv
/S2auhooooooooooooormYvCtzamdbLxPrFrDLcTXHkRpasqNLI0jYLwM2NzN1Jqb/hHtU/6HPXP
+/Nl/wDI9H/CPap/0Oeuf9+bL/5Ho/4R7VP+hz1z/vzZf/I9H/CPap/0Oeuf9+bL/wCR6P8AhHtU
/wChz1z/AL82X/yPR/wj2qf9Dnrn/fmy/wDkej/hHtU/6HPXP+/Nl/8AI9H/AAj2qf8AQ565/wB+
bL/5Ho/4R7VP+hz1z/vzZf8AyPWZplhq97qGtW7+LtaVbG8W3QiKyywMEMuT/o/XMpH0ArT/AOEe
1T/oc9c/782X/wAj0f8ACPap/wBDnrn/AH5sv/kej/hHtU/6HPXP+/Nl/wDI9H/CPap/0Oeuf9+b
L/5Ho/4R7VP+hz1z/vzZf/I9H/CPap/0Oeuf9+bL/wCR6P8AhHtU/wChz1z/AL82X/yPR/wj2qf9
Dnrn/fmy/wDkej/hHtU/6HPXP+/Nl/8AI9H/AAj2qf8AQ565/wB+bL/5HqXStCbTtQu7+fVL7ULq
5iihaS6EQ2pGZCoAjjQdZX6gnpW3RRRRRRRRVDV9Ni1nR73S7hnWG8ge3kaMgMFdSpwSDzg+lZ3/
AAj2qf8AQ565/wB+bL/5Ho/4R7VP+hz1z/vzZf8AyPR/wj2qf9Dnrn/fmy/+R6P+Ee1T/oc9c/78
2X/yPR/wj2qf9Dnrn/fmy/8Akej/AIR7VP8Aoc9c/wC/Nl/8j0f8I9qn/Q565/35sv8A5Ho/4R7V
P+hz1z/vzZf/ACPR/wAI9qn/AEOeuf8Afmy/+R6P+Ee1T/oc9c/782X/AMj0f8I9qn/Q565/35sv
/kej/hHtU/6HPXP+/Nl/8j0f8I9qn/Q565/35sv/AJHo/wCEe1T/AKHPXP8AvzZf/I9H/CPap/0O
euf9+bL/AOR6P+Ee1T/oc9c/782X/wAj0f8ACPap/wBDnrn/AH5sv/kej/hHtU/6HPXP+/Nl/wDI
9H/CPap/0Oeuf9+bL/5Ho/4R7VP+hz1z/vzZf/I9H/CPap/0Oeuf9+bL/wCR6u6LpaaLpgs0uJ7g
+bLM8s+3e7ySNI5O1VX7znoAK06KKKKKKKKKKKKKKKKKKKKKKK5/w9/yG/Fn/YVj/wDSK1roKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK5/wAPf8hvxZ/2
FY//AEita6Ciiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
iuf8Pf8AIb8Wf9hWP/0ita6Ciiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
iiiiiiiiiiiiiiuf8Pf8hvxZ/wBhWP8A9IrWugoooooooooooooooooooooooooooooooooooooo
oooooooooooooooooornW8YaSs00aR6pN5Urwu9vpF3Mm9GKsA6RlThgQcE8g0v/AAmWmf8APrrn
/givf/jNH/CZaZ/z665/4Ir3/wCM0f8ACZaZ/wA+uuf+CK9/+M0f8Jlpn/Prrn/givf/AIzR/wAJ
lpn/AD665/4Ir3/4zR/wmWmf8+uuf+CK9/8AjNH/AAmWmf8APrrn/givf/jNH/CZaZ/z665/4Ir3
/wCM0jeL9KdSrWmuFSMEHQb3kf8AfmvN/h5psHhTxRr+oXp8RTwPL5enh9IvnzEQCXYeV97AVMnn
5D2Ir0n/AITLTP8An11z/wAEV7/8Zo/4TLTP+fXXP/BFe/8Axmj/AITLTP8An11z/wAEV7/8Zo/4
TLTP+fXXP/BFe/8Axmj/AITLTP8An11z/wAEV7/8Zo/4TLTP+fXXP/BFe/8Axmj/AITLTP8An11z
/wAEV7/8Zo/4TLTP+fXXP/BFe/8Axmj/AITLTP8An11z/wAEV7/8Zo/4TLTP+fXXP/BFe/8Axmre
ma9Y6vPPBafalmgVHkjubOa3cK5YK22VVJBKMMj+6a1qKKKKKKKKq317b6fYXF7dSCO2tommlkIJ
2ooJY4HPABrI/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe/
/GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/
AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/
AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0
z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8A
BFe//GaP+Ey0z/n11z/wRXv/AMZo/wCEy0z/AJ9dc/8ABFe//GaP+Ey0z/n11z/wRXv/AMZo/wCE
y0z/AJ9dc/8ABFe//Ga09M1K11eyS9sXd4GZ0y8TRsGRijKVYBlIZSCCB0q9RRRRRRRRRRRRRXPe
Df8AkCXP/YV1L/0tmqbUPE2nabqJsJhfSXKxLMyWun3FxtRiwUkxIwGSjdfQ1p29xDdW8VxBLHNB
KoeORGDK6kZBBHBBHOar6fqdrqqTyWjySJBcSWzs0ToPMjba4XcBuAYEbhkZBGeDWhRRRRRVO2vb
e5nvIYJN8lrKIpxtI2OUWQDnr8rqePX1zUsMyzrvQSBQ7IQ8bIcqxU8MAcZHB6EYIyCDU9FU7a9t
7me8hgk3yWsoinG0jY5RZAOevyup49fXNR6VqdrrOmW+pWLySWtwm+J3jeMsvY7XAOD1BxyMEcEV
oUUUUVz9n/yUPWf+wVYf+jbuugoooooooorn/Hf/ACT3xL/2Crr/ANFNXQVgQ+LdInvTapJdAi4a
2857GdIPNVzGU85kEed42D5uWwBkkCtTUL6303Trm/u5PLtraJ5pX2k7UUEscDk4APSnwTrc28dw
gkCSIHUSRsjAEZ5VgCp9iAR3qxRRRRRVTUL6303Trm/u5PLtraJ5pX2k7UUEscDk4APSrdVHvrdN
RisGkxcyxSTRptPzIhQMc9ODIn5+xq3VOzvbe/iaW1k8yNZZYidpGHjdo3HPoysPfHHFF5e29hEs
t1J5cbSxRA7ScvI6xoOPVmUe2eeKuUUUUVz3g3/kCXP/AGFdS/8AS2auhooooooooooooornvBv/
ACBLn/sK6l/6WzVlX0euv451ltButNhnXSLM7L62eVZG8272jckilBnOThuvTjnldF1CYanp9jp9
75EdtLZW1hBe6lKl19lSOFZkNnGhjlYH7QjSH7jK+Soiyuekl7pbX1nZ35tk828fTnvdZuYibr7b
dIfLjVXN2wCQExHOSRwTKxbqpJtRt/Bes6lFf3c9xJq80LGe6ZEgtk1B43UOoJiQRbyZACyDnOEQ
LU0JbvWdbsrKXWZ20p4r6SJNN1WedJET7GAv2plV5MSPK25T8uTHuwGSjw3rn29bC81rVb461N9g
NnbW9x5bTwyW9u0kgt8hJI/Me4LvsJVVfBBjXbn6NqerXWmySXGsQW832BZNVVdUuLh0n8yHcJh5
eNP489G2EbNzMARDld9dSkb4X+Jriyupw1taXRguYtQa7jBEO4NBcsA8ihifmblXDqDhRjP8Vzan
pmqvYQ6nsZNPSSwnvtVmt3kvGkm3skUUbC6bIhPk42rlVVQHxS6TBE3xg1ayh1S+jxLNeXNol85E
mIrAxlkLHC7nkxjGQuzJQFKyr3VtZNxexf2kkTq92NMlu9Untz9oF7dJiOKNG+1lVS3HkkEAbFC/
vCDu6pe6/Dfa1p1hLfNJpkV/f2jorSSSu0MZgRgch4/MnuVRccm2UDJjbNay1G7/ALG1aS11OB9N
WWxR5LPWJ9QEKNPi6c3UiqU/ckEhW/dhd/ybgx2/Bcdpex+KIre9u7q0l1LZHcNK6yNGbO3AKyDD
EY+7JklgFbcxO48jZ3R0/wAGadGdSu7a4i8MWlxokX22RDc3zLKzIi7v9IO4W4ERDqoZVCgNg994
PWaSyv7y4vLu5km1K9jAmlLLFHHdTKiIOgAHfk9BnaqheY8N2UmoQeFYb7VdYuP7S0Nr66c6lNGz
yoLYIQY2XaAszggY38M+5gGqpo2uXl/a6deXmqTnxBNLpZtbUXBj8+1kitmuJBbKQki5e6JfYdu1
sEeWNsa3V5a+FvCEt7qkklrfaabq8utS1uXT1a4KQeWvnxqTnaZcR8B8M7bmBY+laGbt9A0xtQk8
y9NrEZ5PLMe+TYNx2lVK5OeCqkdMDpVKz/5KHrP/AGCrD/0bd10FFFFFFFFFcP4r8T6NqPhTxfpV
tqELahaabdpNak7ZFIhbkA9R7jIruK8xgj1JdHe6u7q1OgReIria4jjt2WeFU1CRxIZTIU2LIqM+
UXEe85yoJwRdahqvgrXRfXyNJ/wjtzNqUEOrXFxKt2FRl8yMoq2pBEoMKsA2WXayocSajqOrWltr
kcOp+TeWkWpLIp1e4muxbRxziAm3KlYfu27CfcC2FJYtLhum8XvPo8ujWkt//wAS5orlri51DWZd
PEk+6IpmeNc7iGmIiG1MA4AEagUNOm1hbW41O/1a+l1C21XS7XZveOEedFZLOfJKr9/zX+V1+QnK
qjbia6ay48LRSWWpX1xrUtpbya0jX7GG0czQicTH5ms2CvP9wJtVZDjMa7T7fMNJSW61uyGmG7lW
2X/hILqGBh5cWMaj5YaVlfzsRkkHewz+4wu/4n1G8XwtoNwsk8FvcSx/b31G6OnukZgkYefNEuYG
8wRg7QAWITo2KyP7Rvk0/T9+qztFJE51CS1mkljhsvtirFIJX2MP3RkXzsKXQSTb2MKbq2v39u/h
/wASJc6jfSa48OqxTWSXRZYrdUn8lpLcnEUZRYcSKqlmaPkiRt2zq2tvZahqmny388d5Nr+nfZIQ
7b/szG0V2AH3YS3moW4UsWXO5sHn7PUbx/JvNP1C9u/EK+Fr6a4hbM/kX/8AoxZFUg7ZN4AMA4TC
/Iu75p7TUnLqJdZhTw093Cl3Naa9cXaQ/urhiWvXCGPLrbDYr8fLnHm4fpPC1w0Pw9vblJNSnZJ9
SkV47dRduRczHIiZQPNP90qBu4KjpXGT6ja6hp+p29xqkJ0qzu9HuDJZ+Ip7xIme8ZJGa4bay/Iq
naTtXarjDHNdB4x1KS28Q6zGuq31vdQ6LBNpdrFMyRy3pe52DA4eQlVAiJIkAOUfYNp4k1t7LxjD
HDd+TdC/srdI7nVWid45JIlfybMLsmjKu4MjHcG8zBHlrjL0HV9Rk8Lw3GjapqOoao3hie4ulmZp
5I7xUh+zDy2GEJDS7cKPNA3HzPvVLp891qOq6dZ22tY0u41COJv7M1ue/wAn7LdtIpuZEBG4LD8i
sSm0ONjMrH1iue8G/wDIEuf+wrqX/pbNXQ0UUUUUUUUUUUUVz3g3/kCXP/YV1L/0tmroaKKKrrPC
1y9uJUM6IrvGGG5VYkKSOoBKsAe+0+lDTwrcpbmVBO6M6RlhuZVIDEDqQCygntuHrUd5f2enxCW8
u4LZCWw08gQHapduT6KrMfQKT0FXKrtPCtyluZUE7ozpGWG5lUgMQOpALKCe24etWKKrtPCtyluZ
UE7ozpGWG5lUgMQOpALKCe24etWKqXV9aWe/7VeQwbYnnPmyBcRpje/P8K7lyegyM9at0UUUUVxU
vhzRNW+ImrtqWj6fesNNsnBubZJCGMl0CfmB5IRR9FHoK1f+EE8If9Cpof8A4Lof/iaP+EE8If8A
QqaH/wCC6H/4mj/hBPCH/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H/wCJo/4QTwh/0Kmh/wDguh/+
Jo/4QTwh/wBCpof/AILof/iaP+EE8If9Cpof/guh/wDiaP8AhBPCH/QqaH/4Lof/AImj/hBPCH/Q
qaH/AOC6H/4muH8S/CrwrpOh+Ktdi0+N7trC6lgQqFitj5TY8tFAAxjOTk56Yr1iiiiiiiiiq888
VvGHmljiQuqBnYKCzMFUc9yxAA7kgVYoqvcXENrby3E8scMESl5JHYKqKBkkk8AAc5qxRRWemnQx
61c6mrSefcW8Nu6nG0LG0jKRxnOZWzz2HTvoVQ0jTYtH0ax0yBpHhs7eO3jaQgsVRQoJwAM4HoKv
0Vz3g3/kCXP/AGFdS/8AS2auhooooooooooooornvBv/ACBLn/sK6l/6WzV0NFFZHiXUJtI8Latq
dusZns7Ka4jWQEqWRCwBwQcZHqK4G+v9V0vxteabaald6lczpY2kktqlsLyNdl9PtO/bDv8AkByV
X92w4LYYlxf6qdV0bUbvU7u1uhZ39oIoktpnci8t4EU7coJ33RgncI0kUZAUOrQeJNe1d/Bms2N2
13GUuLyxlF4sHnyRf2VLcASGHMed5GCmPlVQed2d6713XP8AhK7tbZLr7FZ6na2J+a1S0KSLAzmQ
uwmMv75toTgkRjBO4Gv4bv7vUvFHhy9vNSS4nvvDs9+1vsRWtvNe1O0bcHysghdwLfK2Xb+Gxd67
rn/CV3a2yXX2Kz1O1sT81qloUkWBnMhdhMZf3zbQnBIjGCdwNe28TalPBPDLfyQyadbrazSxQRu9
7cPeSWqOinCxuTbPtBJQG4G7Kx/Nkz69rEV1q88zXcN9o+kaqtvJeLAZwRHYzK0gizESGkONoxtC
5Gc56PWvEF1/wk19o9nqM4dYrNY7ewjge485xdSOqtKdiMY4kc+ZkbFIUbnU1zd7q+sSQprv266t
r6y0PXVWN44D89vPHGrSAKQXO1Gbadu6MbQFLBunsdW1STVNOu5L+Rob/WL3TmsjHGIokh+07XQh
d+8/ZlzuZh874A+XbH4P1XWLj/hHjqmpfbTq2itfyDyEjWJ0+zgbAoz8wnJbcTlgCoQfLXdUUUVz
9n/yUPWf+wVYf+jbuugoooooooorn/Hf/JPfEv8A2Crr/wBFNXQUUUUVzPiebVFuLO302W7G9JXk
j05rb7W20oAVFz8hiG4hiPmDNHjgtWZpmu3OptJqra/5dlb3dnaxLFZAQXYnit3DMjAyozNcYX5w
F+TcGw27KtNY8S3OjeF1e81K8utV019Rnk0yG0jlTatuFUCf5Nn70lurFyCu1flC6f4o8SajeQXT
RyKkVxY2832eW0+wHzord5CWZzKz/v32eWxU4iHzZbMVr4h8Q2+l+F7i61Y3U2s2tpczf6PGix5u
rKNlQAfxJcvuJJ+YAp5Y+WpLTxNr+neFrXVbrUI9QuLvwxcavskgVI45YUhKhQmDhvNO/LHJGV2D
5a6PQLq+TxZrOj3Osf2lDZWlpIheONZYnkaYsJDGACxCoR8q/Lt4zlm5XV77VLvwXr8Go6ldiW60
K5u48JbPbzBFUu1rJHkiA7wuJR5hWRCpUqxrXs9Z1WLxLpsIvNRvrK6vZrB7meG2jtyYo5idgTE3
mh4NrFh5ZPmFVAKAYkni7XobbRpk1T7VNq+lw3r2UUUImt3nuLSIeWTgbQJpBH5mfmB3s4GF7bwr
d6ldWt9DqXniS2uvKj+1Pbm4KGKN/wB6ICYw2XbAAHybCRk5PR0UUUVz3g3/AJAlz/2FdS/9LZq6
Giiiiiiiiiiiiiue8G/8gS5/7Cupf+ls1dDRRRWQvhvQ1sXsF0XThZuixvbi1Ty2VXLqCuMEBmZg
OxYnqakl0PSLiK3im0qxkjtomggR7dCIo2XYyKCPlUr8pA4I46VHB4b0O3sjZQ6Jp0VoXZzAlqio
WZDGx2gYyUJUnuCR0qxJpWnTanFqcun2kl/CmyK7aFTKi88K+MgfM3APc+tJbaVp1ncvcW2nWsE0
jyO8kUKqzM5UuSQMksUQk99oz0FLJpWnTanFqcun2kl/CmyK7aFTKi88K+MgfM3APc+tSSWFnLFd
RPaQMl3n7QrRgibKhDvH8XygLz2AHSq+n6HpGkY/s3S7Gyxux9mt0jxu27vugddiZ9dq+gqNfDeh
rYvYLounCzdFje3FqnlsquXUFcYIDMzAdixPU0g8N6EILe3Gi6d5FskqQx/ZU2xLICJAoxgBgSGA
655zVmPStOh1OXU4tPtI7+ZNkt2sKiV144Z8ZI+VeCew9KkhsbS3+z+TaQxfZ4TBBsjC+VGduUXH
3V+ReBx8o9BVuiiiufs/+Sh6z/2CrD/0bd10FFFFFFFFFc/47/5J74l/7BV1/wCimroKKKKKoalp
Onazbrb6nYWt7Arh1juYVlUNgjIDAjOCRn3NEmladNqcWpy6faSX8KbIrtoVMqLzwr4yB8zcA9z6
1HdaFpF7p8GnXmlWVxYwbfJt5bdHjj2jau1SMDAJAx0FSSaVp02pxanLp9pJfwpsiu2hUyovPCvj
IHzNwD3PrSf2VpxS2jOn2uy1VUt18lcRKrIwCcfKA0cZAHdFPYUf2bbJbJFaxx2skNu1tbSwRIGt
0IHEeVIA+VDjBHyrkHFZnhzw3/Yk1xM7WQkkijt1i0+z+ywRxo0jjEe9/mLTSEnODxwCCToRaHo8
P27ytLso/wC0M/bdtug+05znzOPnzubrn7x9ajg8N6FbX0V/b6Jp0N5EgSO4jtUWRFC7AAwGQAvy
49OOlZmm+EEt9Rnub97G6R4p4THFYLD54mMZle4wSssjeVHlgqA/N8uCAu/YWFppllHZ2NpBa20e
dkMEYjRckk4UcDJJP41boooornvBv/IEuf8AsK6l/wCls1dDRRRRRRRRRRRRRXPeDf8AkCXP/YV1
L/0tmroaKKKKKKKKKKKKKKKKKKK5+z/5KHrP/YKsP/Rt3XQUUUUUUUUVz/jv/knviX/sFXX/AKKa
ugoooooooooooooooooooornvBv/ACBLn/sK6l/6WzV0NFFFFFFFFFFFFFc94N/5Alz/ANhXUv8A
0tmroaKKKKKK5X4ieIrzwl4F1HXLBIJLm18rYk6kod0qIcgEHox71X8J+JtY1XxF4l0PWrSygutI
lgKPZyO6NHMhdVJYAllA5bABz90Y55DwX8T9U8ReLrHSbjWfC1xFP5m6Oxtr5Jm2xsw2mVAg5GTk
9M45xWJ8VPGVr/wsrRbG5v5LW00DU7OeeAxORMXPmSS5UkERoIwBt3ZlfGRUvwWjij8Z6jImoTy/
aLCSVZXZ2/tZRdyL9sYEny2XATY3zHcW7nPu9FFFFFFFc/Z/8lD1n/sFWH/o27roKKKKKKKKK5/x
3/yT3xL/ANgq6/8ARTV0FFFFFFFFcT4v8Sa9pfiXw7omhQabLPq63YzfF1VGijDKcpk4ySSMHOMZ
XORQg8fXt58HIvGI/s2wvGQBjdLLJbqwn8piRGC+DgkAZwSMkgE0/wCGfjW+8YnUze6hod39l8rb
/ZUNzHt3b87/AD1Gc7Rjb6HPauG0zw94ai8TeJNMbxTdWmjX2kRySah/aaudSDXJ8y4eb/VqVfMB
UjLBm/vHPbfB6FbXwrqNqpkhaDV7qNtOaRpBpxDD/R1ckhwBhtw4Jc9816LRRRRRRRXPeDf+QJc/
9hXUv/S2auhooooooooooooornvBv/IEuf8AsK6l/wCls1dDRRRRRRWbrWiaf4j0ifSdVt/Psp9v
mRb2TdtYMOVII5APBpLTRdPstW1DVbe28u+1Lyvtcu9j5nlrtTgnAwDjgDPer0cscjyKjqzRttcA
5KnAOD6HBB+hFUdU0TT9aNkdQt/O+xXcd5b/ADsuyZM7W4IzjJ4OR7VQ0HwT4c8Nahd3+j6TBZ3N
1/rXQseM52qCSEXP8K4HA44GOiooooooorn7P/koes/9gqw/9G3ddBRRRRRRRRXP+O/+Se+Jf+wV
df8Aopq6Ciiiiiiisy70XT73VtP1W4tvMvtN837JLvYeX5i7X4BwcgY5Bx2pdF0TT/DmkQaTpVv5
FlBu8uLez7dzFjyxJPJJ5NaVchb/AA18G2g1NINAtETVEKXS/MQVLbsLk/uxuwQE24KqR90Y2NA8
O6T4Y0sabo1ilpaBi+xSWLMepZmJLHoMkngAdAK16KKKKKKK57wb/wAgS5/7Cupf+ls1dDRRRRRR
RRRRRRRXOv4O0nzZpEfVIfNleZkt9Wu4k3uxdiESUKMsxPAHJpf+EN0z/n61z/we3v8A8eo/4Q3T
P+frXP8Awe3v/wAeo/4Q3TP+frXP/B7e/wDx6j/hDdM/5+tc/wDB7e//AB6j/hDdM/5+tc/8Ht7/
APHqP+EN0z/n61z/AMHt7/8AHqP+EN0z/n61z/we3v8A8eo/4Q3TP+frXP8Awe3v/wAeo/4Q3TP+
frXP/B7e/wDx6sPQ/Cmnyav4mRrjWMRakiLt1m7UkfZLdvmIlyxyx5OTjA6AAbn/AAhumf8AP1rn
/g9vf/j1H/CG6Z/z9a5/4Pb3/wCPUf8ACG6Z/wA/Wuf+D29/+PUf8Ibpn/P1rn/g9vf/AI9R/wAI
bpn/AD9a5/4Pb3/49R/whumf8/Wuf+D29/8Aj1H/AAhumf8AP1rn/g9vf/j1H/CG6Z/z9a5/4Pb3
/wCPUf8ACG6Z/wA/Wuf+D29/+PUf8Ibpn/P1rn/g9vf/AI9VrTNAsNHnnuLX7U09wqJJJdXk1wxV
CxUAysxABdjgeprXooooooooqpf2NvqOn3NjdR+bb3MTQzJkjcjAhhkcjIJ6Vk/8Ibpn/P1rn/g9
vf8A49R/whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49R/whumf8
/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1rn/g9vf8A49R/whumf8/Wuf8Ag9vf/j1H
/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49R/whumf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD
29/+PUf8Ibpn/P1rn/g9vf8A49R/whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P
1rn/AIPb3/49R/whumf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1rn/g9vf8A49R/
whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPVpaZptro9illZI6wIzviSV5GLOxdiWcliSzEk
knrV+iiiiiiiiiiiiiiiiiiiiiiiuf8AD3/Ib8Wf9hWP/wBIrWugoooooooooooooooooooooooo
oooooooooooooooooooooooooooooooooooooooooorn/D3/ACG/Fn/YVj/9IrWugooooooooooo
ooooooooooooooooooooooooooooooooooooooooooooooooooooooorn/D3/Ib8Wf8AYVj/APSK
1roKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK5/w9/y
G/Fn/YVj/wDSK1roKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKwrj
xj4XtLl7e68R6RBPExSSKW+iVkYdQQWyDTP+E78If9DXof8A4MYf/iqP+E78If8AQ16H/wCDGH/4
qj/hO/CH/Q16H/4MYf8A4qj/AITvwh/0Neh/+DGH/wCKo/4Tvwh/0Neh/wDgxh/+Ko/4Tvwh/wBD
Xof/AIMYf/iqP+E78If9DXof/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqmt448HshX/hLNEGRjI1GI
H/0KvMfhzrKaX4s8ST694906ezW42W/m6hCBdNtUCY884jWNeOM5HVa9Q/4Tvwh/0Neh/wDgxh/+
Ko/4Tvwh/wBDXof/AIMYf/iqP+E78If9DXof/gxh/wDiqP8AhO/CH/Q16H/4MYf/AIqj/hO/CH/Q
16H/AODGH/4qj/hO/CH/AENeh/8Agxh/+Ko/4Tvwh/0Neh/+DGH/AOKo/wCE78If9DXof/gxh/8A
iqP+E78If9DXof8A4MYf/iqP+E78If8AQ16H/wCDGH/4qr2ma5pOteY2lanZX4iwJDa3CS7M9M7S
cZwfyrSooooooooqrfXtvp9hcXt1II7a2iaaWQgnaigljgc8AGsj/hMtM/59dc/8EV7/APGaP+Ey
0z/n11z/AMEV7/8AGaP+Ey0z/n11z/wRXv8A8Zo/4TLTP+fXXP8AwRXv/wAZo/4TLTP+fXXP/BFe
/wDxmj/hMtM/59dc/wDBFe//ABmj/hMtM/59dc/8EV7/APGaP+Ey0z/n11z/AMEV7/8AGaP+Ey0z
/n11z/wRXv8A8Zo/4TLTP+fXXP8AwRXv/wAZo/4TLTP+fXXP/BFe/wDxmj/hMtM/59dc/wDBFe//
ABmj/hMtM/59dc/8EV7/APGaP+Ey0z/n11z/AMEV7/8AGaP+Ey0z/n11z/wRXv8A8Zo/4TLTP+fX
XP8AwRXv/wAZo/4TLTP+fXXP/BFe/wDxmj/hMtM/59dc/wDBFe//ABmj/hMtM/59dc/8EV7/APGa
P+Ey0z/n11z/AMEV7/8AGaP+Ey0z/n11z/wRXv8A8ZrT0zUrXV7JL2xd3gZnTLxNGwZGKMpVgGUh
lIIIHSr1FFFFFFFFFFFFFc94N/5Alz/2FdS/9LZq6Giiiiiiiiiiiiiiiiiiiufs/wDkoes/9gqw
/wDRt3XQUUUUUUUUVz/jv/knviX/ALBV1/6KaugorA0rxZpGsNbrZPdhblN9u9xYzwJONu4bHkRV
clQWwCSQCegJqRvE+li9mthNOZIt4ylpKySMgJeONwu2SQbWyiFm+RhjKnEen+LNM1W/ays11Izo
xSQS6ZcxLG2wPh2eMKp2kEAkZ3D1Fb9FFU7O9t7+JpbWTzI1lliJ2kYeN2jcc+jKw98ccUXl7b2E
Sy3UnlxtLFEDtJy8jrGg49WZR7Z54q5VO2vbe5nvIYJN8lrKIpxtI2OUWQDnr8rqePX1zUen6na6
qk8lo8kiQXEls7NE6DzI22uF3AbgGBG4ZGQRng1oUUUVUS+t31GWwWTNzFFHNIm0/Kjlwpz05Mb/
AJe4q3RRXPeDf+QJc/8AYV1L/wBLZq6Giiiiiiiiiiiiiue8G/8AIEuf+wrqX/pbNWN4uF5D4w0P
ULEzyTWFhfXLW8OSbiMSWqyR7R99ijMUXgeYseeAazNF8VTW3hzxTPY/ZZ4LC3vdTtZBl1lZ7y+I
yQcMhEKEYx1PPIxpxeIPEd1LAI30q3jvdVu9Nti1vJKV8lpyJX/eLnK25TYO5D7sfu6yE8R6xHqf
iHW40sf+JZpam8DK/wC/+zXN8hWNc/u/M8tjuLPs4G2TORY1Dx9q1vHq11a2fmw2v2+NY2024CQG
2WbEr3OfLkVmhA2KFI80DcShz1t/qV5ovhO/1a+hhlurO0munhgYqh2qzhAxGTgALuwM9dq52jkf
FkusX1hdeH7+bS7iSO70qZ5TYP5Msc155YjaIynOGiDE7sMrFcKfmrQ8X2trd+MdCjvPDv8AbsYs
L0i28uB9p8y1+fEzKvHI4Ofm6YzVew/0jw/4asH/AOPDUtVuY5bM8bLfZdTJauv8Pl7I43jHA8to
zlcgx+KfD3hr/hCfFsVvYWsx063uWjhkt12WEptUfbANoCAjZIdv8Tsc54F/UJz4TuFttG03TtJ0
vYLh3GnSGGaTJDh3hwtsFVUzLIrDD5x+7YHU1jUdYXxDp2k6UbKP7Va3NxJPdI8nl+U8IGEVl3Z8
0jBZeoOfl2tzkvjjVbXStO1C4jtZE1iyjvLVIbaRmtA81vGFdQzG4I+1KfkEZbyyABvG0bxrq/mQ
WTRSQTu85W9bQLxxMkawHK2oIlQZuCu8sRmI/wB8Ba51LUX8QTand2drGl1Z6CW0+5tmL27S3jrg
sWHzxs0hB2jnZwNh3WbTxrro0rRri9h03z9bsoZ7cQo+22Z5raHL5bMgJug+0bNuwpubO8dN4f1H
Ub6XV7bU1tPP0+9Fsj2oYK6+RFJvIYkgkyE7edvAy2Nx5yHxnq62+i3UyWTx63FbXUEaROptY5Lm
1jZGYufMbbdcMAgBTO0hsDQTxHq9z45l0K2jsltopZfMlkVy4jjisn4AOCxNy69gPlbnaVfsq5+z
/wCSh6z/ANgqw/8ARt3XQUUUUUUUUVy3jK+tLrwF4rjtrmGZ4NNuo5ljcMY28puGA6H611NFeZeF
o9Sh0TwDcardWsmlpBD9mNvbNE8Ez2pjiErtIyshV3TICkyNEAPmIGv4Wu4o9I8NaGbSO41TTLeO
K+jYjfpzJAyFzkcFm+RcEb1dmUsgJqO4d44fGrx3n2TbqsJeUllAT7LablZ1BaJWXKmUf6sEv/DR
YajeSfD/AFy50eS4mu7eK4+xPFdHUI3kEQZfImdd067zj5gSHDoPlUCsjTdQuTDO+n6lDOou7NbG
Gy1ifUUknLuJkeaRRlTFjcg3+UqmXZnGRNVt1hhl1TWtVBTS4p7IJcm3ubm/LzfaI1h37ZJg6xL5
Db1jJCbQDg58uuSaPovjESX09s0trf8A9nKjsGadby/3tEBzuUGJnZfurtZiAM1qeJLpX124gu9R
u0vE1zTUtLNZG2SWnmWrF2iwV2ecZP32AdyiPfj5DkaXq+sS6ek02oxo5t4P7bSHVJ7iWFmuLcTN
IrIFsisZucqjLt+Yj/VZXsfAj27v4kezu57u1/tVfJnmJZnT7Lb7cMQC64wFc53LhtzZ3HktDtr+
xj8WtpN9qrzWNrdz2dr9pknVrg3eoRq21yxZsRqNvRm+ZgzYYX/PivPEmn6doev30+gzXcKvcW2p
Pcb5Db3rTReezMw+WOAlQ2VyrLtYhqv6S9xb3ejXS3l88lzrV7psomvJZUaCEXQjXY7FQw+zxZcD
e2CSSWbMeprcyX+vXTanqK+TrtjYwwpdvHHFFMlokoAUjlllfk52n5k2sSxzNVv7mw1q40uS/wBm
iWt3NGsmoa5PZBX8izkRTdKGkdszXBCM3Iz2jUCRZjZajqFzqN/dvq0vh3THuPLupLbfmWVJpCrA
GGIHaXcIrRKzsArMc6/grV9Vvob2OzGnX9hb6n5HmjWZLoRReTA58uZoi053PIfnK4Pyg4Ax31Fc
94N/5Alz/wBhXUv/AEtmroaKKKKKKKKKKKKK57wb/wAgS5/7Cupf+ls1az2Nu+oxX7R5uYopIY33
H5UcoWGOnJjT8vc1hy+AvDMth9gbSUWzKSI1vHI8cbK7s+GVWAYKzuyA58snKbTWrFomnxfZtlvj
7NdS3kXzt8s0vmb268586Tg8DdwBgYzn8FeHpLmS5fT8zSbhIwmkHmK0skrxsA3zRs8rlkOVbIBB
CqBJceEdEupLpp7SSRLpJVkhNxL5Q8xSsjJHu2I7Bny6gMd78/Mc69xbw3VvLbzxRzQSqUkjdQyu
pGCCDwQRxisyDwxpUEDReTPN5ksMzSXN1LPIWicSRjzHYttVxuC525LcfMc6D2Nu+oxX7R5uYopI
Y33H5UcoWGOnJjT8vc1XfRNPktLq0Nv+4upTO6KzALISG3pg/u23APlcHfl/vEmg6Lp76HNo32Ym
wmieGWNnbMivneWbO4s25iWJ3EkknJzUeo+HtM1W4Wa7gkdwgjcJPJGsyAkhJVVgJU5b5XDD5m4+
Y5uPY276jFftHm5iikhjfcflRyhYY6cmNPy9zWefC+jtaWlqbP8AdWVr9jtgJXBiizGRtbOQwMMZ
D53AoCCDUZ8J6QbZIvLukdHZ/tMd7OlwxYAHdOHEjAhUGGYjCIP4FxI/hfR5LqOf7HsMcVvCkcUr
xxhIJfNhHlqQvyOMjjoSOhIqvf8AhezbSbe2sbOAyWNqLSzSaWQKkQaNtodTuVv3Me2TlkZQwyRg
nhXQn0O1v2ligglvbv7S0EErTLGfKjjOZHCtIzeXvZmAJZznJ+YyR+EdFiEyLaSGORNiK88rC3UM
GAgy37gBlQgR7cFEIxsXEmm+GNH0e7N5YWflXDeYWfzXYuZBEHZtxOWbyIyWPJIJJyzE7dcTJoVp
qXxF1czzagh/s2yb/RtRuIBzJdDpG68fKOOgOT1Y51f+EN0z/n61z/we3v8A8eo/4Q3TP+frXP8A
we3v/wAeo/4Q3TP+frXP/B7e/wDx6j/hDdM/5+tc/wDB7e//AB6j/hDdM/5+tc/8Ht7/APHqP+EN
0z/n61z/AMHt7/8AHqP+EN0z/n61z/we3v8A8eo/4Q3TP+frXP8Awe3v/wAeo/4Q3TP+frXP/B7e
/wDx6vOte+E9lpVn4w8StquoSTSWF20MC3EmAvlNxI5YvL06E47EGvZqKKKKKKKKKrrPC1y9uJUM
6IrvGGG5VYkKSOoBKsAe+0+lWKrwTxXEZeGWOVA7IWRgwDKxVhx3DAgjsQRViiiiiiiiue8G/wDI
Euf+wrqX/pbNXQ0UUUUUUUUUUUUVz3g3/kCXP/YV1L/0tmroaKKKxfEt19j0yGXyIJt2oWUWydNy
jfcxJuA/vLu3KezAHtXKWnjXXRpWjXF7Dpvn63ZQz24hR9tszzW0OXy2ZATdB9o2bdhTc2d4TWtX
1HStVmvZ59Our/S9D1SQPArKhZfscih4yxKHkfLvORhsjdgbGta/qtnrF5Y2UCGKGC1ma4FpJctA
JWuAzGGMh5RmGNQFwRvLEkKRWXD4nv7jXIbO0XShfX0VtCL8W8hAI+3M2+Msr8C2I8osDG8jgs23
m5B4h13UrvTrCz/s6GeZdQW4uJondVa1uEh3pGGBIcknYXG3cPmbbh7h8R3l/oPhu6sY4LW513y9
hnUzJb7rd5zlQUL8Rleq/ez2wcfVvEmr/ZPEEEkeiXdrpuiyXNwQrypcSZuozHszgKTACykkphk+
fO9YH1nU9C1bxDiaBmvdfS2iePTZpzD/AKCku4xRuWl+SNEwu3B3OePlCXHivW7vSNcabTbEWtjo
st3NFfWsqNcnddRqDC5BWOQQI+GJKqSvzbty7EXim7Hi22053gntru7ltEEFlOFiKRyPuN0f3Ujf
uirRqAVZiMnyzu7Kiiiiufs/+Sh6z/2CrD/0bd10FFFFFFFFFc/47/5J74l/7BV1/wCimroKKKKK
KKK8qn8VeIFezWzvLox6okE9teXtrb+Qwa7tY8wxxt5giZLhsrKfMA2YYMGNakuq6v8AbrvRI9S1
W5ubS6dEaygtBdzRCG3kLu0oWEKrXG0hVDHMePuuWp2Ov3st7B4kd0jEukaNc6hEi4QxSvdLIdxy
USMyeaT6REEgEkWJ9Z1+Oxt9Qu7y7tY0shqNzHBFbs1kHeR9t3FJtkaJECoPK2yP5UucNtxFJ4g1
po7u8k1GdLSxlu3le0jt38hI7q4QNdRuQ7QiOJQvk4dtkvO7aa9KooooooornvBv/IEuf+wrqX/p
bNXQ0UUUUUUUUUUUUVz3g3/kCXP/AGFdS/8AS2auhoooqneWVvfxLFdR+ZGssUoG4jDxusiHj0ZV
PvjniqB8L6O1paWps/3Vla/Y7YCVwYosxkbWzkMDDGQ+dwKAgg0QeF9Ht+fsfnM0U0MjXMjztKku
zeJC5JkyIo1+bOFQKMDiq6eC9DjMzC2nE83lmS6+2TfaCU37W87f5m4CR13bs7DsztAFSHwjomwq
tpJG5VF86K4lSUbGkYMJFYOHJml3ODubzG3E5NXLXRdOsZbWW3t9j20UsMbl2J2yMryFiT8zMyKx
ZssTk5yTmNvD+nPpFppQgkjtLNES28qeSOSEIu1dkisHU7cqSGyQSDkE5jHhfR1tLu1Fn+6vbX7H
cgyuTLFmQnc2cliZpCXzuJckkmi48M6Vcz3k0kM4mu5UmkkjupY2WRE8sOhVh5bbPlJTaWXg5FA8
L6Otpd2os/3V7a/Y7kGVyZYsyE7mzksTNIS+dxLkkk0L4Z0pNYi1NIZ1uI5XnjQXUohSR1ZWcQ7v
LDEO+TtySzHqSa26KKKK5+z/AOSh6z/2CrD/ANG3ddBRRRRRRRRXP+O/+Se+Jf8AsFXX/opq6Cii
iiiiisiPw3ocN7NeRaJpyXcz75Z1tUDu28SZZsZJ3qrZPcA9RT77Q9I1OKSK/wBKsruOSYTus9uk
gaQKEDkEcsFAXPXAx0qrq/h2G/0abS7IWthBcQCyuGS1BY2u1l8uPBUIQHO0kMq5PynNX7zSdO1C
5tri90+0uZ7R99tJNCrtC2QcoSMqcqDkeg9Kjm0PSJ5baWbSrGWS1lae3d7dCYpGbezqSPlYt8xI
5J561p0UUUUUUVz3g3/kCXP/AGFdS/8AS2auhooooooooooooornvBv/ACBLn/sK6l/6WzV0NFFF
FFFFFFFFFFFFFFFFc/Z/8lD1n/sFWH/o27roKKKKKKKKK5/x3/yT3xL/ANgq6/8ARTV0FFFFFFFF
FFFFFFFFFFFFFc94N/5Alz/2FdS/9LZq6Giiiiiiiiiiiiiue8G/8gS5/wCwrqX/AKWzV0NFYHiX
xTZeFLewmv4rqVLy9jsoxbReawdwSCVHJHynhQT0wDUGi+M7LXvDl7rFlZ6iTYvLFcWL2+25WWMZ
MWzOC5GMAHqQDg5Ay7fxzqmuQXdvo3hHW7TUViDQPrVr9mtsl1QlnDEnaGLlRyQjAc4rlYviLrcX
wT0/VhcJc+J9QS68hmSJcLC0rSS7MqMJFGegPzbAQc89Fe+KtSg+G/hi5W526xrwsbKO7MCusU06
qWlKZUcDeQOm7aMYzRpev+JZ/jDe6JqQhttLGlvdWltGVdiFuBGsrvjO5gGO0HAVlB+YE1mfDnxb
q3iHxbqA1LV7pbee3kvtO0q400RFbVpsRyeaANxCgDA3KQ6kMxDBdyX4o6Hbwa5PNaaqlvo0s8Fz
ObQmMyRuiBFcHaWdpBtBIOAS20YJ5i9+K1zrfizwvpWgW2q2UVzfvFqQn04NKpjYBoMFsDAO6Qjl
FZTnIK10WlfFnw7rCarJbQ6kE06yl1BWkt9gu7eNmVpIcnkblx8205OOzYqTfGnw3bfZTPZa3Ek8
Udw0j2DKsUD7AJmyeY9z7Ny7sshxkFS1+L4o6HJri6W1nqqE6pJpBumtT5C3C4CqXBI+c8AdeMsF
HNGh/FTw1rs2orCL2CGytZL7z7i2ZUntkYq8seMkqCuMEA9sZBAr6f8AF3QNS09riK01VLn7XbWs
VhNbqk0z3A3QlSW2bWUMQSw4XPdc3E8XTnxh4egKXcVjr9lOIrO6szDPbXEHzsX3EHDKxUjBGUUq
cMTXbUUVz9n/AMlD1n/sFWH/AKNu66Ciiiiiiiiuf8d/8k98S/8AYKuv/RTV0FFFFFFFFZHiXUJt
I8LatqdusZns7Ka4jWQEqWRCwBwQcZHqK5DwX4317WfEdvpes2OnRJeaHBrFtJZyOSqsVVlcMOpY
kgD7oGMv1rF/4Whqn/Cw/wCwf7Y8K+R/av2PyPs199p2+bs27tnl+ZjjOdue+Kv/ABQ064bxD4M1
JtSnNsuv2MCWAAEe8u7NKx6s2Aij+6A39449RoooooooornvBv8AyBLn/sK6l/6WzV0NFFFFFFFF
FFFFFc94N/5Alz/2FdS/9LZq6Giud8U+GT4l/sX/AEv7P/Zuqwaj/qt/m+Xu+TqMZ3decY6Gq2i+
DLfTNP8AEWn3lx9tttc1C5u5k2GPak4AaPIbJwAfmGOvQUvhz4eeFvCeoyX2h6X9kuZIjCz/AGiW
TKEgkYdiOqj8q58fB7R7jwBY+G9Tl+2XWnRXK2d/tePynmYtv8tXw2Dt4JOdvbNLrfgn+xvAXhyy
0uKe7/4RvULbUXht490l35bEzbFZ+GO93C5PI2jqK6f/AIRkf8LB/wCEq+2H/kFf2b9l8r/pr5m/
fn8MY981j+FfAFzoHiW41q/8R32sTfZTY2v2tRvigMplw75JkbOMNxjkYxgLHP8ADaG58KeKNCuN
SkKa7qcuoCVIQpgZmR1XBJ3AMgz0yCenWl0z4cjT9a0LUvt1or6ZcXk7QWmmx20UnnoIwqqh+UIq
ryxdm7npinovwng0TSNX02DUIDFd2E9hBKNOiWZFlZyXllHzysAygAFFwg+XOCEvvhRBeSaJKdRg
L2Glw6VKbjTYrgPHGytvjWTKxyHDrlg4AfgZGTa/4Vn/ANRb/mav+Ej/AOPb/wAg/f8A/H//AB2o
fD3wubRLHUtLuPEuo3mj3FlNYW1kAsa28UrszMeoeX5uH2juMYwBHYfCsWXh9tON5pcsyy2zozaF
bmFlhTZiVDl5GcM5Z/MDAt8u0ZDM0XwKdH8R+DtPtnupLPw1ZXc8l7LEoS4luTt8tecgg+YxGDtG
wEktmvTaKK5+z/5KHrP/AGCrD/0bd10FFFFFFFFFc/47/wCSe+Jf+wVdf+imroKKKKKKKKqahY2+
padc2F3H5ltcxPDKm4jcjAhhkcjIJ6Vn2XhfR9M1C2v7Oz8u6tbBdNhfzXO22UgqmCcHBA5PPvW3
WZqmiafrRsjqFv532K7jvLf52XZMmdrcEZxk8HI9q06KKKKKKKK57wb/AMgS5/7Cupf+ls1dDRRR
RRRRRRRRRRXMxeFbm1M62XifWLWGW4muPIjS1ZUaWRpGwXgZsbmbqTU3/CPap/0Oeuf9+bL/AOR6
P+Ee1T/oc9c/782X/wAj0f8ACPap/wBDnrn/AH5sv/kej/hHtU/6HPXP+/Nl/wDI9H/CPap/0Oeu
f9+bL/5Ho/4R7VP+hz1z/vzZf/I9H/CPap/0Oeuf9+bL/wCR6P8AhHtU/wChz1z/AL82X/yPR/wj
2qf9Dnrn/fmy/wDkesfSNM1i71PXoX8Ya2FtL5YY8R2hyDbQyc5gIHMh6YHtnJOx/wAI9qn/AEOe
uf8Afmy/+R6P+Ee1T/oc9c/782X/AMj0f8I9qn/Q565/35sv/kej/hHtU/6HPXP+/Nl/8j0f8I9q
n/Q565/35sv/AJHo/wCEe1T/AKHPXP8AvzZf/I9H/CPap/0Oeuf9+bL/AOR6P+Ee1T/oc9c/782X
/wAj0f8ACPap/wBDnrn/AH5sv/kej/hHtU/6HPXP+/Nl/wDI9S6VoTadqF3fz6pfahdXMUULSXQi
G1IzIVAEcaDrK/UE9K26KKKKKKKKqX9jb6jp9zY3Ufm29zE0MyZI3IwIYZHIyCelZP8Awhumf8/W
uf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49R/whumf8/Wuf+D29/wDj1H/C
G6Z/z9a5/wCD29/+PUf8Ibpn/P1rn/g9vf8A49R/whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/
AOPUf8Ibpn/P1rn/AIPb3/49R/whumf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1r
n/g9vf8A49R/whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49R/wh
umf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1rn/g9vf8A49R/whumf8/Wuf8Ag9vf
/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49Wlpmm2uj2KWVkjrAjO+JJXkYs7F2JZyW
JLMSSSetX6KKKKKKKKKKKKKKKKKKKKKKK5/w9/yG/Fn/AGFY/wD0ita6Ciiiiiiiiiiiiiiiiiii
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiuf8Pf8hvxZ/2FY/8A0ita6Ciiiiii
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiuf8AD3/Ib8Wf9hWP
/wBIrWugoooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooorn
/D3/ACG/Fn/YVj/9IrWugooooooooooooooooooooooooooooooooooooooooooooooooooooooo
oooooooooopjFghKjLAcAnGTXmnw58av4j8XeKLQaNdWh+1C4neVwRCyxRQeWcfxExMfoK9Ooooo
ooooooooooooooooooooooooooooooooooooooooooooooooooooritD0O31qzu769vNYadtSvo/
3Wr3UShUupUQBEkCgBVUcDtWp/whumf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1r
n/g9vf8A49R/whumf8/Wuf8Ag9vf/j1H/CG6Z/z9a5/4Pb3/AOPUf8Ibpn/P1rn/AIPb3/49R/wh
umf8/Wuf+D29/wDj1H/CG6Z/z9a5/wCD29/+PUf8Ibpn/P1rn/g9vf8A49VW2+H2gWc1zNbf2rDL
cv5k7x6xdqZGxjLES5Y+5zVr/hDdM/5+tc/8Ht7/APHqP+EN0z/n61z/AMHt7/8AHqP+EN0z/n61
z/we3v8A8eo/4Q3TP+frXP8Awe3v/wAeo/4Q3TP+frXP/B7e/wDx6j/hDdM/5+tc/wDB7e//AB6j
/hDdM/5+tc/8Ht7/APHqP+EN0z/n61z/AMHt7/8AHqP+EN0z/n61z/we3v8A8eo/4Q3TP+frXP8A
we3v/wAeqvodt/ZvjDVtPiub2S1Wws51S6vJbja7yXKsQZGYjIROAccV1NFFFFFFFFYXjG5mtfBG
v3VtK8U0Om3MkciHDIwiYgg9iCKj/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCE
N0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/w
e3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP
+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+t
c/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo
/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n61z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqP+EN0z/n6
1z/we3v/AMeo/wCEN0z/AJ+tc/8AB7e//HqPB7SnQHSSaabyb++gR55mlfYl1KiAsxLHCqBkkniu
hooooooooooooornvBv/ACBLn/sK6l/6WzV0NFefeJL/AEy38X6gNbutcjsrbSradf7PkvVjizJc
+Y7/AGbheETl+y8dDVvT49R1qe20nxBPdxXFppFlc3K2ly1uz3MplWQs8LAkKYeFUhfmYkNhdtfU
NKjnm8KTPreo3b6hcLFc3VpqU8EV0os5n3rHFIEQM0aP8mPqcnOno/iLztdfQ4oYBHa74dkmob71
Fj+USywuN3ltgbX3uzCSNiMMSsD+JrxfFN7oumaQLm5MspMk9+UiXy4bRiTlWKKRcAYRT8y5I+dm
WfSPFlxrzx3Wl6X5mmjyFmkluAk6GWKOUFY8FWVUmQsfMB4fAbC7szTPFs1lo/iZ5oZLp9IS8vQz
znMii7vFWPkHaFW3AB54IGOObE+v32oeIdCSK1kh019XubUTpccymGG5R0ljwMAyR7lwXBCZbYcA
07D4n2eoqn2eKynkuoo5bSK21ASuvmSxRItyAv7ht08eQPMxiTGSoDbfhS9vr288Rfb43iki1NYx
CZvNWIC1tyQh/uFizDhT82SqkkDI0HxxNeaZa3C6LJFp0b2NtJNJemWTdcxQNGF3DdIVadQ7OV4+
YFySo39Y1q/stYstL07TEvLi7t55g0tx5McQiaIHedrHB83jarHIAxgllxH+IJtdMg1C9sYLe1v7
VbzT5DecGNpIYwbglAIcG5iJ2+YAA/J2jdUk8YX2rz6HNpUNpciHV5ba7Sx1PzI5yLOSUJE+wLIN
rZ+fYBJGF6fONLSfiBo9wLpdR1PRLYW3lEz22qpPbN5nmbU81lT95+6clcdNpycnHZ0UVz9n/wAl
D1n/ALBVh/6Nu66Ciiiiiiiiuf8AHf8AyT3xL/2Crr/0U1dBRRRRXE+Lp7ZfFGjW99LrItHsryQx
6W13uaRXtwpYW3zEAM4yeBu9SKr6TcXOsRaLpk95d/YL63vr2OWK4eOea3jnjFqDKCJADFMjE5Dk
qNx5cMa5pKDQbaddb1K4lj1K3shPbalPEPJa+WMxMEkwzqjmMu2XJXJOemhDrq6X4gi8N28COkbh
Qt5qjG9mDDeZIklyZol3HLGQEeXIAp2AGTXfGdvoOo3NrcQZWGK3m37jyjmcynAU/wCritpZP9rG
0ckZwNW8U3199sGlWnlXUGoWMLtJqEiI6DUprfAAQhdxhw2ByspB3bAGnsvGFxounXd3qtnPLYLf
6pHHcCcPM5hkuZdqoeBGI4WQEsDuUDbtw1D+Jtcs/GclncaTvurmK0toraO/BgVmF7IZVcqDtxEq
tlA3ynCvtXdr6v4uXRvEFvptwlikc8sMKK9+q3UplcIrxwYO6MM2CxZSNkhCkKN1Cy+I0F7b2jLZ
YkuIbFwnmnh53gEiZ2/8s1urds/x+ZgYKti/4d8V3Gt/2abvS/sC6nYfb7UeeJW2L5YfeAAF5mQr
gtlclgh+WuroooornvBv/IEuf+wrqX/pbNXQ0UUUUUUUUUUUUVz3g3/kCXP/AGFdS/8AS2auhorP
TToY9audTVpPPuLeG3dTjaFjaRlI4znMrZ57Dp3zY/CdpBZ2ttaXd9aLbxC1328gR5LYE7YGbbna
oOFcYkXkhwWYtfk0a0kOleWvkR6ZL5ttFAAqL+6eILjH3QshwBjoO3FVxoC/2rHfS397cpBK89va
zOpjglZWVmU7fMPDyAKzlQHwAAF2lv4cs7bxDPriST/aZvM3ISNg3pbocDGelrHjnu3qMULDwPYW
ENrbQXl99ig+zM9ozRlJpYFjWKVzs3hgIYuFZVOwZXlsxXngHTru2vbb7dqMEV+k6XYglVTOskss
oBO3ICPPIQFxkHD7xxV2PwlaRaxbagt5e7ba6lvLe080eTHJKsglONuW3GVm+YkqeFKqSpij8H20
Vh9h/tLUXtIkjSyhaRAtkI3V49gCDeVaOPBl8w/Lg5DOGv6PokOiC8Mdzd3Ml7cfaZpLmQOzSeWi
EjAAAIjB2gYGSFAUBRQsPBem6dpA0yCa6aAXFpcbnZS262WBYxwuMEWyZ47tjGRjXfToZNattTZp
PPt7ea3RRjaVkaNmJ4znMS457nr2yG8Gac1hpdr512BpdmLO1kDruXa8LpIflwXVreNhxtPIKkHF
GoeDrbVtNhstR1HUbrZcNPLLI6Bpg0TwtGQECqhjdlxGEP8AECGJY3dK0FtN1G6vp9UvtQubmKKF
nuhCNqRlyoAijQdZW657VtUUVxUkOtyfEPWDp2oafbD+zbE4ubF5jt8y6wMrMnOQxz6EDAwSdX7H
4v8A+g7of/gmm/8Akqj7H4v/AOg7of8A4Jpv/kqj7H4v/wCg7of/AIJpv/kqj7H4v/6Duh/+Cab/
AOSqPsfi/wD6Duh/+Cab/wCSqPsfi/8A6Duh/wDgmm/+SqPsfi//AKDuh/8Agmm/+SqPsfi//oO6
H/4Jpv8A5Ko+x+L/APoO6H/4Jpv/AJKrzHVtL+JMEHjW4vtTtDoDWd0fLmjJEq+S2TCm9mjHXq+M
84Ne3UUUUVnvp0MmtW2ps0nn29vNbooxtKyNGzE8ZzmJcc9z17UH8MWwRjZ3d1Zzi4luIbiEoXgM
rbpVXcpDI7ZYq4YZIIxsTbZm0Gyk0qDTEWSG2iuIrhSjZZnjmWbLM2SxZ1yxOS2WJOTmorzQFvtR
W4lv742oljnew3qYXljKsjZKl1wyIdqsqkrkg7m3R6r4T0nWr83V/BJKXga3kjEhVXUpIgJxyCFn
nUYI/wBaSckKVpt4Isfs9xHFd30Us/2dnuEaMv5sNy9yJQChXc0srkjbt7BVFWLjwfpl5p0djdef
JardXVy0ZfG83AmEikgA7cXD4xgjC88HMdt4PtoNah1ibUtRvL9HjYyXMiYYok8a/KqBVG25fhQo
JVT1LFpL7wpDfai1yuoXtvFLdwXlxaw+UY55oTGUZiyFxxFGCFZRhemSSYLXwFodobXyo7j/AEWV
ZEzITuVfK8tD/sp9mtsYwx8ldxbc+/Q03w3aaZ/ZHkSzt/ZWntp8G9gd0Z8rJbAGW/cryMDk8dMb
VFFFFc94N/5Alz/2FdS/9LZq6Giiiiiiiiiiiiiue8G/8gS5/wCwrqX/AKWzV0NFFFFFFYl5r62O
orby2F8LUyxwPf7FEKSyFVRcFg7ZZ0G5VZQWwSNrbc/T/G9pqlpDcQaZqii7tRd2cbwAPdLlFYKA
3y7WljBZ9q/NuDFAXEGoeLJYvsE0NpfRvFqEtvfacIkknbbZTTiNdrMrM2ImG1u4BIO4VeuPFtgs
4gso59RkbyRB9jMbLcPIjyhEdmCbhFGZDuI+VkIJLAGFvFkMWomH7Fqr30kUIj01ookYuxuMhSzA
bgLeUkl9hVFKE7vm3rK6F7aJcfZ57dmyGhmTa6MCQQexwQeQSp6gkEE3KKKKKKK5+z/5KHrP/YKs
P/Rt3XQUUUUUUUUVz/jv/knviX/sFXX/AKKaugoooooooooooooooooooornvBv/ACBLn/sK6l/6
WzV0NFFFFFFFFFFFFFc94N/5Alz/ANhXUv8A0tmroaKKKKKK47V/BB1XxBHqhuLE7bq3ud9zYedc
xeS6N5cM28eXG3l8rtPMkh/iwEfwNu0jSLD+0ONO0s6fkwZSf5rdsuu7mNvs+148/MsjDcOtR6Z4
NXQES7ee0VLbUn1RoNN0xoo8fZDb7EiV3Oed/GSTkAc1HpHhbzPBr2UcENus908og1Cz+0RS26Hy
7dZYnIbiCODjKuGRS2TvDSr4DaO1niW+tZhNbwQtb3dgs1qRHLPJs8otkRAzgIgYFBFGNzAEHotF
0z+x9HgsfO83ytxyF2Iu5i2xFydka52ouTtUKMnGa06KKKKKK5+z/wCSh6z/ANgqw/8ARt3XQUUU
UUUUUVz/AI7/AOSe+Jf+wVdf+imroKKKKKKKKoavqUWj6NfanOsjw2dvJcSLGAWKopYgZIGcD1FY
Hhr4gaT4p1M6fa22o21wbOO+iF7amITQvj5kPcKxCk9CfulhzTP+E9/4qH+yP+ET8Vf8ff2b7b/Z
v+jff2+Zv3f6vvux05rkPil448SeHfEbw6NfQW1tp2lx6nLE9ssn2otdLB5bE8quDnK4PXnkFfYK
KKKKKKKK57wb/wAgS5/7Cupf+ls1dDRRRRRRRRRRRRRXPeDf+QJc/wDYV1L/ANLZq6Giiiiiiiii
iiiiiiiiiiufs/8Akoes/wDYKsP/AEbd10FFFFFFFFFc/wCO/wDknviX/sFXX/opq6Ciiiiiiisz
XtM/trw/qWled5P261ltvN27tm9Cu7GRnGc4yKwND8DHRPEGmar/AGj532HQItF8ryNu/Y4bzc7j
jOMbcH60v/Cr/B3/AAkP9vf2P/xM/tf2zz/tM3+u37923ft+9zjGPas7xx8MU8Z61HfHWZ7GOS0W
yvYUgV/PgWYTAKx/1bbh975ug4xkN6FRRRRRRRRXPeDf+QJc/wDYV1L/ANLZq6Giiiiiiiiiiiii
ue8G/wDIEuf+wrqX/pbNXQ0UUUUUVm61ren+HNIn1bVbjyLKDb5kuxn27mCjhQSeSBwKraD4p0Tx
MLz+xtTgvfscvkz+UT8rdjz1U4OGGVODgnBrI0T4o+DvEOrwaVpWsfaL6fd5cX2WZN21Sx5ZABwC
eTVfUPGep2/xR0Xw1HpRj02789ZL24HMzpCJcQgH7q7kBYg5JYDG0kweD/F3ijVPGOoaJ4h0extP
JtRdhbOYytabpCqQzsCVMjJ84xj5RnHOF9Booooooorn7P8A5KHrP/YKsP8A0bd10FFFFFFFFFZm
vaZ/bXh7UtK87yTfWstt5u3ds3oV3YyM4znGapfY/F//AEHdD/8ABNN/8lUfY/F//Qd0P/wTTf8A
yVR9j8X/APQd0P8A8E03/wAlUfY/F/8A0HdD/wDBNN/8lUfY/F//AEHdD/8ABNN/8lUfY/F//Qd0
P/wTTf8AyVR9j8X/APQd0P8A8E03/wAlUfY/F/8A0HdD/wDBNN/8lUfY/F//AEHdD/8ABNN/8lUf
Y/F//Qd0P/wTTf8AyVR9j8X/APQd0P8A8E03/wAlUfY/F/8A0HdD/wDBNN/8lUfY/F//AEHdD/8A
BNN/8lUfY/F//Qd0P/wTTf8AyVR9j8X/APQd0P8A8E03/wAlUfY/F/8A0HdD/wDBNN/8lUfY/F//
AEHdD/8ABNN/8lUfY/F//Qd0P/wTTf8AyVR9j8X/APQd0P8A8E03/wAlUfY/F/8A0HdD/wDBNN/8
lUfY/F//AEHdD/8ABNN/8lVZ0DS59H0r7JcXEdzM1xPcSSxxGJS0szykBSzEAF8Dk9K16KKKKKKK
KKKKKK57wb/yBLn/ALCupf8ApbNXQ0UUUUUVyvxE8O3ni3wLqOh2DwR3N15Wx52IQbZUc5IBPRT2
pNE8OXmmeOfFWuTSQNa6v9j+zqjEuvlRFG3AjAyTxgn8Kg0XwCdE1e31EeLfFV/5O7Ntf6l5sL5U
r8y7RnGcj3AqfW/Dl5qfjnwrrkMkC2ukfbPtCuxDt5sQRdoAwcEc5I/Gsnwf4R8UaX4x1DW/EOsW
N351qLQNZwmJrvbIWSadQAokVPkGM/KcZ4y3oNFFFFFFFc/Z/wDJQ9Z/7BVh/wCjbuugoooooooo
ooooooooooooooooooooooooooooooooooooorkdOtvFOjxXNpbaZo9xA17dXEcsmpyxMVlneUAq
LdgCA+Op6Ve+2eL/APoBaH/4OZv/AJFo+2eL/wDoBaH/AODmb/5Fo+2eL/8AoBaH/wCDmb/5Fo+2
eL/+gFof/g5m/wDkWj7Z4v8A+gFof/g5m/8AkWj7Z4v/AOgFof8A4OZv/kWj7Z4v/wCgFof/AIOZ
v/kWj7Z4v/6AWh/+Dmb/AORaPtni/wD6AWh/+Dmb/wCRaPtni/8A6AWh/wDg5m/+RaPtni//AKAW
h/8Ag5m/+RaPtni//oBaH/4OZv8A5Fo+2eL/APoBaH/4OZv/AJFo+2eL/wDoBaH/AODmb/5Fo+2e
L/8AoBaH/wCDmb/5Fo+2eL/+gFof/g5m/wDkWj7Z4v8A+gFof/g5m/8AkWj7Z4v/AOgFof8A4OZv
/kWj7Z4v/wCgFof/AIOZv/kWj7Z4v/6AWh/+Dmb/AORaZpFlq3/CQajquq29lbfaLW2to4rW5ef/
AFbzMWJaNMZ84DGD0NdHRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRX//Z
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 2. SBP funnel.</P>
<P>SBP funnel plot: standard error of estimated treatment effect vs. estimated treatment effect</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAGQCAMAAABI9Z7tAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Fig 3. DBP funnel.</P>
<P>DBP funnel plot: standard error of estimated treatment effect vs. estimated treatment effect</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAGQCAMAAABI9Z7tAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>